---
document_datetime: 2023-09-21 19:02:21
document_pages: 140
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/zydelig-h-c-3843-ii-0032-g-epar-assessment-report-variation_en.pdf
document_name: zydelig-h-c-3843-ii-0032-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 377.684793
conversion_datetime: 2025-12-22 12:26:25.904252
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22February 2018 EMA/202018/2018 Committee for Medicinal Products for Human use (CHMP)

## Assessment report

## Zydelig

## International non-proprietary name: idelalisib

## Procedure No.EMEA/H/C/003843/II/0032/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidentialnaturedeleted.

30 ChurchillPlace·CanaryWharf·LondonE145EU·UnitedKingdom

Telephone+44(0)203660 6000 Facsimile+44(0)2036605555

Sendaquestionviaourwebsitewww.ema.europa.eu/contact

An agency of the European Union

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Rapporteur(s) and type of application   | Rapporteur(s) and type of application   |
|-----------------------------------------|-----------------------------------------|
| CHMP Rapporteur:                        | Filip Josephson                         |
| CHMP Co-Rapporteur                      | Paula van Hennik                        |
| PRAC Rapporteur:                        | Patrick Batty                           |

## Assessment Timetable

| Timetable                                            | Planned dates   | Actual dates    |
|------------------------------------------------------|-----------------|-----------------|
| Start of procedure:                                  | 18February2017  | 18February 2017 |
| CHMP Co-RapporteurAssessmentReport                   | 12April2017     | 13April 2017    |
| CHMP RapporteurAssessmentReport                      | 12April2017     | 12April 2017    |
| PRACRapporteurAssessment Report                      | 21April 2017    | 19April 2017    |
| PRACmemberscomments                                  | 26April2017     | 28April 2017    |
| UpdatedPRACRapporteurAssessmentReport                | 27 April 2017   | n/a             |
| PRAC Outcome                                         | 5May2017        | 5May2017        |
| CHMPmemberscomments                                  | 8May2017        | 8May2017        |
| Updated CHMP Rapporteur(s)(Joint) Assessment Report  | 11May2017       | 12 May 2017     |
| RequestforSupplementaryInformation                   | 18May2017       | 18May2017       |
| Submission deadline                                  | 8September2017  | 8September2017  |
| Re-start ofprocedure:                                | 11September2017 | 11September2017 |
| CHMP RapporteurAssessmentReport                      | 10 0ctober2017  | 10 October2017  |
| PRAC Rapporteur Assessment Report                    | 13 0ctober2017  | 11 October2017  |
| PRACmemberscomments                                  | 18 October2017  | 18 October2017  |
| UpdatedPRACRapporteurAssessmentReport                | 19 0ctober2017  | 20 October2017  |
| PRACOutcome                                          | 26 0ctober2017  | 26 0ctober2017  |
| CHMP members comments                                | 30 0ctober2017  | 23 0ctober2017  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 3 November 2017 | 3 November 2017 |
| Request for Supplementary Information (RSI)          | 9 November 2017 | 9 November 2017 |
| Submission deadline                                  | 30 January 2018 | 30 January2018  |
| Re-start of procedure:                               | 31 January 2018 | 31 January 2018 |
| CHMP Rapporteur Assessment Report                    | 7 February2018  | n/a             |
| PRACRapporteurAssessmentReport                       | 7 February2018  | n/a             |
| CHMPmemberscomments                                  | 12February2018  | n/a             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Timetable                                 | Planned dates   | Actual dates   |
|-------------------------------------------|-----------------|----------------|
| PRACmemberscomments                       | 12February2018  | n/a            |
| Updated CHMP Rapporteur Assessment Report | 15February2018  | 15February2018 |
| Updated PRAC Rapporteur Assessment Report | 15February2018  | n/a            |
| Opinion                                   | 22February2018  | 22February2018 |

<div style=\"page-break-after: always\"></div>

## Table of contents

1.Background information on the procedure..

1.1.TypeIIgroupofvariations.

2. Scientific discussion.

2.1. Introduction...

2.2. Non-clinical aspects

2.2.1.Ecotoxicity/environmentalriskassessment

Discussiononnon-clinicalaspects..

2.2.2.Conclusion on the non-clinical aspects..

2.3. Clinical aspects ....

2.3.1. C.I.13: Submission of the final report from study GS-US-312-0123.

2.3.2.FinalstudyreportStudy101-08(PAM008).

2.3.3.C.I.6.ExtensionofIndicationpivotalStudyGS-US-312-0115

2.3.4.PSUR cycle.....

2.3.5.DirectHealthcareProfessionalCommunication

2.3.6. Update of SmPC.

2.3.7.Risk management plan.

2.3.8.User consultation..

2.3.9.Quick Response (QR) code.

3.Benefit-RiskBalance...

4.Recommendations .

Annex 1: 1st Request for supplementary information

Annex 2: 2nd Request for Supplementary Information .

8

8

9

9

10

..10

..10

.10

.16

.18

...62

.62

..63

.63

..63

..64

64

.68

.70

. 138

Annex3:ProductInformation annotated with(Co)Rapporteur(s)comments

..140

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR

adverse drugreaction

AE

adverse event

ALT

alanineaminotransferase

AML

acutemyeloidleukemia

ANC

absoluteneutrophil count

AST

aspartate aminotransferase

B

bendamustine

BCR

B-cell receptor

BID

twice daily

BOR

bestoverallresponse

BR

bendamustineandrituximab

CI

confidence interval

CIRS

cumulativeillnessratingscale

CLL

chroniclymphocyticleukemia

CMV

cytomegalovirus

CR

completeresponse

CRi

complete response with incomplete marrow recovery

CSR

clinical study report

CYP3A

cytochromeP4503A

DLBCL

diffuse largeB-cell lymphoma

DMC

datamonitoringcommittee

DOR

duration of response

EC

European Commission

EDC

electronicdata capture

ESMO

European Society for Medical Oncology

EWB

emotional well-being

F

fludarabine

FAS

full analysis set

FDA

FoodandDrugAdministration

FCR

fludarabine, cyclophosphamide, and rituximab

FR

fludarabine andrituximab

FWB

functional well-being

HL

Hodgkin lymphoma

HMG-CoA

3-hydroxy-3-methyl-glutaryl-coenzymeA

HR

hazard ratio

HRQL

health-relatedqualityof life

IDL

idelalisib (Zydelig?)

IGHV

immunoglobulinheavychainvariableregiongene

iNHL

indolent non-Hodgkin lymphoma

IRC

independentreviewcommittee

ISE

integratedsummaryofefficacy

ISS

integratedsummaryofsafety

<div style=\"page-break-after: always\"></div>

| LLI    | intent to treat                                     |
|--------|-----------------------------------------------------|
| IV     | intravenously                                       |
| KM     | Kaplan-Meier                                        |
| LNR    | lymph node response                                 |
| MCL    | mantle cell lymphoma                                |
| MedDRA | MedicalDictionaryforRegulatoryActivities            |
| MID    | minimallyimportantdifference                        |
| MM     | multiple myeloma                                    |
| MST    | Medical Search Term                                 |
| NCCN   | National Comprehensive CancerNetwork                |
| NDA    | new drug application                                |
| NE     | notevaluable                                        |
| NEst   | not estimable                                       |
| NR     | not reached                                         |
| 0      | ofatumumab                                          |
| ORR    | overallresponserate                                 |
| OS     | overall survival                                    |
| PD     | progressive disease                                 |
| PFS    | progression-free survival                           |
| PI3K   | phosphatidylinositol 3-kinase                       |
| PJP    | Pneumocystisjiroveciipneumonia                      |
| PK     | pharmacokinetics                                    |
| PI     | placebo                                             |
| PML    | progressive multifocal leukoencephalopathy          |
| PR     | partial response                                    |
| PT     | preferred term                                      |
| Q1     | first quartile                                      |
| Q3     | third quartile                                      |
| R      | rituximab                                           |
| RCh    | rituximab and chlorambucil                          |
| RL     | rituximabandlenalidomide                            |
| SAE    | serious adverse event                               |
| SAP    | statistical analysis plan                           |
| SD     | stable disease                                      |
| SLL    | small lymphocytic lymphoma                          |
| SmPC   | SummaryofProductCharacteristics                     |
| SMQ    | standardized MedDRA query                           |
| SOC    | system organ class                                  |
| SPD    | sumoftheproductsofthegreatestperpendiculardiameters |
| SWB    | social well-being                                   |
| ULN    | upper limit of normal                               |

<div style=\"page-break-after: always\"></div>

## 1.Background information on the procedure

## 1.1.TypeIIgroupofvariations

PursuanttoArticle7.2ofCommissionRegulation(EC)No1234/2008,GileadSciencesInternationalLtd submitted to the European Medicines Agency on 31 January 2017 an application for a group of variations.

The following variations were requested in the group:

| Variationsrequested   | Variationsrequested                                                                                                             | Type    | Annexes affected   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.1.13                | C.I.13-Other variations not specifically covered elsewhereinthisAnnexwhichinvolvethesubmissionof studiestothecompetentauthority | Type II | None               |
| C.1.13                | C.I.13-Other variations not specifically covered elsewhereinthisAnnexwhichinvolvethesubmissionof studiestothecompetentauthority | Type II | None               |
| C.I.6.a               | C.I.6.a-Change(s)to therapeuticindication(s)-Addition ofanewtherapeuticindicationormodificationof an approvedone                | Type II | I and IIIB         |

forZydeligtoincludeitsuseincombinationwithbendamustine andrituximabbasedontheresultsof controlledstudyevaluatingtheefficacyandsafetyofidelalisib(GS-1101)incombinationwith bendamustine and rituximabforpreviously treated chronic lymphocyticleukemia\"as a consequence,

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local

C.I.13:Submission of the finalreport from study 101-08,a phase 2,single-arm study evaluated idelalisibmonotherapyandincombinationwithrituximabinelderlysubjectswithpreviouslyuntreated CLL or small lymphocytic lymphoma. Inclusion of this report provides additional safety data to support the evaluation of theuseofidelalisibinpatientswith CLL.Submission of thisreportis alsomade in fulfilmentofPAMo08.

C.I.13:Submission of the finalreport fromstudyGS-US-312-0123,aphase3randomized study evaluatedidelalisibincombinationwithbendamustineandrituximabinsubjectswithpreviously untreatedCLL.Inclusionofthisreportissupportiveofacompletesafetyevaluationconcerningthe useofthiscombinationinpatientswithCLL.

The group of variations proposed amendments to the Summary of Product Characteristics and Package Leaflet.

## Informationonpaediatricrequirements

CW/1/2011on the grantingof aclasswaiver.

<div style=\"page-break-after: always\"></div>

## Informationrelatingtoorphanmarketexclusivity

## Similarity

PursuanttoArticle8of Regulation(EC)No.141/2000andArticle3of CommissionRegulation(EC)No 847/2000,theapplicationincludedacriticalreportaddressingthepossiblesimilaritywithauthorised orphanmedicinalproducts.

## Scientificadvice

TheMAHdidnotseekScientificAdviceattheCHMP.

## 2. Scientific discussion

## 2.1.Introduction

Zydelig(idelalisib[IDL])isacompetitiveinhibitorof theadenosine triphosphatebindingsiteof the phosphatidylinositol3kinasep1108(PI3k0)catalyticdomain.

asfirst-linetreatmentforpatientswithCLLwithgeneticmutations(chromosome 17p13.1deletion [17p deletion] and/or TP53 mutation) who are unsuitable for chemo-immunotherapy.

Thefirst-lineindicationwaslatermodifiedfollowingtheconclusionof anArticle20proceduretoinclude therapies.

The Article 20 procedure was initiated due to an increased early fatality rate in studies GS-US-3120123,GS-US-313-0124andGS-US-313-0125.

## Incidenceofdeaths,fatalAEsandSAEsinstudiesGS-US-312-0123,GS-US-313-0124and GS-US-313-0125

|                     | GS-US-312-0123 (1st line CLL)   | GS-US-312-0123 (1st line CLL)   | GS-US-313-0125 (iNHL with median of 2 prior therapies)   | GS-US-313-0125 (iNHL with median of 2 prior therapies)   | GS-US-313-0124 (iNHL with median of 1 prior therapy)   | GS-US-313-0124 (iNHL with median of 1 prior therapy)   |
|---------------------|---------------------------------|---------------------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                     | Idelalisib + BR (n =156)        | Placebo + BR (n = 154)          | Idelalisib + BR (n =318)                                 | Placebo + BR (n =155)                                    | Idelalisib + R (n = 190)                               | Placebo +R (6 = u)                                     |
| All Deaths          | 8%                              | 3%                              | 8%                                                       | 6%                                                       | 5%                                                     | 1%                                                     |
| AE leading to death | 8%                              | 2%                              | 6%                                                       | 3%                                                       | 4%                                                     | %0                                                     |
| SAEs                | 71%                             | 42%                             | 72%                                                      | 35%                                                      | 48%                                                    | 10%                                                    |

BR=bendamustine plus rituximab,R=rituximab

Thesestudieswereterminatedearlyandthearticle20procedureresultedinaminorchangeinthe approvedindications(see\\_above)andamendmentstotheSpCessentiallyfocusedonmeasuresto reduce the riskforinfections,especially the risk foropportunistic infections(pneumocystis and CMV).

<div style=\"page-break-after: always\"></div>

wereconsidered tobe:Thefavourableprognosisof theenrolledpatients,thefavourableriskprofilesof thecontrolregimens and theadd-onimmune-toxicityofIDL,especiallyinrelationtobendamustine+ rituximab (BR).

Applicationsweresubsequentlyfiled tosupporttheuseofIDLincombinationwithofatumumab(O)in patientswithCLLbased on theresultsof thePhase3StudyGS-US-312-0119.

Thepresentgroupofvariationsconsistof:

- use in combination with bendamustine and rituximab (BR) based on the results of the primary analysis ofpivotal Study GS-US-312-0115,entitled\"A Phase 3,Randomized,Double-Blind, Leukemia.\"
- The submission - under the scope of C.1.13 - of the final report from study 101-08, a phase 2, single-armstudyevaluatedidelalisibmonotherapyandincombinationwithrituximabinelderly subjectswithpreviouslyuntreated CLL orsmall lymphocyticlymphoma.Inclusionof thisreport providesadditionalsafetydatatosupporttheevaluationof theuseofidelalisibinpatientswith CLL.ThissubmissionisalsomadeinfulfilmentofPAMoo8oftheMA.
- The submission - under the scope of C.1.13 - of the final report from study GS-US-312-0123, a phase3randomizedstudyevaluatedidelalisibincombinationwithbendamustineandrituximab in subjects with previously untreated CLL.Inclusion of this report is supportive of a complete safetyevaluationconcerningtheuseofthiscombinationinpatientswithCLL.

## 2.2.Non-clinicalaspects

Nonewnon-clinicaldatahavebeensubmittedinthisapplication,whichisconsidered acceptable.

## 2.2.1.Ecotoxicity/environmentalriskassessment

ThisTypeIIvariationforZydeligincludes theinterim analysisof thepivotalStudyGS-US-312-0115, entitled\"APhase3，Randomized,Double-Blind,PlaceboControlledStudyEvaluatingtheEfficacyand indicationstatementwiththeadditionofthefollowing:

Zydeligisindicatedincombinationwithbendamustineandrituximabforthetreatmentofadult patientswith CLLwhohavereceived at least oneprior therapy.

relapsedchroniclymphocyticleukemia.On08December2015,a typeIBvariationwassubmittedto provideanupdatedenvironmental riskassessmentforidelalisibwithaPhaseIIassessment,asagreed recommendations.

<div style=\"page-break-after: always\"></div>

inasignificantincreaseintheextentofuse.\"Accordingly，arevisedERAisnotsubmittedinthe contextofthisvariationastheproposedrevisiontotheapprovedCLLindicationisforanew combination within the currently approved patient populations. It is not anticipated that there would be asignificantincreaseintheextentofuse.

## Comment

Thelackof anupdatedERAisacceptable.

MScommentfrom{confidentialinformationdeleted}:

\"Weagreewiththerapporteurandhaveanadditional comment.Theapplicantacknowledgedthe submissionofaphaseIIenvironmentalriskassessmentinthemarketingauthorisationprocedure ZydeligEMEA/H/C/3843.Thesubmissionwasannouncedforthefourthquarterof2015.OMS riskassessmentincludingthestudyreportsbytheapplicantorbytherapporteur.\"

Therequestedupdatedenvironmentalriskassessmentandstudyreportshavebeensubmittedbythe Consequently,theinformationrequestedby{confidentialinformationdeleted}isavailableinthe mentioned application.Since theupdatedERAwassubmitted asa typeIBvariationitwasapproved via CHMPsilentadoption and consequentlyno CHMPARwereproduced.NoMScommentswere notsubmitted aspartof this applicationtheycannotbere-assessed orrequested.Hence,therequest from{confidentialinformationdeleted}isnotagreedupon.

## Discussion on non-clinicalaspects

Consequently, it is not anticipated that there would be a significant increase in the extent of use.

## 2.2.2.Conclusion on the non-clinical aspects

Therearenonon-clinicalobjectionstothisapplication.

Based on the updated data submitted in this application,the new/extended indication does not lead to asignificant increase inenvironmental exposurefurtherto theuseofidelalisib.

## 2.3.Clinicalaspects

## 2.3.1.C.I.13:SubmissionofthefinalreportfromstudyGS-US-312-0123.

Study312-0123wasaphase3randomizedstudyevaluatedidelalisibincombinationwith bendamustine and rituximab(IDL+BR)vs.Pl+BR in subjects with\\_previously untreated CLL.

<div style=\"page-break-after: always\"></div>

2016,article20procedure).Because thefactorscontributing to the AEswerenotcompletely understood,thedecisionwasmadetoterminatethisstudy.Duetoearlystudytermination,the prespecified efficacy analyses were not conducted.

Issues discussed in the article 20 procedure included whether the side effects of IDL+BR were exaggerated inpatientswithtreatmentnaiveCLLvs.treatmentexperienced，i.e.thattheapparently unfavourableB/Rfirst-linewasnotonlyrelated totheslowprogressionrateinthecontrol(BR)arm. Therefore thisARisfocused onsafety.

Safety IDL/Placebo Exposure(SafetyAnalysisSet)

|                                       | IDL+BR (N=156)   | Placebo+BR (N = 154)   |
|---------------------------------------|------------------|------------------------|
| Duration of Exposure to IDL (months)* |                  |                        |
| N                                     | 156              | 154                    |
| Mean (StD)                            | 9.7 (6.23)       | 13.5 (4.48)            |
| Median                                | 12.1             | 14.5                   |
| Q1,Q3                                 | 3.1, 15.0        | 12.2,16.6              |
| Min, Max                              | 0.2, 22.1        | 0.3, 21.8              |
| Cumulative Exposure to IDL, n (%)     |                  |                        |
| ≥ 1 day                               | 156 (100.0%)     | 154 (100.0%)           |
| 2months                               | 123 (78.8%)      | 147 (95.5%)            |
| ≥4 months                             | 111 (71.2%)      | 145 (94.2%)            |
| 6months                               | 102 (65.4%)      | 140 (90.9%)            |
| ≥12 months                            | 79 (50.6%)       | 123 (79.9%)            |
| ≥ 18months                            | 10 (6.4%)        | 16 (10.4%)             |
| ≥24months                             | 0                | 0                      |
| ≥30months                             | 0                | 0                      |
| ≥36months                             | 0                | 0                      |

BR = bendamustine + rituximab, IDL = idelalisib, Q1 = first quartile, Q3 = third quartile; StD = standard deviation

The Safety Analysis Set included allsubjects who receive ≥ 1 dose of study treatment, with treatment group designated according to the actual teatment received.

+ aep sop oqed/ g -p sop oqed ) = (s)  noamsoxa go om

| Comment: Note the major difference in cumulative exposure already after 2 months.This is of course alsoreflected in the cumulativenumberof doses.   | Comment: Note the major difference in cumulative exposure already after 2 months.This is of course alsoreflected in the cumulativenumberof doses.   | Comment: Note the major difference in cumulative exposure already after 2 months.This is of course alsoreflected in the cumulativenumberof doses.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Cumulative Number of Doses                                                                                                                          |                                                                                                                                                     |                                                                                                                                                     |
| 21                                                                                                                                                  | 156 (100.0%)                                                                                                                                        | 154 (100.0%)                                                                                                                                        |
| 2                                                                                                                                                   | 156 (100.0%)                                                                                                                                        | 154 (100.0%)                                                                                                                                        |
| 24                                                                                                                                                  | 141 (90.4%)                                                                                                                                         | 150 (97.4%)                                                                                                                                         |
| ≥6                                                                                                                                                  | 122 (78.2%)                                                                                                                                         | 146 (94.8%)                                                                                                                                         |
| 8                                                                                                                                                   | 111 (71.2)                                                                                                                                          | 141 (91.6)                                                                                                                                          |
| ≥10                                                                                                                                                 | 95 (60.9)                                                                                                                                           | 133 (86.4)                                                                                                                                          |
| ≥12                                                                                                                                                 | 77 (49.4)                                                                                                                                           | 119 (77.3)                                                                                                                                          |
| 14                                                                                                                                                  | 1 (0.6)                                                                                                                                             |                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

## OverallSummaryofAdverseEvents(SafetyAnalysisSet)

| Adverse Event Category, n (%)         | IDL+BR (N =156)   | PI+BR (N =154)   |
|---------------------------------------|-------------------|------------------|
| Any AE                                | 156 (100.0)       | 153 (99.4)       |
| IDL/PI-Related AE                     | 139 (89.1)        | 110 (71.4)       |
| Rituximab-Related AE                  | 124 (79.5)        | 115 (74.7)       |
| Bendamustine-Related AE               | 140 (89.7)        | 140 (90.9)       |
| Grade3AE                              | 150 (96.2)        | 124 (80.5)       |
| >Grade 3 IDL/PI-Related AE            | 122 (78.2)        | 59 (38.3)        |
| Grade 3 Rituximab-Related AE          | 93 (59.6)         | 68 (44.2)        |
| Grade 3 Bendamustine-Related AE       | 121 (77.6)        | 85 (55.2)        |
| Any SAE                               | 113 (72.4)        | 68 (44.2)        |
| IDL/PI-Related SAE                    | 72 (46.2)         | 30 (19.5)        |
| Rituximab-Related SAE                 | 54 (34.6)         | 34 (22.1)        |
| Bendamustine-Related SAE              | 76 (48.7)         | 32 (20.8)        |
| AE Leading to IDL/Pl Dose Reduction   | 16 (10.3)         | 14 (9.1)         |
| AE Leading to IDL/Pl Dose Intemuption | 115 (73.7)        | 68 (44.2)        |
| AE LeadingtoIDL/PlDiscontinuation     | 60 (38.5)         | 12 (7.8)         |
| AE Leading to Death                   | 12 (7.7)          | 3 (1.9)          |

AE = adverse event, BR = bendamnstine + rituximab; IDL = idelalisib; Pl = placebo; SAE = serious adverse event ean a o prep arn sdisoean msm g s rou q puap s np ps on droa The Safety Analysis Set included all subjects who receive &gt; 1 dose of study treatment, with treatment group designated according to the actual treatment received.

Comment:TheinvestigatorsbetterdifferentiatesIDLfromPlwhenitcomestohighergrade AE/SAE/discontinuations.Thisexpectedforsomeoftheevents,suchascolitis andtransaminitis.

<div style=\"page-break-after: always\"></div>

AdverseEventswith≥4%DifferenceintheIDL+BRGroupwhenComparedtothePlacebo +BR Group by MedDRA PT (Safety Analysis Set)

| Preferred Term,n (%)                                                       | IDL+BR (N =156)   | Placebo +BR (N =154)   | Difference (%)   |
|----------------------------------------------------------------------------|-------------------|------------------------|------------------|
| Number (%) of Subjects with Any AE with > 2% Difference between Two Groups | 156 (100.0)       | 151 (98.1)             |                  |
| Pyrexia                                                                    | 87 (55.8)         | 52 (33.8)              | 22.0             |
| Rash                                                                       | 64 (41.0)         | 34 (22.1)              | 18.9             |
| ALT Increased                                                              | 23 (14.7)         | 3 (1.9)                | 12.8             |
| Hypokalaemia                                                               | 25 (16.0)         | 5 (3.2)                | 12.8             |
| Dianhoea                                                                   | 66 (42.3)         | 46 (29.9)              | 12.4             |
| Rash maculo-papular                                                        | 31 (19.9)         | 12 (7.8)               | 12.1             |
| AST increased                                                              | 20 (12.8)         | 2 (1.3)                | 11.5             |
| Febrile neutropenia                                                        | 33 (21.2)         | 16 (10.4)              | 10.8             |
| Weight decreased                                                           | 19 (12.2)         | 4 (2.6)                | 9.6              |
| Anemia                                                                     | 45 (28.8)         | 30 (19.5)              | 9.4              |
| Mucosal Inflammation                                                       | 15 (9.6)          | 1 (0.6)                | 9.0              |
| Asthenia                                                                   | 22 (14.1)         | 9 (5.8)                | 8.3              |
| Vomiting                                                                   | 37 (23.7)         | 24 (15.6)              | 8.1              |
| Dehydration                                                                | 14 (9.0)          | 3 (1.9)                | 7.0              |
| Pneumonia                                                                  | 20 (12.8)         | 9 (5.8)                | 7.0              |
| Urinary Tract Infection                                                    | 18 (11.5)         | 7 (4.5)                | 7.0              |
| Dyspnoea                                                                   | 24 (15.4)         | 13 (8.4)               | 6.9              |
| Dry Skin                                                                   | 14 (9.0)          | 4 (2.6)                | 6.4              |
| Hypophosphatemia                                                           | 9 (5.8)           | 0                      | 5.8              |
| Dry Mouth                                                                  | 11 (7.1)          | 4 (2.6)                | 4.5              |
| Sepsis                                                                     | 9 (5.8)           | 2 (1.3)                | 4.5              |
| Transaminase Increased                                                     | 7 (4.5)           |                        | 4.5              |
| Chills                                                                     | 21 (13.5)         | 14 (9.1)               | 4.4              |

Comment: There are major differences between study arms, also in summary measures such as weight decrease(12vs.3%) and dehydration(9 vs.2%).

Deaths:There were more deaths in theIDL+BR arm:12/7.7%)vs.3(1.9%),thereof infectious events 8 vs. 1.

<div style=\"page-break-after: always\"></div>

SAEsReported for≥2%ofSubjectsinEither TreatmentGroup(SafetyAnalysisSet)

| Preferred Term, n (%)               | IDL + BR (N=156)   | Placebo + BR. (N =154)   |
|-------------------------------------|--------------------|--------------------------|
| Number of Subjects (%) with any SAE | 113 (72.4)         | 68 (44.2)                |
| Febnile Neutropenia                 | 29 (18.6)          | 16 (10.4)                |
| Pyrexia                             | 26 (16.7)          | 19 (12.3)                |
| Pueumonia                           | 11 (7.1)           | 6 (3.9)                  |
| Sepsis                              | 9 (5.8)            | 2 (1.3)                  |
| Anemia                              | 8 (5.1)            | 2 (1.3)                  |
| Neutropenia                         | 7(4.5)             | 1 (0.6)                  |
| Diarhoea                            | 6 (3.8)            | 1 (0.6)                  |
| Neutropenic Sepsis                  | 5 (3.2)            | 1 (0.6)                  |
| Poeumonitis                         | 5 (3.2)            | 3 (1.9)                  |
| Tumour Lysis Syndrome               | 5 (3.2)            | 4 (2.6)                  |
| Atrial Fibrillation                 | 4 (2.6)            | 3(1.9)                   |
| Rash                                | 4 (2.6)            | 1 (0.6)                  |
| Urinary Tract Infection             | 4 (2.6)            | 1 (0.6)                  |

BRt = bandamsting + rituximab, IDL = idelalisb, PI = placsbo, SAE =serious advarse wvnt

AEs wero claifiod by PT using ModDRA venion 19.0.

ThSayAtidbjdfdytwt din to the achaal treatmgat rocaived.

Maltiple AEs wwre cotd oly mce per mject for ach SOC and PT

Comment:Infectiouseventsdominate.

s((

## Treatment-Emergent Transaminase Elevations (Safety Analysis Set)

|                                                      | IDL+BR (N =156) n (%)   | PI+BR (N =154) n (%)   |
|------------------------------------------------------|-------------------------|------------------------|
| Subjects with any Grade 3 or 4 ALT or AST Elevation  | 41 (26.3)               | 2 (1.3)                |
| Subjects with any Grade 3 or 4 ALT Elevation         | 41 (26.3)               | 2 (1.3)                |
| Subjects with any Grade 3 or 4 AST Elevation         | 26 (16.7)               | 2 (1.3)                |
| Subjects with any Grade 3 or 4 ALT and AST Elevation | 26 (16.7)               | 2 (1.3)                |
| Resolved to Grade 1 or Less                          | 39 (25.0)               | 2 (1.3)                |

ALT = alanine aminotansferase, AST = aspartate aminotransferase, BR = bendamustine + rituximab, IDL = idelalisib, Pl =placebo

The Safety Analysis Set includes allsubjects who receive ≥ 1 dose of study treatment, with treatment group designated according to the actual treatment received.

One subject in theIDL + BR group(subject and no subject in theplacebo+BR group experienced ASTor ALT&gt;3× ULN withconcurrent elevation of bilirubin&gt;2× ULN and elevated(&gt; 1.5 ULN) alkaline phosphatase.

Conclusions: A side by side comparison between studies 0123 and 0115 is warranted in order to try to understand whether\"first-line\"is a risk factor per se forIDL add-on toxicity.

Obviously patients are selected for inclusion in study 0115 based on tolerability to prior therapy. Here, however,the BR arms may serve as\"normalizer\".Due tomajordifferences in time ofexposure,data per 2 months period could provide easier to interpret data.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Final study report Study 101-08 (PAM008)

## (fromoverview2014)

APhase2SingleArmStudytoInvestigate theSafety andClinicalActivity ofidelalisib in CombinationwithRituximabinElderlyPatientswithPreviouslyUntreatedChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma(interim analysis)

A totalof5sitesintheUnitedStates(US)participatedinthisstudy

First subject screened:28-SEP-2010

Lastsubjectobservation:22-MAR-2013

## Eligibility

Patients≥65yearswithCLLorSLLBinetStageCorRaiStageIIIorIVor activeandsymptomatic diseaseandWorldHealthOrganization(WHO)performancestatusof≤2.Patientsshouldhavehadno

## Experimental/treatment

weeks and rituximab 375 mg/m2 intravenously weekly for 8 doses (Cycles 1 and 2). Subjects completingProtocol101-08withaclinicalresponsefollowing48weeksofidelalisibtreatmentwere eligibletocontinue thetreatmentunderalong-termextensionprotocol(101-99).

Primaryendpoint:ORR.Aresultof70%ORRwiththeadditionofidelalisibtorituximabwas considered tobeclinicallymeaningfulfor thisstudy.

The mean and median age was about 71-72yearswith a rangefrom65to 90.Altogether 1/3 patients

Of high-riskcriteria,unmutatedIGHVwaspresentina majority(58%）of the subjects,whereas only 14 % were positive for TP53 Mutation/del(17p).

Results Table1:OverallResponseRate(ITTAnalysisSet)

|                       | IDELA+Rituximab (N=64) (9)   | IDELA+Rituximab (N=64) (9)   | IDELA+Rituximab (N=64) (9)   | IDELA+Rituximab (N=64) (9)   | IDELA+Rituximab (N=64) (9)   |
|-----------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                       | Total                        | 17p-/TP53 Mutation           | 17p-/TP53 Mutation           | IGHVMutation                 | IGHVMutation                 |
| Best Overall Response | (N=64)                       | Either (N=9)                 | Neither (N=52)               | Mutated (N=23)               | Unmutated (N=37)             |
| Conplete Response     | 9(14.1)                      | 3 (33.3)                     | 4(7.7)                       | 5 (21.7)                     | 2(5.4)                       |
| Partial Response      | 53 (82.8)                    | 6 (66.7)                     | 46 (88.5)                    | 17 (73.9)                    | 34 (91.9)                    |
| Stable Disease        | 0                            | 0                            | 0                            | 0                            | 0                            |
| Progressive Disease   | 0                            | 0                            | 0                            | 0                            | 0                            |
| Not Evaluable         | 0                            | 0                            | 0                            | 0                            | 0                            |
|                       | 2(3.1)                       | 0                            | 2 (3.8)                      | 1(4.3)                       | 1(27)                        |
| Overall Response Rate | 62 (96.9)                    | 9(100.0)                     | 50 (96.2)                    | 22 (95.7)                    | 36(97.3)                     |
| 95%CT                 | 89.2-99.6                    | 66.4-100                     | 86.8-99.5                    | 78.1-99.9                    | 85.8-99.9                    |

Theoverallresponserateof97%isveryhighandincludedinthisfirst-lineelderlypopulationCRin about 14%.No subjects had a relapse while on the study.

assessmentwas\"notdone\"had withdrawnfrom the study due todose limiting toxicity(Grade3rash,

<div style=\"page-break-after: always\"></div>

elevated ALT and AST and Grade3rash,respectively).The CRrate of 14%indicates thatBMbiopsies showedremainingtumourinfiltration.Afteramedianfollow-upof14+months,PFSdata are immature,butthere arenoevents ofPD.

## Update

- Primary Endpoint)

The results of the second of two cohorts (IDL alone) are now reported. Results in the IDL + rituximab cohortwerereportedabove. In Cohort 2, eligible subjects received IDL 150 mg orally twice daily on Days 1 through 28 of each 28accordingtomodifiedstandardcriteria. deaths and serious adverse events (SAEs), generally due to infections, in a pooled analysis conducted US-312-0123, GS-US-313-0124, and GS-US-313-0125) evaluating the addition of IDL to standard therapies infirst-line CLL or early-line relapsed indolent non-Hodgkin lymphoma(iNHL).Subsequently, a decision was made to terminate all ongoing studies treating first-line CLL and early-line iNHL populations,whichincludedCohort2ofStudy101-08. with17pdeletionand/orTP53mutation.TheKMestimateof medianDORwas22.5monthsand medianPFSwas26.2months. Safety: The most common AEs were diarrhoea (28 subjects, 68.3%); nausea, pyrexia, and rash (14 subjects,34.1%,each);and fatigue (13 subjects,31.7%). ThemostcommonAEs of≥Grade 3severitywerediarrhoea(11subjects,26.8%),ALTincreased(9 subjects,22.0%),and AST increased (7 subjects,17.1%). Altogether8subjects（19.5%)had≥Grade3infections.Themedian timetoonsetof thefirst≥ Grade 3 infection was 24.8 weeks (range: 4.9 to 35.7 weeks). Three subjects permanently subject; this event led to the subject's death). No subject had a ≥ Grade 3 AE of febrile neutropenia during the study. Fifteensubjects(36.6%)had≥Grade3AEsof diarrhea/colitis(14subjectswithGrade3and 1subject withGrade 4events).The median time toonset of thefirst≥ Grade3event of diarrhoea/colitis(n= 15) was 33.4 weeks (range: 6.1 to 92 weeks), and the median time to resolution of any ≥ Grade 3 diarrhea/colitis (n = 14) was 1.5 weeks (range: 0.9 to 9.0 weeks). Nine subjects (22.0%) permanently discontinuedIDLdueto≥Grade3diarrheaorcolitis. Conclusions: Also monotherapy may seem rather poorly tolerated in elderly treatment naive CLL

patientsnotassumed to toleratechemotherapy(22%discontinued due to diarrhea/colitis).This,

PAMoo8isfulfilled.

<div style=\"page-break-after: always\"></div>

## 2.3.3. C.1.6.Extension of Indication pivotal Study GS-US-312-0115

## 2.3.3.1.Introduction

## 2.3.3.2.Pharmacokinetics

## Population-PKGS-US-312-0115

based on data from 10 clinical trials (101-01, 101-02,101-04, 101-05,101-06, 101-07,101-08, 10109, 101-11, and 339-0101). The final model structure was a 2-compartment model with a first-order absorptionrate constant and absorptionlag time.A popPK modelfor metaboliteGS-563117based on 6 studie (101-02, 101-05, 101-08, 101-09, 101-11, and 339-0101) has also been developed.

AnexternalvalidationusingPKdatafromphase3studyGS-US-312-0115and thefinalpopPKmodel foridelalisibandGS-563117wasconductedTheplasmaconcentration datafor207CLLpatientsin studyGS-US-312-0115(Idelalisib150mgBIDincombinationwithBR)weremeasuredusingthesame assay as was used for the studies in the model development dataset.The targetpopulation comprises adults with previously treated CLL who have measurable lymphadenopathy,require treatment for CLL, and randomized in a 1:1 ratio to receive either idelalisib/bendamustine/rituximab combination therapy (ArmA)orbendamustine/rituximabcombination therapy(ArmB).

PredictedidelalisibandGS-563117plasmaconcentrationsforvalidationpatientswereobtainedby fixing the parameters in the structural and variance model to the parameter estimates in the final model.ThepredictedIDELA/GS-563117concentrations（PRED)werecomparedwiththe corresponding observed IDELA/GS-563117 concentrations (DV) as well as the individual weighted residuals(IWRES)orCWRESversusPREDortime.

<div style=\"page-break-after: always\"></div>

## Thegeneralgoodness-of-fitplotsfor theIDELAexternalvalidation patients

<!-- image -->

Left:Individual predicted (IPRED)plasma IDELA concentrations versus observed IDELA concentrations (upper) and population predicted (PRED) plasma IDELA concentrations versus observed plasma IDELA concentrations (lower).Middle:individual IWRES versus PRED (upper) and CWRES versus PRED (lower). Points are individual data.Red solid lines represent the unit diagonal (left) or line at zero (middle and right). Blue dashed lines represent |CWRES| of 6.

Thepreviouslydevelopedmodelwasusedtocreateapredictioncorrectedvisualpredictivecheck (pcVpC)usingtheparameterestimatesfromthepreviousmodeltoshowthetimecourseofthe predictedmeanandspreadofconcentrations(5thto95thpercentile)versusthenewobserveddata.

<div style=\"page-break-after: always\"></div>

## Figure 1.

Prediction-correctedVPCofIDELAplasinaconcentrationversus time-after-previous-doseforvalidationpatients

<!-- image -->

Points are the observed plasma IDELA concentrations, solid red lines represent the median observed value, and dashed lines represent 5th percentile and 95th percentiles of the observed values.Blue shaded areas represent the spread of the median predicted values (5th to 95th percentile), and red shaded areas represent the spread (5th percentile and 95th percentile) of the 5and 95th predictedpercentile concentrations.

TheMAHconcludedthatagoodagreementbetweenthepredictedconcentrationsandtheobserved concentrationswasobservedintheGOFplotsandnobiaswasobservedovertimeandacross predicted concentrations.Further,theMAHdeterminedthatthepcVPCplotsshow thatthemodel adequatelydescribesthecentraltendencyandthespreadoftheobservedPKconcentrations.

The impact of type of cancer/background treatment, age, gender, race, body weight, baseline CLcr, aspartate aminotransferase(AST),and alanine aminotransferase(ALT)weretested.The MAH concludedthatnoneoftheintrinsicfactorsevaluatedaffectedidelalisibexposures,consistentwith previous data.

Table 2.showsparameter estimatesfor CL/F,Q/F,Vc/F andVp/F tobe compared withpreviously reported in subjects with hematologic malignancies of 14.9 L/h, 11.8 L/h, 22.7 L, and 73.0 L for idelalisib, and 4.39 L/h,1.28 L/h, 7.54 L, and 16.1 L for GS-563117 (for CL/F, Q/F,Vc/F and Vp/F respectively).Table3.showsidelalisibexposuresfromstudyGS-US-312-0115(idelalisibwith backgroundtreatment)andforstudy101-02(idelalisibmonotheraphy).

<div style=\"page-break-after: always\"></div>

Table 2. IDLandGS-563117PopulationPKParametersin

## Study GS-US-312-0115

|                                                  | Parameter Estimates Median (s 9sPercentile)   |
|--------------------------------------------------|-----------------------------------------------|
| IDL                                              | Study GS-US-312-0115 (N=207)                  |
| Apparent Oral Clearance,CLF (L/hr)               | 14.3 (8.50~23.4)                              |
| Apparent Inter-Comparmental Clearance,Q/F (L/r)  | 11.6 (8.70-14.3)                              |
| Apparent Central Volume,V/F (L)                  | 19.4 (12.5-83.9)                              |
| Apparent Peripheral Volume.V/F (L)               | 70.3 (40.3 -108.3)                            |
| GS-563117                                        |                                               |
| Apparent Oral Clearance,CL/F (L/hr)              | 3.99 (1.91-10.2)                              |
| Apparent Inter-Compartmental Clearance,Q/F(L/hr) | 1.28 (1.23 -1.32)                             |
| Apparent Central Volume,V/F (L)                  | 7.51 (4.77 -13.1)                             |
| ApparentPeripheral Volume,V/F (L)                | 16.1 (15.5 -16.6)                             |

Source:QP2016-1001

Table 3. IDLExposuresin CombinationwithBackgroundTreatnentversus Monotherapy AcrossDiseaseIndication (PKAnalysisSets)

| IDL PK, Mean (%CV)   | IDL+BR (Study GS-US-312-015;R/R CLL) (N = 207)   | IDL Monotherapy*(101-02; CLL/NHL) (N = 61)   |
|----------------------|--------------------------------------------------|----------------------------------------------|
| AUCa (ngh/mL)        | 10,811.7 (33.5)                                  | 10,598.1 (40.8)                              |
| Cmax (ng/mL)         | 1959.7 (31.4)                                    | 1861.4 (43.3)                                |
| Cu(ng/mL)            | 372.8 (60.9)                                     | 381.3 (57.9)                                 |

The PK analysis set included subjects in the Safety Analysis Set who bad baseline and on-study measurements to provide interpretable results, with treatment group designated according to the actual treatment received

b AUCua represents half the AUCo.s Values shown in the source table.

Subjects in Study 101-02 with CLL, non-Hodgkin lymphoma, acute myeloid leukemia, or mnltiple myeloma who received IDL 150 mg twice daily monotherapy are inclnded.

## Comment

ThepreviouslydevelopedmodelwasusedforexternalvalidationofnewdatafromstudyGS-US-3120115.This approach is reasonable to indicate thatPKis similar toprevious studies.However, the data shouldalsohavebeenpooledwithpreviousdataandthemodelshouldhavebeenupdatedand covariate analysisandconcomitantmedicationshouldhavebeentestedasacovariate.From the popPK report, this does not appear to have been conducted but in the clinical summary, updated parameters such as CL/F can be found.Further,PK in the two different study arms, idelalisib/bendamustine/rituximabcombinationtherapy(ArmA)orbendamustine/rituximab combinationtherapy(ArmB),shouldhavebeencompared.

ThetableshowingnewparameterswasfoundintheclinicalsummaryreportandpopPKmodeling The results do indicate similar PK also for CLL patients. However it is again not clear if there may be a differencebetweenarmA and armB.

<div style=\"page-break-after: always\"></div>

Itisnotagreedthatnobiaswasobservedovertimeandacrosspredictedconcentrations,there appearstobeacleartrend inPREDvs.DVplotand trendscanbeseenalsointheVPC.

GS-US-312-0123(IDELA +bendamustine/rituximab inuntreated CLL),GS-US-313-0124(IDELA + rituximabinrelapsed/refractoryiNHL),and GS-US-313-0125(IDELA+bendamustine/rituximab in relapsed/refractory iNHL).As before, the previously developed model was used.Predicted idelalisib and structuralandvariancemodeltotheparameterestimatesinthefinalmodel.Thepreviouslydeveloped modelwasused tocreateapredictioncorrectedvisualpredictivecheck.

## Comment

does not represent the patient population in this procedure (previously treated CLL patients) and thereforthevalueofthePKinformationfrom312-0123and313-0124and313-0125islimitedforthis procedure.

dataset and popPK model should have been updated and some clear model misspecification can be seenintheVPCs.

AUC,CmaxandCtauwerepresentedforthe3differentstudiesusingindividualmodelparameters.The VPCs and the calculated AuC,Cmax and Ctau indicate thatPK appears to be fairly similar between the 3studies.

## Drug drug interaction

## DDIforthenewproposedcombination

ThereisalackofdiscussionaboutpotentialDDIbetweenidelalisib/bendamustine/rituximabbythe MAH.TheidelalisibandrituximabcombinationisalreadyapprovedbutbendamustinepotentialforDDI withidelalisibshouldbediscussedbytheMAH.

## Comment

In the GS-US-312-0115study,2armswere studied,one withidelalisib/bendamustine/rituximaband theotherwithidelalisib/rituximab.Thus,ageneraldiscussiononpotentialDDI ofBendamustinewith idelalisib or rituximab,supported by apresentationof thepharmacokinetics(PK)from the 2 different armsisdesiredandshouldbeprovidedbytheMAH.

## Cyp3A4substrates

GS-563117, the primary oxidative metabolite of IDL, is a strong time-dependent CYP3A inhibitor. Coadministration ofIDL,150mg twice daily,increased the exposure toa single,5mg,oral dose of midazolam (Cmax increased 2.4-fold and AUC increased 5.4-fold). The MAH proposes to change the languageinSection7.2to:\"Avoidcoadministrationof Zydeligwithsensitiveornarrow therapeutic index CYP3A substrates (e.g., pimozide, quinidine, ergotamine, dihydroergotamine, quetiapine, significanttherapeuticneedfortheuseofco-medicationsandisconsistentwiththeoriginalFDA Clinical Pharmacology divisionreview comments.

<div style=\"page-break-after: always\"></div>

Comment

Acceptablefromaclinicalperspective.

## 2.3.3.3.PK/PDmodelling

NofullPK/PDmodellingreportcanbefound,onlyareportwithPK/PDtables/figureswhichcannotbe fully assessed due to lack of information on how they were produced. In the clinical summary, conductedusingexposuresderivedfrom thepopPKmodel.Theefficacymetricsusedtoevaluate the diameters[SPD]ofindexlesions),bestoverall response(BOR),duration ofresponse(DOR),PFS,and discussed indetailin.StudiesGS-US-312-0123(IDL+BRinuntreated CLL),GS-US-313-0124(IDL+ R inrelapsed/refractoryiNHL),and GS-US-313-0125(IDL + BRinrelapsed/refractory iNHL)were relationshipbetweenidelalisibexposureandvariousefficacyendpoints,indicatingthatidelalisib150 mgtwiceincombinationwithBRproducedrobustandconsistenttherapeuticeffectsinsubjectswith consistentwith theresultsfromexposure-efficacyanalysesreportedpreviouslyforsubjectswithCLL and iNHL.

SafetyparametersthatwereassessedincludedlaboratoryabnormalitiesofASTandALTandallGrade ≥3AEs,including colitis,diarrhea,infection,neutropenia,pneumonia,pneumonitis,and skinrashfor Study GS-US-312-0115(tablev),and infection and neutropenia forStudies GS-US-312-0123,GS-US313-0124,andGS-US-313-0125.

Study GS-US-312-0115:GS-563117Exposuresfor SubjectsReceiving IDL150mgTwice Daily in CombinationwithBRwithGrade3or4AdverseEvents

| Mean (%CV)         | Any AE Grade≥3   | Any AE Grade≥3   | Neutropenia Grade≥3   | Neutropenia Grade≥3   | Diarrhea Grade≥3   | Diarrhea Grade≥3   | Rash Grade≥3   | Rash Grade≥3          | Infection Grade≥3   | Infection Grade≥3   | Pneumonia Grade≥3   | Pneumonia Grade≥3   | Colitis Grade ≥3   | Colitis Grade ≥3   | Diarrhea/Colitis Grade≥3   | Diarrhea/Colitis Grade≥3   | Pneumonitis Grade≥3    | Pneumonitis Grade≥3   |
|--------------------|------------------|------------------|-----------------------|-----------------------|--------------------|--------------------|----------------|-----------------------|---------------------|---------------------|---------------------|---------------------|--------------------|--------------------|----------------------------|----------------------------|------------------------|-----------------------|
| Mean (%CV)         | Yes              | No               | Yes                   | No                    | Yes                | No                 |                | No                    | Yes                 | No                  | Yes                 | No                  | Yes                | No                 | Yes                        | No                         | Yes                    | No                    |
| N                  | 194              | 13               | 151                   | 56                    | 19                 | 188                | 13             | 194                   | 80                  | 127                 | 24                  | 183                 | 2                  | 205                | 21                         | 186                        | 3                      | 204                   |
| Cmx (ng/mL)        | 4076.9 (46.1)    | 3656.4 (41.7)    | 4051.5 (48.2)         | 4047.7 (39.2)         | 4208.3 (53.8)      | 4034.5 (45.1)      | 4163.0 (43.8)  | 4042.9 (46.1)         | 4533.2 (46.7)       | 3746.4 (43.0)       | 5083.0 (44.6)       | 3915.1 (45.0)       | 2458.5 (36.0)      | 4066.0 (45.7)      | 4041.7 (54.9)              | 4051.5 (44.9)              | 5926.1 (22.9)          | 4022.9 (46.1)         |
| AUC0.24a (ngoh/mL) | 82023.2 (50.1)   | 71384.18 (42.9)  | 81725.4 (52.3)        | 80356.5 (42.5)        | 82157.1 (62.6)     | 81274.0 (48.6)     | (44.1)         | 84998.081110.9 (50.3) | 91443.6 (51.3)      | 75000.1 (46.3)      | 101914.3 (48.3)     | 78658.84 (49.1)     | 49808.4 (31.6)     | 81662.8 (49.7)     | 79076.28 (63.1)            | 81612.3 (48.4)             | 119360.880796.1 (21.8) | (50.1)                |

AnincreaseintheincidenceofGrade3or4AEofinfectionswasobservedwithhigherIDLexposures whenadministeredincombinationwithBR.Similarresultswereobservedfor≥Grade3infections versussteady-stateAUc0-24h.Themediandailydosewasidenticalbetweensubjectswithandwithout ≥Grade3infections.

## Comment

FullassessmentofPK/PDmodelingwasnotpossibleduetolackofaPK/PDmodelingreport.The

AnincreaseintheincidenceofGrade3or4AEsofinfectionswithhigheridelalisibexposureswas observedacrossstudies.SimilarresultswereobservedforGrade≥3infectionsversussteady-state AUC0-24h.

<div style=\"page-break-after: always\"></div>

## 2.3.3.4.Conclusionsonclinicalpharmacology

The following measures are considered necessary to address issues related to clinical pharmacology:

- ·Adiscussiononpotential DDIofBendamustinewithidelalisiband rituximab,supportedby a presentation of the pharmacokinetics from the 2 different arms in study GS-US-312-0115 shouldbeprovidedbytheMAH.

## 2.3.3.5.Clinical efficacy

## Main study

StudyGs-us-312-0115ispivotalforthissubmissionandwasdiscussedinthearticle20procedure includingsurvival data(notpartofthepublication\"IdelalisibPlusBendamustine and Rituximab(BR)Is Phase3RandomizedDouble-BlindPlacebo-ControlledStudy,Zelenetzetal.Blood 2015).Atthattime availabledatawereconsideredtobecompatiblewithanacceptablerisk.

- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and SafetyofIdelalisib(GS-1io1)inCombinationwithBendamustineandRituximabforPreviously TreatedChronicLymphocyticLeukemia.

Subjectswere enrolled attotalof 110sitesinthefollowingcountries:Australia,Belgium,Canada, Croatia, Czech Republic, France, Greece, Hungary, Ireland, Italy, New Zealand, Poland, Portugal, Romania, Russia, Spain, Turkey, United Kingdom, and United States.

StudyPeriod:15June2012(FirstSubjectScreened)

02 May 2016 (Last Subject Observation for Follow-Up Assessments of Safety and Overall Survival [os])

## Methods

Randomisation:1:1,fixed-blockcentralizedrandomization

Stratification: 17p deletion and/or TP53 mutation in CLL cells (either versus neither[or indeterminate]),

Immunoglobulin heavy chain variable region (IGHV) mutation (unmutated [or IGHV3-21] versus mutated [or indeterminate])

## Treatments

Rituximab: 375 mg/m2 intravenously onDay 1 in the first cycle and 500 mg/m2 intravenously on Day

Bendamustine:70mg/m2/infusion;bendamustinewasgivenonDays1 and2of eachof the6planned cycles.

Bendamustine and rituximab were administered until the earliest of subject withdrawal from study, definitive progression of CLL, intolerable bendamustine- or rituximabrelated toxicity, pregnancy, substantialnoncompliancewithstudyprocedures,studydiscontinuation,oramaximumof6cycles.

<div style=\"page-break-after: always\"></div>

continuouslyuntiltheearliestofsubjectwithdrawalfromstudy,definitiveprogressionofCLL, discontinuation,evenifbendamustineand/orrituximabwerediscontinued.The150-mgdosewasused reduction.

According to licensed dosages.

## StudyProcedures

Clinic/laboratoryvisits:every2weeksthroughWeek24andevery6weeksbetweenWeeks24and48, past Week 48 every 12 weeks. Subjects were assessed for safety at each clinic visit.

SubjectswereassessedforCLLdiseasestatusbyphysicalandlaboratoryexaminationsateachclinic visit and by computed tomography (CT) or magnetic resonance imaging (MRI) at Weeks 12, 24, 36,

## Maineligibilitycriteria

- DiagnosisofB-cell CLL,IWCLL criteria.
- CLL that warrants treatment (IWCLL)
- Measurable lymphadenopathy (defined as the presence of ≥ 1 nodal lesion that measures ≥ as assessedby CT orMRI)
- Prior treatmentfor CLL comprising:

orbendamustine，and ofatumumab,obinutuzumab)

- Documentation of CLL progression &lt; 36 months since the completion of the last prior therapy for CLL
- Discontinuation of all therapy (including radiotherapy, chemotherapy, immunotherapy, or
- All acute toxic effects of any prior antitumor therapy resolved to Grade≤ 1 before randomization (with the exception of alopecia [Grade 1 or 2 permitted], neurotoxicity [Grade 1
- ·Karnofskyperformance status(KPS) score of≥ 60

## Outcomes/endpoints

## Primary Endpoint:

PFSbyIRC-definedastheintervalfromrandomizationtotheearlierofthefirstdocumentationof definitivediseaseprogressionor deathfromanycause;definitive diseaseprogressionis CLL progressionbasedonstandardcriteriaotherthanlymphocytosisalone.

<div style=\"page-break-after: always\"></div>

## SecondaryEndpoints:

By IRC:Overallresponse rate (ORR),lymph node response(LNR)rate, OS,and completeresponse

(CR)rate (type 1 control).

ForaCR,allofthefollowingcriteriaweretobemet:

- No evidence of new disease
- ALC in peripheral blood of &lt; 4 x 109/L
- ? Regressionof all indexnodal masses tonormalsize≤ 1.5cm inthe LD
- Normalspleenandliversize
- Regressiontonormalofallnodalnon-indexdiseaseanddisappearanceofalldetectablenonnodal, non-index diseas.e
- Morphologically negativebone marrow defined as&lt;30%of nucleated cells being lymphoid
- Peripheral blood counts meeting all of the following criteria: ANC&gt; 1.5x 109/L without need forexogenousgrowthfactors.ANCvalueswithin4weekspostbaseline,within2weeks after from theneutrophilresponserateevaluation.

Plateletcount≥100x109/L withoutneedforexogenousgrowthfactors.Plateletvalueswithin 4weekspostbaselineorwithin8daysafteratransfusionwereexcludedfromtheplatelet response rate evaluation.

Hemoglobin ≥ 110 g/L (11.0 g/dL) without red blood cell transfusions or need for exogenous growth factors. Hemoglobin values within 4 weeks postbaseline, within 4 weeks of receiving packed cell/whole blood transfusion or within 6 weeks receiving exogenous growth factors (eg,

## \"PatientWell-Being\"

OS, change from baseline in HRQL domain and symptom scores based on FACT-Leu questionnaire, Changes from baseline in KPS (no type 1 error controil).

## Long-term, follow-up

Follow-upforsurvivalwasconducted atapproximately6-monthintervalsfor5years,startingatthe end-of-studyvisit.Informationgatheredincludedmedical status,antitumortreatments,secondary malignancies,andsurvival.

## Statistical methods

Pleasereferto thereporting of endpoints.

Amendments:Therewere altogether9protocolamendments,December2012-October2016. The study was opened was cross-over (a. 6, Dec 2015) but the possibility was removed in March 2016 due to safety concerns (article 20). Other amendments focused on updates on PK and DDI, safety clarifications.In no case these changes threatened the integrity of the trial.

<div style=\"page-break-after: always\"></div>

Comment: The study is viewed as a standard-designed, add-on trial with proper background therapy for the line of therapy. Outcome measures are standard, but it is noticed that OS was not selected as a secondary endpoint (no protected alpha). This will not affect the reporting of OS data in the SPC, whilstHRQoL(no alphaprotection)arenotaccepted forinclusionintheSPC.

## Results

## Disposition of Subjects with Respect to continuation on Study based on Data through 02 May 2016 (ITT)

|                                             | IDL+BR (N =207)   | P1+BR (60t=N）   | Total (N =416)   |
|---------------------------------------------|-------------------|-----------------|------------------|
| Subjeet Disposition                         | n (%)             | n (%)           | n (%)            |
| Randomized                                  | 207 (100)         | 209 (100)       | 416 (100)        |
| Randomized but NotTreated With Any Drug     | 0                 | 0               | 0                |
| Randomized but Not Treated With IDL/Placebo | 0                 | 1 (0.5)         | 1 (0.2)          |
| Treated with Any Drug                       | 207 (100)         | 209 (100)       | 416 (100)        |
| Ongoing in Study                            | 70 (33.8)         | 23 (11.0)       | 93 (22.4)        |
| Met Prinary Study Endpoint                  | 73 (35.3)         | 142 (67.9)      | 215 (51.7)       |
| Disease Progression                         | 57 (27.5)         | 127 (60.8)      | 184 (44.2)       |
| Death                                       | 16 (7.7)          | 15 (7.2)        | 31 (7.5)         |
| Discontinued Study                          | 64 (30.9)         | 44 (21.1)       | 108 (26.0)       |
| Adverse Event                               | 27 (13.0)         | 13 (6.2)        | 40 (9.6)         |
| Withdrawal by Subject                       | 20 (9.7)          | 8 (3.8)         | 28 (6.7)         |
| Physician Decision                          | 7 (3.4)           | 19 (9.1)        | 26 (6.3)         |
| Other                                       | 4 (1.9)           | 3 (1.4)         | 7 (1.7)          |
| Noncompliance with Study Dnug               | 3 (1.4)           | 0               | 3 (0.7)          |
| Other Anticancer/Experimental Therapy       | 2 (1.0)           | 1 (0.5)         | 3 (0.7)          |
| Lost to Follow-Up                           | 1 (0.5)           | 0               | 1 (0.2)          |

BR =bendamustine+nituximab,IDL=idelalisib,Pl =placebo

b Any drug refers to any protocol-specified dirug, ie, bendamustine, rituximab, IDL, or placebo

a Reason for discontimuation as determined by the investigator

Comment: There were more patients continuing on study in the experimental arm (34% vs. 11%). Reasonsfor discontinuing study showed cleardifferences,forexample,forPFS35%vs.68%.

## Conductofthe study

The most frequently reported important protocol deviation was not\\_re-consenting the subject with a revised ICF at the first opportunity (33.3% of subjects in the IDL + BR group and 26.3% of subjects in the placebo+ BR group).

<div style=\"page-break-after: always\"></div>

## ImportantProtocolDeviations(ITT)

| Protocol Deviation,n (%)                                         | IDL+BR (N=207)   | PI+BR （607=N)   | Total (N = 416)   |
|------------------------------------------------------------------|------------------|-----------------|-------------------|
| Number of Subjects with at Least 1 Important. Protocol Deviation | 109 (52.7)       | 89 (42.6)       | 198 (47.6)        |
| Number ofSubjects per SpecificDeviation                          |                  |                 |                   |
| Informed Consent Form                                            | 69 (33.3)        | 55 (26.3)       | 124 (29.8)        |
| Other                                                            | 37 (17.9)        | 33 (15.8)       | 70 (9.6)          |
| Eligibility Criteria                                             | 7 (3.4)          | 9 (4.3)         | 16 (3.8)          |
| Other Treatment Compliance Issue                                 | 9 (4.3)          | 5 (2.4)         | 14 (3.4)          |
| Treatment/Dosing Compliance                                      | 7 (3.4)          | 7 (3.3)         | 14 (3.4)          |
| Excluded ConcomitantMedicationReceived                           | 2 (1.0)          | 2 (1.0)         | 4 (1.0)           |

Comment:Note thatre-consentingwasrequired inrelationto the article20events.

## Baseline data

Demographics: About 3/4 of the patients were male, around 90% Caucasians, median=mean age about63years,KPS&lt;70 in about 10%,90 and above in about60%.

## CLL Disease History (ITT)

| Disease Characteristic         | IDL+BR (N=207)   | P1+BR (N=209)   | Total (N=416)   |
|--------------------------------|------------------|-----------------|-----------------|
| Time Since Diagnosis (years)a  |                  |                 |                 |
| N                              | 207              | 208             | 415             |
| Mean (StD)                     | 7.3 (4.50)       | 7.0 (4.27)      | 7.2 (4.38)      |
| Median                         | 6.2              | 6.3             | 6.2             |
| Rai Stage at Screening, n (%)  |                  |                 |                 |
| 0                              | 1 (0.5)          | 5 (2.4)         | 6 (1.4)         |
| I                              | 42 (20.3)        | 41 (19.6)       | 83 (20.0)       |
| ⅡI                             | 63 (30.4)        | 69 (33.0)       | 132 (31.7)      |
| III                            | 17 (8.2)         | 17 (8.1)        | 34 (8.2)        |
| IV                             | 82 (39.6)        | 70 (33.5)       | 152 (36.5)      |
| Not Available                  | 2 (1.0)          | 7 (3.3)         | 9 (2.2)         |
| Binet Stage at Screening,n (%) |                  |                 |                 |
| A                              | 18 (8.7)         | 26 (12.4)       | 44 (10.6)       |
| B                              | 87 (42.0)        | 89 (42.6)       | 176 (42.3)      |
| C                              | 98 (47.3)        | 89 (42.6)       | 187 (45.0)      |
| Not Available                  | 4 (1.9)          | 5 (2.4)         | 9 (2.2)         |

study background therapy.

<div style=\"page-break-after: always\"></div>

## SubjectDistributionbyStratificationFactors(ITT)

|                                          | IDL+BR (N =207)   | P1+BR (N=209)   | Total (N=416)   |
|------------------------------------------|-------------------|-----------------|-----------------|
| 17p Deletion and/or TP53 Mutation Status |                   |                 |                 |
| 17p Deletion and/or TP53 Mutation        | 69 (33.3)         | 68 (32.5)       | 137 (32.9)      |
| Neither 17p Deletion nor TP53 Mutation   | 138 (66.7)        | 141 (67.5)      | 279 (67.1)      |
| IGHV Mutation Status                     |                   |                 |                 |
| Mutated                                  | 34 (16.4)         | 36 (17.2)       | 70 (16.8)       |
| Unmutated                                | 173 (83.6)        | 173 (82.8)      | 346 (83.2)      |
| Disease Status                           |                   |                 |                 |
| Refractory                               | 70 (33.8)         | 68 (32.5)       | 138 (33.2)      |
| Relapsed                                 | 137 (66.2)        | 141 (67.5)      | 278 (66.8)      |

The median (Q1, Q3) number of prior CLL regimens was 2.0 (1.0, 4.0) with a range of 1 to 13 prior regimens received. The most common prior regimens were fludarabine + cyclophosphamide + rituximab (66.8%; 278 subjects), fludarabine + cyclophosphamide (22.4%; 93 subjects), single-agent chlorambucil (18.0%; 75 subjects), and bendamustine + rituximab (11.3%, 47 subjects).

The median (Q1, Q3) time since last prior regimen was 18.1 (4.8, 26.9) months for subjects in the IDL +BR group and 13.9 (5.9, 27.2) months for subjects in the placebo+ BR group.

<div style=\"page-break-after: always\"></div>

## Outcomesandestimation

## PrimaryEndpoint:PFSbyIRCAssessment,07October2015(ITT)

|                                      | IDL+BR (N=207)    | P1+BR (N=209)     |
|--------------------------------------|-------------------|-------------------|
| Number (%) ofSubjects with Events    | 84 (40.6)         | 149 (71.3)        |
| Disease Progression                  | 60 (29.0)         | 130 (62.2)        |
| Death                                | 24 (11.6)         | 19 (9.1)          |
| Number (%) of Subjects Censored      | 123 (59.4)        | 60 (28.7)         |
| Ongoing                              | 82 (39.6)         | 31 (14.8)         |
| Discontinued Study                   | 39 (18.8)         | 27 (12.9)         |
| Received Another Antitumor Treatment | 2 (1.0)           | 2 (1.0)           |
| KMEstimateofPFS(Months)              |                   |                   |
| Q1 (95% CI)                          | 11 (8.3, 13.6)    | 6.9 (5.6, 8.1)    |
| Median (95% CI)                      | 20.8 (16.6, 26.4) | 11.1 (8.9, 11.1)  |
| Q3 (95% CI)                          | 30.3 (26.4, NR)   | 16.1 (14.0, 19.3) |
| KM of PFS Rate [95% CI]              |                   |                   |
| At 24 weeks                          | 88.5 (83.0, 92.3) | 82.1 (76.0, 86.7) |
| At 48 weeks                          | 75.0 (68.0, 80.6) | 50.5 (43.2, 57.5) |
| Adjusted HR (95% CIb                 | 0.33 (0.25, 0.44) | 0.33 (0.25, 0.44) |
| P-value                              | 6.540 × 10-16     | 6.540 × 10-16     |

BR=bencamstine+nituxinab,CI=confidence intervalHR=hazardratio,IDL=idelalisib,IRC=independent reviewcommittee, KM = Kaplan-Meier, NR = not reached, PFS = progression-free suurvival; P1 = placebo, Q1 = first quartile, Q3 = third quartile,

b HR and95%CIs are calculated using the Cox proportional hazards model adjusted for randomization stratification factors in EDC (1 7p deletion/TP53 mutation, IGHV mutation status,and disease status).

a PFS (months)=(minimmm [date ofPD,date of death]-date ofrandomization +1)/30.4375.

C

P-value is from stratified log-rank test, adjusted for randomization stratification factors.

Comment:Witheventratesof70%and40%andtheobserveddifferences,theeventcurvesarelikely tobestableand theresultsareconsideredconvincing.NotethatBRisadministeredfor6fourweek cycles, while IDL is administered until PD or unacceptable toxicity.

DuetothemagnitudeofthetreatmenteffectinvestigatorassessedPFSwillnotberequested.

<div style=\"page-break-after: always\"></div>

## ForestplotPFS

<!-- image -->

Comment:Therearenoconspicuousfindings.

<div style=\"page-break-after: always\"></div>

## Secondaryandexploratoryendpoints

## ORR by IRC Assessment(ITT)

|                                                         | IDL+BR (N = 207)   | P1+BR (60=N)   |
|---------------------------------------------------------|--------------------|----------------|
| Best Overall Response, n (%)                            |                    |                |
| Complete Response (CR)                                  | 3 (1.4)            | 0              |
| Complete Response with Incomplete Marrow Recovery (CRi) | 0                  | 1 (0.5)        |
| Partial Response (PR)                                   | 142 (68.6)         | 93 (44.5)      |
| Stable Disease (SD)                                     | 47 (22.7)          | 85 (40.7)      |
| Progressive Disease (PD)                                | 1 (0.5)            | 19 (9.1)       |
| Not Evaluable (NE)                                      | 14 (6.8)           | 11 (5.3)       |
| ORRa                                                    | 145 (70.0)         | 94 (45.0)      |
| 95% CIb                                                 | 63.3,76.2          | 38.1, 52.0     |
| Odds Ratio for Overall Response                         | 3.09               | 3.09           |
| 95% CI for Odds Ratio                                   | 2.02, 4.72         | 2.02, 4.72     |
| P-value                                                 | 1.054 × 107        | 1.054 × 107    |

BR =bendamustine +rituximab,CI =confidence interval,IDL= idelalisib,IRC= Independent Review Commmittee, ORR=overall response rate,Pl=placebo

b 95% CI for ORR was based on the exact method.

a ORR was the percentage of subjects who had best overallresponse of CR, CRi, or PR

Odds ratio, 95% CI, and p-value were calculated from the CMH Chi-square test stratified by stratification factors in EDC (17p deletion/TP53 mmutation, IGHV mutation status, and disease status).

Otherwise,response status was cateorized as SD.

Subjects with CR, CRi, or PR who maintained the response for at least 12 weeks were defined to have confirmed response.

An additional 22subjects in theIDL+BRgroup and 8subjects intheplacebo+BRgrouppotentially

Time to response: Among subjects who responded, the median(Q1,Q3)TTR was 2.9 (2.8,3.3) months for both treatment groups (IDL + BR, N = 145; placebo + BR, N = 94).

## LymphNodeResponseRatebyIRCAssessment(ITT)

|                       | IDL+BR (N = 207)   | PI+BR (N=209)   |
|-----------------------|--------------------|-----------------|
| LNR Ratea             | 186/192 (96.9)     | 120/197 (60.9)  |
| 95% CI for LNR Rate   | 93.3, 98.8         | 53.7, 67.8      |
| Odds Ratio°           | 28.72              | 28.72           |
| 95% CI for Odds Ratio | 10.48, 78.72       | 10.48, 78.72    |
| P-value               | 1.681 × 10-19      | 1.681 × 10-19   |

BR =bendamstine +rituximab,CI=confidence interval,IDL =idelalisibLNR= lymph node response,Pl=placebo Analysis only inchuded subjects in the ITT analysis set who had both baseline and at least 1 evaluable postbaseline SPD.

95% CI for response rate was based on the exact method.

a LNR rate was defined as the percentage of subjects who achieved a ≥ 50% decrease from baseline in the SPD of index lymph nodes. Denominator is the mmber of subjects with baseline and at least 1 postbaseline measurement.)

Odds ratio, 95% CL, and p-value was calculated from the CMH Chi-square test stratified by stratification factors in EDC (17p deletion/TP53 mutation, IGHV mutation status,and disease status)

<div style=\"page-break-after: always\"></div>

## Splenomegalyand HepatomegalyResponse Rates(ITT)

|                            | IDL+BR (N=207)   | PI+BR (N=209)   |
|----------------------------|------------------|-----------------|
| SplenomegalyResponseRatea  | 125/148 (84.5%)  | 80/141 (56.7%)  |
| 95% CTb                    | 77.6, 89.9       | 48.1, 65.0      |
| Hepatomegaly Response Rate | 57/99 (57.6%)    | 47/109 (43.1%)  |
| I%S6                       | 47.2, 67.5       | 33.7, 53.0      |

BR = bendamstine +rituximab, CI =confidence interval,IDL =idelalisib,Pl= placebo

- measurement. Responders were subjects with a 50% decrease (minimum 2 cm) from baseline in the enlargement of the spleen in its LVD or to = 12 cm by imaging.
- Analysis only included subjects who had hepatomegaly at baseline and hadat least 1 evaluable postbaseline liver measuement.Responders were subjects with a 50% decrease (minimuun 2 cm) from baseline in the enlargement of the liver in its LVD or to 18cm by imaging
- 95% CI for the response rate was based on the exact method.

## ALC,Platelet,Hemoglobin,andANCResponseRates(ITT)

|                           | IDL+BR (N=207)   | P1+BR (N=209)   |
|---------------------------|------------------|-----------------|
| ALC Response Rate*        | 169/170 (99.4%)  | 158/165 (95.8%) |
| I%S6                      | 96.8, 100        | 91.5,98.3       |
| Platelet Response Rate    | 71/80 (88.8%)    | 49/63 (77.8%)   |
| 95% CIb                   | 79.7, 94.7       | 65.5, 87.3      |
| Hemoglobin Response Rated | 58/66 (87.9%)    | 50/71 (70.4%)   |
| I%56                      | 77.5, 94.6       | 58.4, 80.7      |
| ANC Response Ratea        | 24/28 (85.7%)    | 26/32 (81.3%)   |
| I%S6                      | 67.3, 96.0       | 63.6, 92.8      |

ALC = absolute lymphocyte cout; ANC = absolute neutrophil count; BR = bendamustine + nituximab, CI = confidence interval, IDL =idelalisib,Pl =placebo,

- b 95% CI for the response rate was based on the exact method.
- Analysis only included subjects who had lymphocytosis (ALC ≥ 4 × 10°/L) at baseline and had ALC values 28 days postbaseline.Responders were subjects who achieved on-study ALC &lt; 4 x 10°/L or ≥50% decrease inALC from baseline
- C Analysis only included subjects who had tlhrombocytopenia (platelet coumt &lt;: 100 × 10°/L) at baseline and had platelet values 28 days postbaseline. Responders were subjects who achieved on-study platelet coumt of ≥ 100 × 10/L or ≥ 50% increase in platelet couut from baseline.
- Analysis only included subjects who had neutropenia (ANC  1.5 × 10°/L) at baseline and had ANC values 28 days postbaseline. Responders were subjects who achieved on-study ANC of &gt; 1.5 × 10°/L or ≥ 50% increase in ANC from baseline.
- d Analysis only included subjects who had anemia (hemoglobin &lt; 110 g/L [11 g/dLJ at baseline and had hemoglobin values 28 days postbaseline. Responders were subjects who achieved on-study hemoglobin ≥ 110 g/L (11 g/dL) or ≥ 50% increase in hemoglobin from baseline.

<div style=\"page-break-after: always\"></div>

## WaterfallPlotofBestPercentChangefromBaselineinSPDperIRCAssessment:IDL+BR Group (ITT)

<!-- image -->

IDL +R/B(=192)

B=bendammstine,IDL = idelalisib,IRC= independent review comitte,R=rifuximab,SPD= sum of the products of greatestperpendicular diameters

## WaterfallPlotofBestPercent Change fromBaseline inSPDperIRCAssessment: Placebo+BRGroup(ITT)

<!-- image -->

Plsceba+R/B(u=197)

Comment: Irrespective of response parameter, IDL shows a major add-on effect to BR. The only exception of interestisCR,butnote that thefrequencymightbeunderestimated due tomissingbone marrowdata(22vs.8individuals).

MRDisnotmentionedintheprotocolorthestudyreport.

Note absenceofprogressionasbestresponseintheIDL+BRarm.

<div style=\"page-break-after: always\"></div>

## OverallSurvivalbasedonData through02May2016(ITT)

|                                         | IDL+BR (N=207)    | P1+BR (N = 209)   |
|-----------------------------------------|-------------------|-------------------|
| Number (%) of Subjects with Events      | 53 (25.6)         | 70 (33.5)         |
| Death                                   | 53 (25.6)         | 70 (33.5)         |
| Number (%)of Subjects Censored          | 154 (74.4)        | 139 (66.5)        |
| Discontimued Study                      | 84 (40.6)         | 116 (55.5)        |
| Ongoing                                 | 70 (33.8)         | 23 (11.0)         |
| KM Estimate of OS (Months)              |                   |                   |
| Q1 (95% CI)                             | 23.5 (16, NR)     | 15.7 (13.2, 20.3) |
| Median (95% CI)                         | NR (NR, NR)       | 40.6 (31.6, NR)   |
| Q3 (95% CI)                             | NR (NR, NR)       | NR (40.6, NR)     |
| Adjusted HR (95% CI)b                   | 0.67 (0.47, 0.96) | 0.67 (0.47, 0.96) |
| P-value from Stratified Log-Rank Test   | 3.637 × 10-2      | 3.637 × 10-2      |
| P-value from Unstratified Log-Rank Test | 5.874 × 10-2      | 5.874 × 10-2      |

BR = bendamustine +rituximab, CI = confidence interval, HR = hazard ratio, IDL = idelalisib,KM =Kaplan Meier, NR = not reached, Pl = placebo, OS = overall survival, Q1 =first quartile,Q3 = third quartile

- b Hazard ratio and 95% CI were calculated using the Cox proportional hazards model adjusted for randomization stratification factors (17p deletion/TP53 mutation, IGHV mutation status, and disease status).

a OS （months)=（date of death- date ofrandomization + 1)/30.4375

<!-- image -->

Comment:Notethat40and55%hasdiscontinmued thestudyandwerecensoredintheOSanalysis. Afterdiscontinuation,follow-upforsurvivalwasundertakenevery6months.Itisunclearifallpatients acceptedtoparticipate inthelong termOsfollow-up and if missingnessis an issue,reasonsfor censoringisthusunknownIpatientswholeftthestudy.

Dataareconsideredimmature.

<div style=\"page-break-after: always\"></div>

## ForestPlotforOverallSurvivalbasedonDatathrough02May2016(ITT)

<!-- image -->

## Ancillaryanalyses

EfficacyAnalysisby17pdeletionand/orTP53MutationStatus

This study included 137 subjects with 17p deletion and/or TP53 mutation (69 in the IDL + BR group and 68 PI+ BR),and 279 subjects with neither 17p deletion nor TP53 mutation(138 IDL + BR and 141Pl+BRgroup).Efficacyresultsforbothgroups are summarized in the tablebelow.

EfficacyResultsby17pDeletionand/orTP53MutationStatus(ITTAnalysisSet,StudyGSUS-312-0115)

<div style=\"page-break-after: always\"></div>

|                                                                      | Subjects with 17p Deletion and/or TP53 Mutation   | Subjects with 17p Deletion and/or TP53 Mutation   | SubjectswithNeither17pDeletion norTP53Mutation   | SubjectswithNeither17pDeletion norTP53Mutation   |
|----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Endpoint (Measure)                                                   | IDL+BR (N=69)                                     | PI+BR (N=68)                                      | IDL+BR (N=138)                                   | Pl+BR (N =141)                                   |
| KM estimateofPFS,median (95% CI)monthsa (data through07 Oct 2015)    | 11.3 (8.8,16.6)                                   | 8.3 (5.9, 8.5)                                    | 24.6 (19.5, 30.3)                                | 11.2 (11.1, 13.6)                                |
| PFS,unadjustedHR(95%CI)b (data through07 Oct 2015)                   | 0.47 (0.31, 0.72)                                 | 0.47 (0.31, 0.72)                                 | 0.27 (0.18, 0.39)                                | 0.27 (0.18, 0.39)                                |
| Odds ratio for Overall Response (95% CI) (data through07 Oct 2015)   | 4.67 (2.25, 9.70)                                 | 4.67 (2.25, 9.70)                                 | 2.45 (1.47,4.06)                                 | 2.45 (1.47,4.06)                                 |
| Odds ratio for LNR (95% CI) (data through07 Oct 2015)                | 31.29 (9.91, 98.82)                               | 31.29 (9.91, 98.82)                               | 22.81 (5.36, 97.01)                              | 22.81 (5.36, 97.01)                              |
| OS,Unadjusted HR(95%CI)d (data through07 Oct 2015)                   | 0.61 (0.36, 1.03)                                 | 0.61 (0.36, 1.03)                                 | 0.65 (0.36,1.18)                                 | 0.65 (0.36,1.18)                                 |
| OS,Unadjusted HR(95% CI)d (data through 02 May 2016)                 | 0.7 (0.43, 1.15)                                  | 0.7 (0.43, 1.15)                                  | 0.67 (0.4, 1.12)                                 | 0.67 (0.4, 1.12)                                 |
| KM estimate ofDOR, median (95% CI)months.f (data through07 Oct 2015) | 11.1 (10.8, NR)                                   | 10.5 (5.6, 13.7)                                  | 22.8 (20.0, 27.2)                                | 11.2 (8.6, 16.6)                                 |

BR = bendamustine + rituximab; DOR =duration of response; HR =hazard ratio; IDL =idelalisib; KM =Kaplam-Meier, LNR = lymph node response rate; NR = not reached; OS = overall survival; PFS = progression free survival b HR and 95% Cls are calculated usimg the Cox proportional hazards model without any adjustment.

PFS (months) = (mimimum [date of PD, date of death] - date of randomization + 1) / 30.4375.

C Odds ratio and 95% CI were calculated without any adjustment.

e DOR(months) =(minimum [date of PD, date of death] - date of first documented CR, CRi, or PR + 1) / 30.4375

d HR and 95% CI were calculated usimg the Cox proportional hazards model without any adjustments.

f Analysis included only subjects who achieved a CR, CRi,or PR.

Subjects with CR, CRi, or PR who maimtaimed the response for at least 12 weeks were defimed to have confirmed response. Otherwise, response status was categorized as SD.

<div style=\"page-break-after: always\"></div>

BRandn=40Pl+BR)orwithout(n=169IDL+BRandn=169Pl+BR)aresummarizedinthe following table:Efficacy Results by only 17p Deletion Status(Study GS-US-312-0115)

|                                                                       | Subjects with 17p Deletion   | Subjects with 17p Deletion   | Subjects without 17p Deletion   | Subjects without 17p Deletion   |
|-----------------------------------------------------------------------|------------------------------|------------------------------|---------------------------------|---------------------------------|
| Endpoint (Measure)                                                    | IDL+BR (N=38)                | PI+BR (N=40)                 | IDL+BR (N =169)                 | Pl+BR (N =169)                  |
| KM estimate ofPFS, median (95% CI) months² (data through07 Oct 2015)  | 11.0 (7.9, 13.3)             | 5.9 (3.4, 8.4)               | 24.6 (19.5, 30.3)               | 11.1 (10.8, 11.5)               |
| PFS,unadjusted HR(95%CI)b (data through07 Oct 2015)                   | 0.62 (0.37, 1.04)            | 0.62 (0.37, 1.04)            | 0.29 (0.21, 0.40)               | 0.29 (0.21, 0.40)               |
| Odds ratio for Overall Response (95% CI)c (data through07 Oct 2015)   | 4.74 (1.77, 12.65)           | 4.74 (1.77, 12.65)           | 2.64 (1.68,4.16)                | 2.64 (1.68,4.16)                |
| Odds ratio for LNR (95% CI) (data through07 Oct 2015)                 | 42.67 (8.44, 215.82)         | 42.67 (8.44, 215.82)         | 18.38 (6.46, 52.28)             | 18.38 (6.46, 52.28)             |
| OS, Unadjusted HR(95% CI)d (data through07 Oct 2015)                  | 0.72 (0.36,1.42)             | 0.72 (0.36,1.42)             | 0.65 (0.40, 1.06)               | 0.65 (0.40, 1.06)               |
| OS, Unadjusted HR(95% CId (data through 02 May 2016)                  | 0.79 (0.42, 1.48)            | 0.79 (0.42, 1.48)            | 0.67 (0.43, 1.04)               | 0.67 (0.43, 1.04)               |
| KM estimate ofDOR,median (95% CI) monthsf.g (data through07 Oct 2015) | 11.1 (8.0, 23.7)             | 13.6 (5.4, 15.7)             | 22.8 (20.0, NR)                 | 11.2 (8.4,16.2)                 |

BR = bendamustine + rituximab; DOR =duration of response; HR= hazard ratio;IDL =idelalisib; KM=Kaplan-Meier; LNR = lymph node response rate; NR = not reached; OS = overall survival; PFS = progression free survival

- b HR and 95% CIs are calculated using the Cox proportional hazards model without any adjustment.
- a PFS (months) = (mimimum [date of PD, date of death] - date of randomization + 1) / 30.4375.
- C Odds ratio and 95% CI were calculated without any adjustment.
- e DOR (months) = (mimimum [date of PD, date of death] - date of first documented CR, CRi, or PR + 1)/ 30.4375
- d HR and 95% CI were calculated using the Cox proportional hazards model without any adjustments.
- f Analysis included only subjects who achieved a CR, CRi, or PR.
- g Subjects with CR, CRi, or PR who maintained the response for at least 12 weeks were defimed to have confirmed response. Otherwise, response status was categorized as SD.

## Comments

TheimprovementinPFSwithIDL+BRwaslowerforpatientswith17pdeletionand/orTP53mutation (3 months)and patients with 17p deletion(5.1months),compared to the overall studypopulation(9.7 patientswithorwithout17pdeletionand/orTP53mutation.Furthermore，theapplicantisaskedto discuss theobserveddifferencesinPFSimprovementbetweenthesetwopatientgroups.

The ORR was 60.9%with IDL + BR vs.25% with placebo + BR in patients with17p deletion and/or TP53 mutation.In patients with17p deletion,the ORR was 57.9%vs 22.5%,respectively.

NosignificantdifferencesinOshavebeenobservedforbothpatientgroups.

## HRQOL

EQ-5D,KPS,FACT-Leu:Nospecifichypotheses were tested and there wasno alphaprotection.No differencesbetweentreatmentarmsweredemonstrated.

<div style=\"page-break-after: always\"></div>

## Summary of main study

Thefollowing table summarises theefficacyresultsfromthemainstudies supportingthepresent application and should be read in conjunction with the discussion on clinical eficacy as well as the benefit risk assessment (see later sections).

## StudyGS-US-312-0115

Population:

CLL previously treated with purine analogue and anti-CD20 MoAb,with progressive disease warranting therapy (IWCLL)

Study period:

15 June 2012 (First Subject Screened)

02 May 2016 (Assessments of Safety and Overall Survival). The study is ongoing.

Design:Doubleblind:

Bendamustine+rituximab+IDL/Placeboinlabelleddosages

Randomisation:1:1,fixed-blockcentralizedrandomization

Stratification:

17pdeletionand/orTP53mutationinCLLcells

Immunoglobulinheavy chainvariableregion(IGHV)mutation

Disease status:refractory versus relapsed

Outcomemeasures:

Primary

PFS by IRC

Secondary

Overall response rate (ORR), lymph node response (LNR)rate,and complete response (CR) rate (type 1 control).

Additional

OS(formally no control of alpha),HRQoL, etc.

| PFS                                   | IDL + BR (N = 207)   | PI+ BR (N = 209)   |
|---------------------------------------|----------------------|--------------------|
| Number(%)of SubjectswithEvents        | 84 (40.6)            | 149 (71.3)         |
| Disease Progression                   | 60 (29.0)            | 130 (62.2)         |
| Death                                 | 24 (11.6)            | 19 (9.1)           |
| KM Estimate of PFS (Months)a          |                      |                    |
| Median (95% CI)                       | 20.8 (16.6, 26.4)    | 11.1 (8.9, 11.1)   |
| At 24 weeks                           | 88.5 (83.0, 92.3)    | 82.1 (76.0, 86.7)  |
| At 48 weeks                           | 75.0 (68.0, 80.6)    | 50.5 (43.2, 57.5)  |
| Adjusted HR (95% CI)b                 | 0.33 (0.25, 0.44)    | 0.33 (0.25, 0.44)  |
| P-valuec                              | 6.540 × 10-16        | 6.540 × 10-16      |
| OS(02May2016)                         | IDL + BR (N = 207)   | PI+ BR (N =209)    |
| Number(%)of Subjects with Events      | 53 (25.6)            | 70 (33.5)          |
| KM Estimate of OS (Months)a           |                      |                    |
| Q1 (95% CI)                           | 23.5 (16, NR)        | 15.7 (13.2, 20.3)  |
| Median (95% CI)                       | NR (NR, NR)          | 40.6 (31.6, NR)    |
| Adjusted HR (95% CI)b                 | 0.67 (0.47,0.96)     | 0.67 (0.47,0.96)   |
| P-value from Stratified Log-Rank Test | 0.0364               | 0.0364             |
| Response Rate                         | IDL + BR (N = 207)   | PI+ BR (N =209)    |

<div style=\"page-break-after: always\"></div>

| Best Overall Response, n (%)a   | Best Overall Response, n (%)a   | Best Overall Response, n (%)a   |
|---------------------------------|---------------------------------|---------------------------------|
| Complete Response (CR)          | 3 (1.4)                         | 0                               |
| Partial Response (PR)           | 142 (68.6)                      | 93 (44.5)                       |
| Progressive Disease (PD)        | 1 (0.5)                         | 19 (9.1)                        |
| ORR(CR+CRi+PR)                  | 145 (70.0)                      | 94 (45.0)                       |
| 95% CIC                         | 63.3, 76.2                      | 38.1, 52.0                      |

## Analysisperformedacrosstrials

## EnrolmentCriteriaforStudiesGS-US-312-0115,GS-US-312-0119,GS-US-312-0116

| StudyGS-US-312-0115                                                                                                                                                                                                                                                                                                                                                                                                           | StudyGS-US-312-0119                                                                                                                                                                                                                                                             | StudyGS-US-312-0116                                                                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RelapsedCLLwithpriortreatment with the following: ≥ 2 cycles of a regimen containingapurineanalog (eg,fludarabine,pentostatin, cladribine)orbendamustine, and ≥ 2 doses with a regimen containing an anti-CD20 monoclonal antibody (eg,rituximab,ofatumumab, obinutuzumab)                                                                                                                                                    | Relapsed CLL with prior treatment comprising therapy with either of the following given alone or in combination: A purine analog (eg,fludarabine,pentostatin, cladribine)administeredfor ≥ 2 cycles of cytotoxic treatmentor Bendamustineadministeredfor ≥2 cycles of treatment | Relapsed CLL with prior treatment withany of thefollowing: ≥1 regimen containing a therapeuticanti-CD20 monoclonal antibody administeredfor≥2dosesof antibodytreatment ≥ 1 cytotoxic agent administeredfor≥2cyclesof cytotoxictreatment |
| Sufficientlyfittoreceivecytotoxic chemotherapy,includingANC ≥ 1.5 x 10°/L, platelets ≥ 75 x 10°/L,and hemoglobin≥100 g/L (10.0 g/dLor6.2mmol/L)(although ≥ Grade 2 neutropenia, thrombocytopenia，oranemiawas permittedifabnormalitywasrelated tobonemarrowinvolvementwith CLL[as documented bybone marrow biopsy/aspirate obtained since thelastprior therapy] Creatinineclearance≥40mL/min Norestrictionsregarding CIRSscore | Norestrictionsregarding myelotoxicity;creatinineclearance >30ml/min;any CIRS score                                                                                                                                                                                              | Unfit to receive cytotoxic therapy becauseofchemotherapy-induced myelotoxicityorcreatinineclearance >30and<60mL/minor comorbidities asmeasured byCIRS score>6                                                                           |
| Karnofskyperformancescoreof ≥60                                                                                                                                                                                                                                                                                                                                                                                               | Karnofskyperformancescoreof ≥60                                                                                                                                                                                                                                                 | Karnofskyperformancescoreof ≥40                                                                                                                                                                                                         |

CIRS=cumulativeillnessratingscale;ANC=absoluteneutrophilcount

<div style=\"page-break-after: always\"></div>

## OS for Individual Phase 3 Studies (ITT Analysis Sets)

|                                       | tudy GS-US-312-0115 (Data through 02 May 2016)   | tudy GS-US-312-0115 (Data through 02 May 2016)   | Study GS-US-312-0119   | Study GS-US-312-0119   | Study GS-US-312-0117 (byInitial Randomization in Study GS-US-312-0116)   | Study GS-US-312-0117 (byInitial Randomization in Study GS-US-312-0116)   |
|---------------------------------------|--------------------------------------------------|--------------------------------------------------|------------------------|------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
|                                       | IDL+BR N =207                                    | PI+BR N =209                                     | IDL+0 N=174            | O Alone N=87           | IDL+R N=110                                                              | PI+R N=110                                                               |
| Number (%) of Subjects Who Died       | 53 (25.6)                                        | 70 (33.5)                                        | 63 (36.2)              | 32 (36.8)              | 38 (34.5)                                                                | 49 (44.5)                                                                |
| Number (%) of Subjects Censored       | 53 (25.6)                                        | 70 (33.5)                                        | 111 (63.8)             | 55 (63.2)              | 72 (65.5)                                                                | 61 (55.5)                                                                |
| Ongoing                               | 154 (74.4)                                       | 139 (66.5)                                       | 34 (19.5)              | 1 (1.1)                | 10 (9.1)                                                                 | 13 (11.8)                                                                |
| Discontinued Study                    | 84 (40.6)                                        | 116 (55.5)                                       | 77 (44.3)              | 54 (62.1)              | 62 (56.4)                                                                | 48 (43.6)                                                                |
| KM Estimate of OS (Months)a           |                                                  |                                                  |                        |                        |                                                                          |                                                                          |
| Q1 (95% CI)                           |                                                  | 23.5 (16, NR)15.7 (13.2, 20.3)                   |                        |                        | 18.2 (12.3, 22.9)12.7 (6.0, 19.3)20.5 (15.4, 25.4)                       | 9.2 (7.3, 12.6)                                                          |
| Median (95% CI)                       | NR (NR, NR)                                      | 40.6 (31.6, NR)                                  | NR (31.5, NR)          | 30.2 (23.0, NR)        | NR (28.5, NR)                                                            | 37.3 (16.6, NR)                                                          |
| Q3 (95% CI)                           |                                                  | NR (NR, NR)NR (40.6, NR)                         | NR (NR, NR)            | NR (NR, NR)            | NR (NR, NR)                                                              | NR (NR, NR)                                                              |
| Adjusted Hazard Ratio (95% CI)        | 0.67 (0.47, 0.96)b                               | 0.67 (0.47, 0.96)b                               | 0.74 (0.48, 1.14)b     | 0.74 (0.48, 1.14)b     | 0.63 (0.41, 0.96)c                                                       | 0.63 (0.41, 0.96)c                                                       |
| P-value From Stratified Log-Rank Test | 0.0364d                                          | 0.0364d                                          | 0.1995d                | 0.1995d                | 0.0029                                                                   | 0.0029                                                                   |

## PFSforIndividualPhase3Studies(ITT)

|                                              | Study GS-US-312-0115   | Study GS-US-312-0115   | Study GS-US-312-0119   | Study GS-US-312-0119   | ptudy GS-US-312-0116   | ptudy GS-US-312-0116   |
|----------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                              | IDL+BR N=207           | P1+BR N=209            | IDL + 0 N =174         | OAlone N=87            | IDL+R N =110           | P1+R N =110            |
| Number (%) of Subjects with Events           | 84 (40.6)              | 149 (71.3)             | 103 (59.2)             | 57 (65.5)              | 25 (22.7)              | 70 (63.6)              |
| Disease Progression                          | 60 (29.0)              | 130 (62.2)             | 76 (43.7)              | 51 (58.6)              | 17 (15.5)              | 62 (56.4)              |
| Death                                        | 24 (11.6)              | 19 (9.1)               | 27 (15.5)              | 6 (6.9)                | 8 (7.3)                | 8 (7.3)                |
| Number (%) of Subjects Censored              | 123 (59.4)             | 60 (28.7)              | 71 (40.8)              | 30 (34.5)              | 85 (77.3)              | 40 (36.4)              |
| Open-Label IDL CompletedStudy/Crossedover to | NA                     | NA                     | NA                     | NA                     | 69 (62.7)              | 33 (30.0)              |
| Ongoing                                      | 82 (39.6)              | 31 (14.8)              | 28 (16.1)              | 1 (1.1)                |                        | 一                      |
| Discontinued Study                           | 39 (18.8)              | 27 (12.9)              | 37 (21.3)              | 28 (32.2)              | 16 (14.5)              | 7 (6.4)                |
| Received Another Antitumor Treatment         | 2 (1.0)                | 2 (1.0)                | 0                      | 1 (1.1)                | 0                      | 0                      |
| Missed≥2ConsecutiveTumor Measurements        | 0                      | 0                      | 6 (3.4)                | 0                      | 0                      | 0                      |
| KM Estimate ofPFS (Months)                   |                        |                        |                        |                        |                        |                        |
| Q1 (95% CI)                                  | 11 (8.3, 13.6)         | 6.9 (5.6, 8.1)         | (7.5, 10.8) 8.6        | 3.5 (1.8, 5.3)         | (8.3, 13.9) 10.7       | (1.8, 3.8) 3.5         |
| Median(95% CI)                               | (16.6,26.4) 20.8       | (8.9, 11.1) 11.1       | (13.6, 21.7) 16.6      | 8.0 (5.7, 8.2)         | (12.3, NR) 19.4        | (4.0, 7.3) 6.5         |
| Q3 (95% CI)                                  | (26.4, NR) 30.3        | (14.0, 19.3) 16.1      | 31.1 (24.9, NR)        | 9.2 (8.2, 16.4)        | (19.4, NR) NR.         | (8.1, 10.9) '8         |
| Adjusted Hazard Ratio (95%CI)                | 0.33 (0.25, 0.44)f     | 0.33 (0.25, 0.44)f     | 0.24 (0.17, 0.35)f     | 0.24 (0.17, 0.35)f     | 0.15 (0.09, 0.24)d     | 0.15 (0.09, 0.24)d     |
| P-value from Stratified Log-Rank Test        | <0.0001                | <0.0001                | <0.0001=               | <0.0001=               | <0.0001                | <0.0001                |

## 2.3.3.6.Discussiononclinicalefficacy(Rapporteur)

Study312-0115isastandard,well-conductedadd-onstudyofIDLvs.placeboonabackgroundof bendamustine+ rituximab in patients previously treated with a purine analogue and an anti-CD20 MoAb.

In patients likely to tolerate bendamustine + rituximab, e.g. based on tolerability to prior lines of therapy, this is an appropriate design, also in del17p/TP53 CLL when the study was initiated. Patients werepre-treatedwithamedianoftwopriorregimens,about1/3werecharacterisedasrefractoryand

<div style=\"page-break-after: always\"></div>

similarly1/3showeddel.17p/Tp53.Therewerenoimbalancesoflikelyimportance.Informationas regards thelastpriorregimenisrequested(oc).If bendamustinewaspartof thelastregimen,ORR

In terms of standard outcome measures, superiority in terms of ORR and PFS has been convincingly demonstrated.ItshouldbenoticedthatBRwasadministeredforsixcyclesfollowedbyIDLorplacebo only.Itisthereforeofimportancethatasurvivalbenefithasbeenshown,eventhoughonlyborderline (p=0.036).Survival dataareimmature ataneventrateof about30%,however,and theeventrate Clarificationshouldbeprovidedasregardssampling ofsurvivaldata afterstudydiscontinuation,

The conducted subgroup analyses raise no concerns, but the submitted forest plots should be resubmitted with medians added.

## 2.3.3.7.Conclusionsontheclinicalefficacy

(andtoxicity)survivaldataareconsideredessential.

## 2.3.3.8.Discussiononclinicalefficacy(CoRapporteur)

inPFS，OSandORRfortheIDL+BRcombinationcomparedtoplacebo+BR.However，theprecise targetpopulationofthetriplecombinationisunclearinthecontextofthealreadyapprovedidelalisib isinparticularrelevantconsideringtheadversesafetyprofileofthetriplecombinationrelativetothe will be further discussed in the B/R section of this report,but, for reference, in the IDL + R study GSUS-312-0116, median PFS was 19.4 months in the IDL + R arm, compared to 6.5 months for placebo +R,which indicates an improvement inmedianPFS of 12.9 month due to the addition of IDL.A lower GS-US-312-0115. For the secondary endpoints ORR, and OS, as well as HRQoL the results showed the PFSinthispatientgroupseems tobelowerwithIDL+BR.

Thestudypopulationof thecurrentpivotal trialwithIDL+BR(eligibleforchemotherapy)differed from the study population for the IDL + R study 0116 (non-eligible for chemotherapy). Acknowledging theuncertainties associatedwith cross-studycomparison,for themorefitIDL+BRstudypopulation withlesscomorbidities andless advanceddisease,improvedefficacyresultswouldhavebeen additionofbendamustinetotheapprovedIDL+Rcombinationis thusuncertaininrelationtothe benefit from IDL + R alone.

## 2.3.3.9. Conclusions on clinical efficacy

Altogether,inpivotal studyGS-US-312-015statisticallysignificantincreasesinPFS,OS,and ORRwere observedforthecombinationofIDLwithBRcomparedtoplacebo+BR.However,theclinicalbenefit

<div style=\"page-break-after: always\"></div>

indication. The applicant should discuss the precise target population of the triple combination, in the contextoftheresultsobservedforrelapsed/refractoryCLLforthealreadyapprovedidelalisib indication.

## 2.3.3.10.Clinicalsafety

## Introduction

Serious infections, including opportunistic infections, constitute the main concern in the treatment with CD20 MoAbs.Late colitis in need of steroid therapy, such as budesonide, is a specific IDL reaction.

toxicity (SJS and TEN)

<div style=\"page-break-after: always\"></div>

## StudyDrugExposure(SafetyAnalysisSet)

|                                                   | DL+BR (N=207)   | PI+BR (N = 209)   | Total (N=410)   |
|---------------------------------------------------|-----------------|-------------------|-----------------|
| Duration of Expo sure to IDL/PI (Months)          |                 |                   |                 |
| N                                                 | 207             | 208               | 415             |
| Mean (StD)                                        | 16.1 (10.25)    | 11.4 (6.49)       | 13.7 (8.88)     |
| Median                                            | 18.2            | 11.1              | 13.4            |
| Q1.Q3                                             | 5.8, 24.0       | 5.8, 16.6         | 5.8, 20.3       |
| Min, Max                                          |                 | 0.5, 28.5         |                 |
| Cumwlative Exposure to IDL/PL, n (%)              |                 |                   |                 |
| 21 Day                                            | 207 (100.0)     | 208 (99.5)        | 415 (99.8)      |
| ≥ 2 months                                        | 186 (89.9)      | 199 (95.2)        | 385 (92.5)      |
| 24months                                          | 171 (82.6)      | 173 (82.8)        | 344 (82.7)      |
| 2 6 months                                        | 154 (74.4)      | 154 (73.7)        | 308 (74.0)      |
| 2 12 months                                       | 127 (61.4)      | 90 (43.1)         | 217 (52.2)      |
| ≥ 18 months                                       | 104 (50.2)      | 34 (16.3)         | 138 (33.2)      |
|                                                   | 51 (24.6)       | 9(4.3)            | 60 (14.4)       |
| spuom OE                                          | 17 (8.2)        | 0                 | 17 (4.1)        |
| 2: 36 months                                      | 2 (1.0)         | 0                 | 2 (0.5)         |
| Subjects with No Dose Modification, n (%)         | 88 (42.5)       | 154 (73.7)        |                 |
| Subjects with Dose Modification, n (%)            | 119 (57.5)      | 55 (26.3)         | 二               |
| Subjects with Dose Intemuption                    | 117 (56.5)      | 54 (25.8)         | 二               |
| Subjects with Dose Rechallenged                   | 117 (54.5)      | 54 (25.8)         | 二               |
| Subjects Rechallenged at 150 mg                   | 87 (42.0)       | 40 (19.1)         |                 |
| Subjects Rechallenged at 100 mg                   | 30 (14.5)       | 14 (6.7)          |                 |
| Subjects With Dose Re-escalation                  | 11 (5.3)        | 4 (1.9)           |                 |
| Subjects with Dose Redaxction Without Lntemuption | 2 (1.0)         | 1 (0.5)           |                 |
| Subjects with Dlose Re-escalated                  | 1 (0.5)         | 0                 |                 |
| Modification dne to AE                            | 101 (48.8)      | 46 (22.0)         |                 |
| Modification due to Other                         | 1 (0.5)         | 2 (1.0)           | 二               |
| Modification due to AE and Other                  | 17 (8.2)        | 7 (3.3)           |                 |

AE = adwm ownt, BR. = badmwtin + ritimab, DL =idlisib, FI = placobo, Q1 = fist quate, Q3 = third quatia, StD = sandand deviation

b Finst rechallanged dove afiar thg finst imtemuption was comsidared for this aalysia.

Duration of asponue (montha) = (min [ast IDL/PI dosing date an captned on study drug coupletion oCRF page, data cutoff dat]-fwIDL/Pldosing dat+1}/30.4375.

Subject in the DL + BR. group was dispansod 1 botlia of placobo, shis was raported as an iportant protocol

deviation (Appandix 16.2, Listing 4.4).

Comment:Note thatBRwastobe administeredfor6cycles(á 4weeks)followed byplacebo or IDL.

<div style=\"page-break-after: always\"></div>

## Overall Summary ofAdverseEvents(SafetyAnalysisSet)

| Adverse Event Category,n (%)           | IDL+BR (N=207)   | P1+BR (N=209)   |
|----------------------------------------|------------------|-----------------|
| Any AE                                 | 207 (100)        | 203 (97.1)      |
| IDL/P1-Related AE                      | 170 (82.1)       | 125 (59.8)      |
| Rituximab-Related AE                   | 145 (70.0)       | 145 (69.4)      |
| Bendamustine-Related AE                | 168 (81.2)       | 173 (82.8)      |
| ≥Grade 3 AE                            | 196 (94.7)       | 163 (78.0)      |
| Grade3 IDL/P1-Related AE               | 141 (68.1)       | 68 (32.5)       |
| ≥Grade 3 Rituximab-Related AE          | 105 (50.7)       | 83 (39.7)       |
| Grade3Bendamustine-RelatedAE           | 148 (71.5)       | 120 (57.4)      |
| Any SAE                                | 147 (71.0)       | 94 (45.0)       |
| IDL/P1-RelatedSAE                      | 75 (36.2)        | 28 (13.4)       |
| Rituximab-Related SAE                  | 48 (23.2)        | 28 (13.4)       |
| Bendamustine-RelatedSAE                | 70 (33.8)        | 40 (19.1)       |
| AELeadingtoIDL/P1DoseReduction         | 34 (16.4)        | 13 (6.2)        |
| AE Leading to IDL/P1 Dose Interruption | 122 (58.9)       | 49 (23.4)       |
| AE Leading to IDL/P1 Discontinuation   | 68 (32.9)        | 31 (14.8)       |
| AE Leading to Death                    | 25 (12.1)        | 19 (9.1)        |

BR = bendamustine + ituximab, IDL = idelalisib,NA = not applicable,Pl = placebo

Relationship to study dug was determined by investigator, AEs with missing relationships were considered to be related.

Comment:\"Relatedness\"was determined bythe investigators.Withrespectto\"anyAE\"itis ofinterest tonoticethesimilaritybetweentreatmentarmsforbendamustinandrituximabrelatedAEsandthe cleardifferencewithrespecttoSAEandgrade≥3,areasonableinterpretationbeing thatIDLaddsto BR\"related\"AE.OverallIDLaddsconsiderablyto thetoxicityof BR.

<div style=\"page-break-after: always\"></div>

## Adverse Events Reported for ≥ 10% of Subjects in Either Treatment Group by Decreasing SOC and PT (Safety Analysis Set)

| System Organ Class Preferred Term, n (%)          | IDL+BR (N = 207)   | P1+BR (N= 209)   |
|---------------------------------------------------|--------------------|------------------|
| Number of Subjects with AEs                       | 207 (100.0)        | 203 (97.1)       |
| Blood and Lymphatic System Disorders              | 160 (77.3)         | 146 (69.9)       |
| Neutropenia                                       | 132 (63.8)         | 114 (54.5)       |
| Anaemia                                           | 55 (26.6)          | 50 (23.9)        |
| Febrile Neutropenia                               | 49 (23.7)          | 13 (6.2)         |
| Thrombocytopenia                                  | 43 (20.8)          | 46 (22.0)        |
| Infections and Infestations                       | 150 (72.5)         | 125 (59.8)       |
| Pneumonia                                         | 50 (24.2)          | 27 (12.9)        |
| Upper Respiratory Tract Infection                 | 36 (17.4)          | 24 (11.5)        |
| Gastrointestinal Disorders                        | 138 (66.7)         | 127 (60.8)       |
| Diarrhoea                                         | 84 (40.6)          | 47 (22.5)        |
| Nausea                                            | 57 (27.5)          | 73 (34.9)        |
| Vomiting                                          | 34 (16.4)          | 31 (14.8)        |
| Constipation                                      | 32 (15.5)          | 35 (16.7)        |
| GeneralDisorders andAdministrationSite Conditions | 132 (63.8)         | 118 (56.5)       |
| Pyrexia                                           | 90 (43.5)          | 63 (30.1)        |
| Fatigue                                           | 43 (20.8)          | 52 (24.9)        |
| Chills                                            | 23 (11.1)          | 13 (6.2)         |
| Asthenia                                          | 22 (10.6)          | 21 (10.0)        |
| Respiratory, Thoracic and Mediastinal Disorders   | 97 (46.9)          | 92 (44.0)        |
| Cough                                             | 49 (23.7)          | 48 (23.0)        |
| Dyspnoea                                          | 22 (10.6)          | 28 (13.4)        |
| Skin and Subcutaneous Tissue Disorders            | 103 (49.8)         | 81 (38.8)        |
| Rash                                              | 35 (16.9)          | 28 (13.4)        |
| Investigations                                    | 90 (43.5)          | 46 (22.0)        |
| Alanine Aminotransferase Increased                | 32 (15.5)          | 3 (1.4)          |
| Weight Decreased                                  | 21 (10.1)          | 12 (5.7)         |
| Metabolism and Nutrition Disorders                | 74 (35.7)          | 46 (22.0)        |
| Decreased Appetite                                | 22 (10.6)          | 15 (7.2)         |
| Musculoskeletal and Connective Tissue Disorders   | 65 (31.4)          | 55 (26.3)        |
| Arthralgia                                        | 25 (12.1)          | 16 (7.7)         |
| Nervous System Disorders                          | 56 (27.1)          | 54 (25.8)        |
| Headache                                          | 20 (9.7)           | 22 (10.5)        |
| Injury, Poisoning and Procedural Complications    | 43 (20.8)          | 59 (28.2)        |
| Infusion Related Reaction                         | 31 (15.0)          | 49 (23.4)        |

Comment:Notethemajorincreaseininfectiouseventsincludingfebrileneutropenia

<div style=\"page-break-after: always\"></div>

≥Grade3AEsReportedfor≥2%ofSubjectsinEitherTreatmentGroupbyDecreasingSOC and PT(SafetyAnalysisSet)

| Systeim Organ Class Preferred Term, n (%)   | IDL+BR (N=207)   | PI+BR (N =209)   |
|---------------------------------------------|------------------|------------------|
| Number of Subjects with ≥ Grade 3 AE        | 196 (94.7)       | 163 (78.0)       |
| BloodAndLymphaticSystemDisorders            | 149 (72.0)       | 129 (61.7)       |
| Neutropenia                                 | 124 (59.9)       | 99 (47.4)        |
| Febrile Neutropenia                         | 49 (23.7)        | 13 (6.2)         |
| Anaemia                                     | 32 (15.5)        | 27 (12.9)        |
| Thrombocytopenia                            | 27 (13.0)        | 26 (12.4)        |
| Leukopenia                                  | 12 (5.8)         | 9 (4.3)          |
| Granulocytopenia                            | 6 (2.9)          | 6 (2.9)          |
| Autoimmune Haemolytic Anaemia               | 0                | 5 (2.4)          |
| Infections and Infestations                 | 85 (41.1)        | 54 (25.8)        |
| Pneumonia                                   | 29 (14.0)        | 17 (8.1)         |
| Sepsis                                      | 12 (5.8)         | 6 (2.9)          |
| Urinary Tract Infection                     | 5 (2.4)          | 4 (1.9)          |
| Lower Respiratory Tract Infection           | 4 (1.9)          | 6 (2.9)          |
| Neutropenic Sepsis                          | 3 (1.4)          | 6 (2.9)          |
| Respiratory Tract Infection                 | 3 (1.4)          | 5 (2.4)          |
| Septic Shock                                | 5 (2.4)          | 1 (0.5)          |

<div style=\"page-break-after: always\"></div>

| Investigations                                       | 54 (26.1)   | 9 (4.3)   |
|------------------------------------------------------|-------------|-----------|
| Alanine Aminotransferase Increased                   | 22 (10.6)   | 1 (0.5)   |
| Aspartate Aminotransferase Increased                 | 11 (5.3)    | 0         |
| Transaminases Increased                              | 8 (3.9)     | 0         |
| Neutrophil Count Decreased                           | 6 (2.9)     | 1 (0.5)   |
| Platelet Count Decreased                             | 6 (2.9)     | 1 (0.5)   |
| Gastrointestinal Disorders                           | 38 (18.4)   | 13 (6.2)  |
| Diarrhoea                                            | 25 (12.1)   | 4 (1.9)   |
| Abdominal Pain                                       | 5 (2.4)     | 1 (0.5)   |
| General Disorders and Administration Site Conditions | 25 (12.1)   | 23 (11.0) |
| Pyrexia                                              | 15 (7.2)    | 7 (3.3)   |
| Fatigue                                              | 7 (3.4)     | 5 (2.4)   |
| Asthenia                                             | 1 (0.5)     | 6 (2.9)   |
| Respiratory, Thoracic and Mediastinal Disorders      | 22 (10.6)   | 18 (8.6)  |
| Dyspnoea                                             | 6 (2.9)     | 8 (3.8)   |
| Pulmonary Embolism                                   | 3 (1.4)     | 6 (2.9)   |
| Metabolism and Nutrition Disorders                   | 23 (11.1)   | 14 (6.7)  |
| Hypokalaemia                                         | 5 (2.4)     | 6 (2.9)   |
| Decreased Appetite                                   | 5 (2.4)     | 0         |
| Skin And Subcutaneous Tissue Disorders               | 18 (8.7)    | 1 (0.5)   |
| Rash                                                 | 6 (2.9)     | 0         |
| Injury, Poisoning and Procedural Complications       | 9 (4.3)     | 7 (3.3)   |
| Infusion Related Reaction                            | 5 (2.4)     | 4 (1.9)   |

Comment: The apparent discrepancy between the rather minor increase in grade ≥3 neutropenia and the major increase in neutropenic fever and other infections is worth noting.

<div style=\"page-break-after: always\"></div>

## Incidence of infectious events by Time Interval (SafetyAnalysisSet)

|                      | 0to12Weeks          | 0to12Weeks          | >12to24Weeks>24to36Week>36 to48Week>48to60Weeks   | >12to24Weeks>24to36Week>36 to48Week>48to60Weeks   | >12to24Weeks>24to36Week>36 to48Week>48to60Weeks   | >12to24Weeks>24to36Week>36 to48Week>48to60Weeks   | >12to24Weeks>24to36Week>36 to48Week>48to60Weeks   | >12to24Weeks>24to36Week>36 to48Week>48to60Weeks   | >12to24Weeks>24to36Week>36 to48Week>48to60Weeks   | >12to24Weeks>24to36Week>36 to48Week>48to60Weeks   |
|----------------------|---------------------|---------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Adverse Event, n (%) | IDL+ BR             | PI+BR               | IDL+ BR                                           | PI+BR                                             | DL+ BR (N=207)(N=209）(N=207）(N=209）(N=207)        | P1+BR                                             | +TT BR                                            | P1+BR                                             | +T0 BR                                            | P1+BR （607=N(L07=N（60=ND（L0=N）（607=ND             |
| Infection            |                     |                     |                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |
| All Grades           | 90/207 (43.5)       | 63/209 (30.1)       | 78/192 (40.6)                                     | 61/200 (30.5)                                     | 49/172 (28.5)                                     | 45/170 (26.5)                                     | 31/144 (21.5)                                     | 29/143 (20.3)                                     | 22/134 (16.4)                                     | 19/109 (17.4)                                     |
| >Grade 3             | 49/207 (23.7)       | 29/209 (13.9)       | 41/192 (21.4)                                     | 20/200 (10.0)                                     | 21/172 (12.2)                                     | 11/170 (6.5)                                      | 11/144 (7.6)                                      | 6/143 (4.2)                                       | 10/134 (7.5)                                      | 7/109 (6.4)                                       |
| Febnile Neutropenia  | Febnile Neutropenia | Febnile Neutropenia | Febnile Neutropenia                               | Febnile Neutropenia                               | Febnile Neutropenia                               | Febnile Neutropenia                               | Febnile Neutropenia                               | Febnile Neutropenia                               | Febnile Neutropenia                               | Febnile Neutropenia                               |
| All Grades           | 28/207 (13.5)       | 8/209 (3.8)         | 15/192 (7.8)                                      | 5/200 (2.5)                                       | 3/172 (1.7)                                       | 2/170 (1.2)                                       | 5/144 (3.5)                                       | 0                                                 | 2/134 (1.5)                                       | 0                                                 |
| ≥Grade 3             | 28/207 (13.5)       | 8/209 (3.8)         | 15/192 (7.8)                                      | 5/200 (2.5)                                       | 3/172 (1.7)                                       | 2/170 (1.2)                                       | 5/144 (3.5)                                       | 0                                                 | 2/134 (1.5)                                       | 0                                                 |
| CMV                  | CMV                 | CMV                 | CMV                                               | CMV                                               | CMV                                               | CMV                                               | CMV                                               | CMV                                               | CMV                                               | CMV                                               |
| All Grades           | 4/207 (1.9)         | 2/209 (1.0)         | 5/192 (2.6)                                       | 0                                                 | 3/172 (1.7)                                       | 0                                                 | 0                                                 | 1/143 (0.7)                                       | 1/134 (0.7)                                       | 0                                                 |
| >Grade 3             | 2/207 (1.0)         | 2/209 (1.0)         | 4/192 (2.1)                                       | 0                                                 | 1/172 (0.6)                                       | 0                                                 | 0                                                 | 1/143 (0.7)                                       | 0                                                 | 0                                                 |
| PJP                  | PJP                 | PJP                 | PJP                                               | PJP                                               | PJP                                               | PJP                                               | PJP                                               | PJP                                               | PJP                                               | PJP                                               |
| All Grades           | 0                   | 0                   | 1/192 (0.5)                                       | 0                                                 | 2/172 (1.2)                                       | 0                                                 | 0                                                 | 0                                                 | 0                                                 | 0                                                 |
| ≥Grade 3             | 0                   | 0                   | 1/192 (0.5)                                       | 0                                                 | 1/172 (0.6)                                       | 0                                                 | 0                                                 | 0                                                 | 0                                                 |                                                   |

Comment: As any grade include less relevant events such as common cold, etc.the focus is on grade ≥3.

Uptoweek24,theincreaseingrade≥3infectionsandfebrileneutropenialookasexpected.The ratherhighincidencealsoafterweek24inthetrueplaceboarmmightlooksurprisingbutcouldrelate to the prolonged immunosuppresive effects of bendamustine/rituximab and the underlying disease.

RatherfewindivudualshadCMv/PJpinfections.Itisuclearhowinvestigatorsadheredto recommendationsasregardsprophylaxis.

## Diarrhoea/Colitis

Through the cut-off date (02 May 2016), 28 subjects (13.5%) in the IDL + BR group and 4 subjects (1.9%)intheplacebo+BRgrouphad≥Grade3diarrhoeaand/orcolitis

In the IDL + BR group, the median(Q1, Q3) time to onset of the first ≥ Grade 3 event of diarrhoea/colitis(N =28)was 38.6(11.1, 79.6) weeks,and the median(Q1,Q3) time to resolution of highest grade diarrhoea/colitis (N =23)was 2.0(0.9,4.3)weeks.

In the placebo + BR group, the median (Q1, Q3) time to onset of the first ≥ Grade 3 event of diarrhoea/colitis (N = 4) was 16.4 (10.4, 29.6) weeks, and the median (Q1, Q3) time to resolution of highest grade diarrhoea/colitis (≥ Grade 3)(N = 4) was 0.9 (0.4,1.8)weeks.

In the IDL + BR group, 4 subjects had their study drug dose reduced, 16 subjects had an interruption instudy drug,and 4subjects discontinued IDL due to≥Grade3 diarrhoea and/or colitis.

In the placebo + BR group, 2 subjects (1.0%) had an interruption in study drug, and no subject had a dosereductionordiscontinuedthestudydrug

<div style=\"page-break-after: always\"></div>

Nodeathsduetodiarrhoeaand/orcolitiswerereportedinthisstudy.

Comment:Data essentially confirmresultsinpriortrials;delayed onset of colitis.

## Skintoxicity

Altogether13 subjects(6.3%)in the IDL+ BR group and no subject in the placebo+BR group had ≥ Grade 3 rash. Two subjects had their study drug dose reduced, 4 subjects had an interruption in study drug, and 3 subjects discontinued IDL due to≥ Grade 3 rash.

Onedeathwasreported in theIDL+BRgroupwhichwas attributed toSJS.Subject had beguntakingacyclovironStudyDay13inresponsetomucosal lesions at2anatomicalsites and developedpapulareruptionsandhyperemiaofskin,pruritusandfever.ShewashospitalizedonStudy Day 14 and study drug (IDL/placebo) was withdrawn on that day. Three days later the subject was study drug or BR and potentially associated with acyclovir. Cases of SJS and toxic epidermal necrolysis (TEN)withfataloutcomeshavebeenreportedwhenIDLwasadministeredconcomitantlywithother medicationsassociatedwiththesesyndromes.

Onstudyday313asubjectdevelopedarashafterrecentlystartingonazithromycinfollowedby levofloxacin.Additionalconcomitantmedicationsincludedacyclovir,furosemide,andomeprazole.A diagnosisofSjSwasmadeandthesubjectwastreatedwithsteroidsandtheeventwasconsidered resolved on Study Day 313.

No case of TEN was reported in this study.

Comment:SkintoxicityincludingSJSiscapturedbysections4.4and4.8.

## CLL Transformation and Second Malignancies Adjusted for Exposure (Safety Analysis Set)

|                     | IDL+BR (N=207)                 | IDL+BR (N=207)                      | IDL+BR (N=207)                         | P1+BR (N = 209)                | P1+BR (N = 209)                     | P1+BR (N = 209)                         |
|---------------------|--------------------------------|-------------------------------------|----------------------------------------|--------------------------------|-------------------------------------|-----------------------------------------|
|                     | Number of Subjects with Events | Drug Exposure at Risk (Person Year) | Incidence Rate per Person Year (95%CI) | Nunber of Subjects with Events | DrugExposure at Risk. (Person Year) | Incidence Rate per Person Year (95% CT) |
| CLL Transformation  | 4                              | 288.9                               | 0.01 (0.0038, 0.0354)                  | 7                              | 213.2                               | 0.03 (0.0132, 0.0676)                   |
| Second Malignancies | 27                             | 267.1                               | 0.10 (0.0666, 0.1471)                  | 14                             | 207.6                               | 0.07 (0.0369, 0.1132)                   |

Comment:Asexpected,skinmalignancies dominated.Therewas noincrease innumber of transformations.

## Deaths

IntheIDL+BRgroup,33subjects diedonstudy(deathsbetweenrandomizationandwithin30days follow-up.

<div style=\"page-break-after: always\"></div>

Eventswerethoseexpected inpatientswithadvancedCLL.Themostcommoneventsleadingtodeath were pneumonia(2.4% of the IDL + BR group and 2.4% of the placebo + BR group) and sepsis (1.4% of the IDL + BR group and 1.0% of the placebo + BR group).

Comment: No signal

## SAEsReportedfor≥2%ofSubjectsinEitherTreatmentGroup(SafetyAnalysisSet)

| Preferred Term, n (%)               | IDL+BR (N=207)   | P1+BR (N=209)   |
|-------------------------------------|------------------|-----------------|
| Number of Subjects (%) with any SAE | 147 (71.0)       | 94 (45.0)       |
| Febrile Neutropenia                 | 43 (20.8)        | 10 (4.8)        |
| Pneumonia                           | 36 (17.4)        | 16 (7.7)        |
| Pyrexia                             | 25 (12.1)        | 11 (5.3)        |
| Sepsis                              | 10 (4.8)         | 4 (1.9)         |
| Diarhoea                            | 12 (5.8)         | 1 (0.5)         |
| Neutropenia                         | 9 (4.3)          | 3 (1.4)         |
| Anaemia                             | 6 (2.9)          | 5 (2.4)         |
| Lower Respiratory Tract Infection   | 6 (2.9)          | 5 (2.4)         |
| Neutropenic Sepsis                  | 3 (1.4)          | 6 (2.9)         |
| Respiratory Tract Infection         | 3 (1.4)          | 5 (2.4)         |
| Urinary Tract Infection             | 5 (2.4)          | 3 (1.4)         |
| Pulmonary Embolism                  | 2 (1.0)          | 5 (2.4)         |
| Bronchitis                          | 1 (0.5)          | 5 (2.4)         |
| Septic Shock                        | 5 (2.4)          | 1 (0.5)         |
| Squamous CellCarcinoma              | 1 (0.5)          | 5 (2.4)         |

BR=bendamustine +rituximab,IDL=idelalisib,Pl=placebo

Subjects who experienced multiple events within the same PT were counted once per PT.

AEs were classified by PT using MedDRA version 19.0.

Comment:The difference inSAEsisdrivenbydifference ininfectiousevents.

<div style=\"page-break-after: always\"></div>

AEsLeading toStudyDrugDiscontinuationin≥2SubjectsTotal(SafetyAnalysisSet)

| Preferred Terin,n(%)                                              | IDL+BR (N = 207)   | P1+BR (N=209)   |
|-------------------------------------------------------------------|--------------------|-----------------|
| Number of Subjects (%) with AEs Leading to IDL/P1 Discontinuation | 68 (32.9)          | 31 (14.8)       |
| Pneumonia                                                         | 11 (5.3)           | 5 (2.4)         |
| Pyrexia                                                           | 4 (1.9)            | 2 (1.0)         |
| Diarrhoea                                                         | 5 (2.4)            | 0               |
| Febrile Neutropenia                                               | 3 (1.4)            | 2 (1.0)         |
| Sepsis                                                            | 3 (1.4)            | 2 (1.0)         |
| Anaemia                                                           | 2 (1.0)            | 1 (0.5)         |
| Colitis                                                           | 3 (1.4)            | 0               |
| Hepatocellular Injury                                             | 3 (1.4)            | 0               |
| Neutropenia                                                       | 3 (1.4)            | 0               |
| Thrombocytopenia                                                  | 3 (1.4)            | 0               |
| Abdominal Pain                                                    | 2 (1.0)            | 0               |
| Acute Myocardial Infarction                                       | 0                  | 2 (1.0)         |
| Asthenia                                                          | 0                  | 2 (1.0)         |
| Autoimmune haemolytic anaemia                                     | 0                  | 2 (1.0)         |
| Cough                                                             | 2 (1.0)            | 0               |
| Lung Adenocarcinoma                                               | 1 (0.5)            | 1 (0.5)         |
| Nausea                                                            | 2 (1.0)            | 0               |
| Pancytopenia                                                      | 2 (1.0)            | 0               |
| Pneumonia Cytomegaloviral                                         | 1 (0.5)            | 1 (0.5)         |
| Pneumonitis                                                       | 2 (1.0)            | 0               |
| Pruritus                                                          | 1 (0.5)            | 1 (0.5)         |
| Respiratory Failure                                               | 1 (0.5)            | 1 (0.5)         |
| Respiratory Tract Infection                                       | 1 (0.5)            | 1 (0.5)         |
| Vomiting                                                          | 2 (1.0)            | 0               |

Comment: The overall discontinuation rates are high.Reporting by the induction period IDL/PL+BR vs. thecontinuationperiodIDL/PLwouldbeofvalue(oc)

Overall, 16.4% (34 subjects) of the IDL + BR group and 6.2% (13 subjects) of the placebo + BR group hadAEsleadingtodosereductionofstudydrug(IDL/placebo).

The most frequently reported AEs leading to reduction of study drug were increased ALT (2.9% IDL + BR) and (0.5% placebo + BR) and diarrhoea (3.9% IDL + BR and 0.5% placebo + BR).

All other AEs leading to dose reduction of study drug occurred in ≤ 2% of either treatment group.

## AdverseEventsLeading toIDLDoseInterruption

Among subjects in the IDL + BR group,122 of 207 subjects (58.9%）had an AE that led to IDL dose diarrhoea (28 subjects, 13.5%), ALT increased (19 subjects, 9.2%), febrile neutropenia (15 subjects, 7.2%), and pneumonia (11 subjects, 5.3%).

<div style=\"page-break-after: always\"></div>

## AdverseEventsLeadingtoIDLDoseInterruptionReportedfor≥2%o

| PreferredTern                                 | IDL+BR (N=207) n(%)   |
|-----------------------------------------------|-----------------------|
| SubjectswithAnyAELeadingtoIDLDoce Intemuption | 122 (58.9)            |
| Dianhoea                                      | 28 (13.5)             |
| Alanine Aminotransferase Increased            | 19 (9.2)              |
| Pneumonia                                     | 11 (5.3)              |
| FebrileNeutropenia                            | 15 (7.2)              |
| Pyrexia                                       | 9 (4.3)               |
| Aspartate Aminotransferase Increased          | 10 (4.8)              |
| Neutropenia                                   | $ (3.9)               |
| Colitis                                       | 2(1.0)                |
| Fatigue                                       | (0D）                  |
| Rash                                          | 5(2.4)                |
| Traaminases Increaed                          | 6 (2.9)               |
| Dehydration                                   | 2(1.0)                |
| Pnumocynisjirovecii Pneumonia                 | 1 (0.5)               |
| Abdominal Pain                                | 1 (0.5)               |
| Sepsis                                        | 2(1.0)                |
| Preumozitis                                   | 1 (0.5)               |

## Assessors comment

suspectedtoberelatedtostudydrug(idelalisib/placebo）during thecourseofstudytreatment,then studydrugadministrationmaybeheld,asnecessary,until theadverseeventresolvesorstabilizesto anacceptabledegree.Ifpermanentdiscontinuationisnotrequired,thestudydrugmaybereinstituted ateitherthestartingdoselevel(150mg/doseBID)oratDoseLevel-1(100mg/doseBID).Rituximab doseswillnotbemodifiedduringthestudy.Ifasubjectexperiencesanadverseeventthatis suspectedtobebendamustine-relatedandrequiresadosemodificationduring thecourseofstudy therapy,thenthebendamustinedoseshouldbereducedby1doselevel.

The number of subjects withdose discontinuations，dose reductions and interruptions was high with IDL+BRtreatment.Themediantimetothedoseinterruptionandthedurationof thedose numberofsubjectshavebeenreportednotthenumberofevents).Accordingtotheprotocol reescalationofthedoseisnotneeded,evenif thereisminimalornotoxicitywiththereduceddose(at the discretion of the investigator). As such, dose re-escalation was only performed in 9 subjects (4.3%)with IDL + BR in study GS-US-312-0115.It is uncertain to what aspect the dose modifications of IDL+BR have influenced thepercentage ofexpecteddoses takenand the number of days(or infusions)withtreatment.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Treatment-Emergent Transaminase Elevations(SafetyAnalysisSet)

|                                                      | IDL+BR (N = 207) n (%)   | Pl+BR (N=209) n (%)   |
|------------------------------------------------------|--------------------------|-----------------------|
| Subjects with any Grade3 or 4 ALT or AST Elevation   | 47 (22.7)                | 8 (3.8)               |
| Subjects with any Grade 3or 4ALT Elevation           | 44 (21.3)                | 6 (2.9)               |
| Subjects with any Grade 3 or 4AST Elevation          | 32 (15.5)                | 7 (3.3)               |
| Subjects with any Grade 3 or 4 ALT and AST Elevation | 29 (14.0)                | 5 (2.4)               |
| Resolved to Grade 1 or Less                          | 44 (21.3)                | 8 (3.8)               |
| Subjects Rechallenged after Dose Interuption         | 35 (16.9)                | 4 (1.9)               |
| Rechallenged at 150 mg BID                           | 23 (11.1)                | 2 (1.0)               |
| Recurrence of Grade 3 or 4 ALT or AST Elevation      | 5 (2.4)                  | 0                     |
| Resolved to Grade 1 or Less                          | 4 (1.9)                  | 0                     |
| Rechallenged at 100 mg BID                           | 12 (5.8)                 | 2 (1.0)               |
| Recurrence of Grade3or 4ALTorAST Elevation           | 4 (1.9)                  | 1 (0.5)               |
| Resolved to Grade 1 or Less                          | 4 (1.9)                  | 0                     |

Comment: The increased frequency in the IDL arm is obvious. Of note, re-challenge at the same dose (150mg)wassuccessful in18/23subjects.

## Median(Q1,Q3)ALT(U/L)overTime,SafetyAnalysisSet

<!-- image -->

Comment:The gradual increase up to weeks 8-10 followed by a\"plateau\"onIDL monotherapy is noteworthy.

The around w. 8-10 peak has similarities with the colitis peak and might inform about the underlying mechanisms.

<div style=\"page-break-after: always\"></div>

## Haematology

BR and IDL+BR are undoubtedly myelosuppressive, as demonstrated in the overviews of ARs, at the same time response to therapy is associated with haematological improvement in case of CLL-related haematotoxicity.ThisisillustratedherebytheshifttableforIDL+BRand thefigurebelow.

ShiftfromBaselinetoworstCTCAESeverityGradeSafetyAnalysisSet,Haemoglobin

|                     | IDL + R/B Baseline Severity Grade[a]   | IDL + R/B Baseline Severity Grade[a]   | IDL + R/B Baseline Severity Grade[a]   | IDL + R/B Baseline Severity Grade[a]   | IDL + R/B Baseline Severity Grade[a]   | IDL + R/B Baseline Severity Grade[a]   | IDL + R/B Baseline Severity Grade[a]   |
|---------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|                     | Gzade0                                 | Grade 1                                | Grade 2                                | Grade 3                                | Grade                                  | Missing                                | Total                                  |
| Hemoglobin (Anemia) | 6                                      | 68                                     | 35                                     |                                        |                                        |                                        | 207                                    |
| Worst Grade [b]     |                                        |                                        |                                        |                                        |                                        |                                        |                                        |
| Grade 0             | 23.(23.7)                              | 1(1.5)                                 |                                        |                                        | 0                                      |                                        | 24( 11.6)                              |
| Grade 1             | 46(47.49)                              | 33 （48.5)                              | 8.6)                                   |                                        | 0                                      | 0                                      | 82(39.6)                               |
| Gzade 2             | 18( 18.66)                             | 19( 27.94)                             | 15( 42.94)                             | 5 (71.49)                              | 0                                      | 0                                      | 57( 27.5#)                             |
| Gzade 3             | 10 ( 10.3)                             | 14(20.6)                               | 17 ( 48.6)                             | 2(28.6)                                | 0                                      |                                        | 43( 20.8#)                             |
| Gzade4              |                                        |                                        | 。                                      |                                        | 0                                      | 0                                      |                                        |
| Missing             | 0                                      | 1 (1.5#)                               |                                        |                                        | 0                                      |                                        | 1 (0.5#)                               |

Median(Q1,Q3)Hemoglobin(g/L)overTime(SafetyAnalysisSet-Subjectswith AbnormalityatBaselineandatLeast1PostbaselineMeasurement)

<!-- image -->

## Treatment-EmergentHematologicAbnormalities

Neutropenia(allgrades)wasthemostcommontreatment-emergenthematologicabnormalityoverall occurring in 89.9%(186 subjects)of the IDL + BR group and in 90.0%(188 subjects)of the placebo + BR group. Grade 3 or 4 neutropenia was observed in 72.9%(151 subjects) of the IDL + BR group and in 63.2%(132 subjects)of the placebo + BR group.

<div style=\"page-break-after: always\"></div>

GS-US-312-0115: Summary of Treatment-Emergent Hematology Abnormalities In

| Parameter, n (%)                        | IDL+BR (N = 207)   | P1+BR (N = 209)   |
|-----------------------------------------|--------------------|-------------------|
| Hemoglobin Decreased (Anaemia)          |                    |                   |
| Any Grade                               | 124 (59.9)         | 130 (62.2)        |
| ≥Grade 3                                | 41 (19.8)          | 36 (17.2)         |
| Lymphocyte Count Increased              |                    |                   |
| Any Grade                               | 8 (3.9)            | 9 (4.3)           |
| Grade 3                                 | 5 (2.4)            | 4 (1.9)           |
| Lymphocyte Count Decreased              |                    |                   |
| Any Grade                               | 155 (74.9)         | 144 (68.9)        |
| ≥Grade 3                                | 103 (49.8)         | 94 (45.0)         |
| Neutrophil Count Decreased              |                    |                   |
| Any Grade                               | 186 (89.9)         | 188 (90.0)        |
| Grade 3                                 | 151 (72.9)         | 132 (63.2)        |
| Platelet Count Decreased                |                    |                   |
| Any Grade                               | 105 (50.7)         | 108 (51.7)        |
| ≥Grade 3                                | 42 (20.3)          | 35 (16.7)         |
| Leukocytes (White Blood Cell Deereased) |                    |                   |
| Any Grade                               | 169 (81.6)         | 167 (79.9)        |
| ≥Grade 3                                | 94 (45.4)          | ()16              |

BR = bendamustine + riruximab, IDL = idelalisib, P1 = placebo

Grades were obtained per CTCAE version 4.03.

Worst grade at post baseline; baseline was the last observation on or before the first dose of study drug.

Source: Section 15.1, Table 8.2.2

Themostcommonlyobserved(&gt;10%incidence）Grade3or4hematologiclaboratoryabnormalities included the following:neutrophil count decreased(39.6%),lymphocyte count decreased(33.4%), leukocytes decreased(22.3%),and platelet count decreased(11.5%）(table 62,Summary of clinical safety).

## Treatment-EmergentNeutropenia

Among subjects with any disease type or therapy regimen(N = 1952), the incidence of treatmentemergentneutropenialaboratoryabnormalitiesofanygradewas61.6%，andtheincidenceofGrade3 1.6 months, with a KM estimate of median time to resolution of 3.9 weeks (ISS Table 8.15.4).Among subjectswithCLLinStudiesGS-US-312-0115,GS-US-312-0116,andGS-US-312-0119,theincidence of treatment-emergent neutropenialaboratory abnormalities of any grade was highand similar between the IDL + BR and placebo + BR groups, with 89.9% and 90.0% of subjects in the respective 55.6%, 72.8%， and 58.1% of subjects, respectively. The incidence of Grade 3 or 4 treatmentemergent neutropenia intheIDL + BR group was higher thanin the placebo+BR group,with72.9% and 63.2% of subjects in the respective groups having such events. The incidence of Grade 3 or 4 treatment-emergent neutropenia was lowerin theIDL+R,placebo+ R,IDL+ O,and Oalone groups, occurring in 41.8%,29.6%,49.1%,and 32.6% of subjects,respectively.The prevalence of Grade 3 or 4 treatment-emergent neutropenia was generally highest during the first 12 weeks on study and decreasedthereafter.

<div style=\"page-break-after: always\"></div>

## Incidence of Laboratory Abnormalities of Neutropenia, Subjects with CLL in Studies GS-US-312-0115,GS-US-312-0116,andGS-US-312-0119

|                         | IDL+BR (N=207)   | BR (N= 209)   | IDL+R (N =110)   | R (N=108)   | IDL+0 (N=173)   | 0 (N =86)   |
|-------------------------|------------------|---------------|------------------|-------------|-----------------|-------------|
| Neutropenia, n (%)      |                  |               |                  |             |                 |             |
| Any Change Postbaseline | 186 (89.9)       | 188 (90.0)    | 70 (63.6)        | 60 (55.6)   | 126 (72.8)      | 50 (58.1)   |
| Any Grade 3 or4         | 151 (72.9)       | 132 (63.2)    | 46 (41.8)        | 32 (29.6)   | 85 (49.1)       | 28 (32.6)   |
| Grade 3                 | 45 (21.7)        | 62 (29.7)     | 26 (23.6)        | 18 (16.7)   | 37 (21.4)       | 13 (15.1)   |
| Grade 4                 | 106 (51.2)       | 70 (33.5)     | 20 (18.2)        | 14 (13.0)   | 48 (27.7)       | 15 (17.4)   |

IDL + BR = DL + beadamustine + rituwximab in Smudy GS-US-312-0115; BR = placebo + bendamustine and riximab in Snady GS-US-312-0115;

O = ofatummmmab alone fn Sudy GS-US-312-0119

IDL + R = IDL +ritximab in Study GS-US-312-0116; R = placebo +ritmximb in Study GS-US-312-0116; IDL + O = DL + ofatmmmab in Study GS-US-312-0119;

Treatment-emergent lab abuormality = abnormality worsening by ≥&gt; 1 grade compared with baseline from first treatment dose to 30 days after last dose.

Source: ISS Table 8.2.1

For subjects in Stady GS-Us-312-0116 who received open-label DL, teatment-emergent Iab abnormality = abnommality worsening by ≥ 1 grade compared with baseline from first stuady treatment dose to the dlay before the first dose of open-label IDL.

## Assessorscomment

It is noticed that a significant proportion of patients in IDL + BR and BR arm have treatment-emergent haematological abnormalities，although thisis tobe expected insubjectswithCLL,inclusioncriteria weresetforadequateneutrophilandplateletcountsaswellasHblevel.Withrespecttoneutropenia grade 3-4 neutropenia.It is known that haematologic toxicities occur with bendamustine treatment in CLL such as neutropenia,thrombocytopenia,and anaemia,however,the triple combinationIDL + BR increasestheriskforgrade4neutropenia.

<div style=\"page-break-after: always\"></div>

GS-US-312-0115:SummaryofTreatment-EmergentSerumChemistryAbnormalities:Events withAnyOccurrenceof≥Grade3Severity

| Parameter, n(%)                    | IDL+BR (N=207)   | P1+BR (N=209)   |
|------------------------------------|------------------|-----------------|
| Albumin Decreased                  |                  |                 |
| Any Grade                          | 48 (23.2)        | 30(14.1)        |
| Grade3                             | 3(1.4)           |                 |
| Alkaline Phosphatase Increased     |                  |                 |
| Any Grade                          | 78(37.7)         | 44(21.1)        |
| Grade3                             | 3(.4)            | 0               |
| ALT Increased                      |                  |                 |
| Any Grade                          | 131 (63.3)       | 67 (32.1)       |
| Grade3                             | 44(21.3)         | 6 (2.9)         |
| AST Increased                      |                  |                 |
| Any Grade                          | 111 (53.6)       | 61 (29.2)       |
| Grade3                             | 32 (15.5)        | 7(3.3)          |
| Bilirubin Lncreased                |                  |                 |
| Any Grade                          | 49 (23.7)        | 38(18.2)        |
| Grade3                             | 1(0.5)           | 2(1.0)          |
| Abumin-Corrected Calcium Increased |                  |                 |
| Any Grade                          | 6(2.9)           | 6 (2.9)         |
| Grade3                             | 1(0.5)           |                 |
| Albumin-CorrectedCalciumDecreased  |                  |                 |
| Aany Grade                         | 11 (5.3)         | (00D1           |
| Grade3                             | 3(1.4)           | 2 (1.0)         |
| Cholesterol High                   |                  |                 |
| Auy Grade                          | 18(8.7)          | 5(2.4)          |
| Grade3                             | 1(0.5)           | 0               |
| Creatinine Increased               |                  |                 |
| Any Grade                          | 14(6.8)          | 23 (11.0)       |
| Grade3                             | 0                |                 |
| Creatinine Clearance Decreased     |                  |                 |
| Any Grade                          | 57 (27.5)        | 63 (30.1)       |
| Grade3                             | 1(0.5)           | 0               |

Blood chemistry laboratory abnormalities ≥ Grade 3 observed in ≥ 5% of subjects with any disease type or therapy regimen (N = 1952) in either treatment group, are summarized in the above. The mostcommonlyobserved（&gt;10%incidence）Grade3or 4chemistrylaboratoryabnormalitieswere phosphate decreased (in IDL+BR only), ALT increased and AST increased.ALT increase and AST

Therearenonewphysicalfindingsorotherunreportedobservationsrelatedtosafetyinthis supplemental application.

## Assessorscomment

Patientswith ongoinghepatitis,liver cirrhosis，portalhypertension，orliver injurywere excluded from studyGS-US-312-0115andthusconstituteanareaofmissinginformation.

Thelaboratoryabnormalitiesinrelationtoidelalisibexposureshouldbefurtherelucidatedwithrespect topotassium,albuminandphosphate.

<div style=\"page-break-after: always\"></div>

## Specialpopulations

## Age

In the pivotal Study GS-US-312-0115, an additional analysis of ADRs, defined as AEs assessed by the investigator asrelated totreatmentwithIDL,wasperformedforsubjectswhoreceivedIDL+BR treatment in 3 age groups: &lt; 65 (N = 131), 65 to &lt; 75 (N = 60), and 75 to &lt; 85 (N = 16) years of age. The overall incidence of ADRs was similar across the 3 age groups.Categories of ADRs with a higher incidence in the oldest age group (75 to&lt; 85 years of age) compared with either of the 2 younger age groups were as follows:

Allserious ADRs:&lt;65years(45 subjects,34.4%),65 to&lt;75years(20 subjects,33.3%),75 to &lt; 85years(10 subjects,62.5%)

Fatal serious ADRs: &lt; 65 years (2 subjects, 1.5%), 65 to &lt; 75 years (1 subject, 1.7%), 75 to &lt; 85 years (1 subject, 6.3%)

AEs leading to drop-outs (study drug withdrawn): &lt; 65 years (19 subjects, 14.5%),65 to &lt; 75 years (11 subjects,18.3%),75 to &lt; 85 years (4 subjects, 25.0%)

Infections and infestations S0C: &lt; 65 years (28 subjects, 21.4%), 65 to &lt; 75 years (15 subjects, 25.0%), 75 to &lt; 85 years (9 subjects, 56.3%)

Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, and fractures: &lt; 65 years (2 subjects, 1.5%), 65 to &lt; 75 years (1 subject, 1.7%), 75 to &lt; 85 years (1 subject, 6.3%)

Comment: The IDL+BR regimen appears poorly tolerated in patients &gt;75 years of age, but the sample is very small.

Therewerenoapparentgenderorracerelateddifferences.

## Cross-study comparison

## Adverse Events ≥ Grade 3 selected by the assessor in Studies GS-US-312-0115, GS-US-312-0116,andGS-US-312-0119(SafetyAnalysisSet)

| Preferred Term                      | IDL + BR (N = 207) (%)u   | PI+ BR (N =209) (%)u   | IDL + R (N =110) (%)u   | PI+R (N=108) (%)u   | IDL + O (N = 173) (%)u   | OAlone (N = 86) (%)u   |
|-------------------------------------|---------------------------|------------------------|-------------------------|---------------------|--------------------------|------------------------|
| SubjectswithAny≥Grade3 AE           | 196 (94.7)                | 163 (78.0)             | 81 (73.6)               | 58 (53.7)           | 160 (92.5)               | 48 (55.8)              |
| Pneumonia                           | 29 (14.0)                 | 17 (8.1)               | 11 (10.0)               | 10 (9.3)            | 28 (16.2)                | 7 (8.1)                |
| FebrileNeutropenia                  | 49 (23.7)                 | 13 (6.2)               | 5 (4.5)                 | 5 (4.6)             | 21 (12.1)                | 3 (3.5)                |
| Diarrhoea                           | 25 (12.1)                 | 4 (1.9)                | 10 (9.1)                | 0                   | 41 (23.7)                | 1 (1.2)                |
| AlanineAminotransferase Increased   | 22 (10.6)                 | 1 (0.5)                | 4 (3.6)                 | 0                   | 14 (8.1)                 | 0                      |
| Sepsis                              | 12 (5.8)                  | 6 (2.9)                | 6 (5.5)                 | 3 (2.8)             | 13 (7.5)                 | 1 (1.2)                |
| Colitis                             | 3 (1.4)                   | 0                      | 5 (4.5)                 | 0                   | 14 (8.1)                 | 0                      |
| InfusionRelated Reaction            | 5 (2.4)                   | 4 (1.9)                | 0                       | 4 (3.7)             | 5 (2.9)                  | 1 (1.2)                |
| AspartateAminotransferase Increased | 11 (5.3)                  | 0                      | 1 (0.9)                 | 0                   | 6 (3.5)                  | 0                      |

<div style=\"page-break-after: always\"></div>

| Preferred Term                   | IDL + BR (N = 207) (%)u   | PI+ BR (N =209) (%)u   | IDL + R (%)u   | PI+R (N =110)(N=108) (%)u   | IDL + O (N = 173) (%)u   | O Alone (N = 86) (%)u   |
|----------------------------------|---------------------------|------------------------|----------------|-----------------------------|--------------------------|-------------------------|
| Urinary Tract Infection          | 5 (2.4)                   | 4 (1.9)                | 1 (0.9)        | 2 (1.9)                     | 6 (3.5)                  | 0                       |
| Neutropenic Sepsis               | 3 (1.4)                   | 6 (2.9)                | 2 (1.8)        | 0                           | 4 (2.3)                  | 2 (2.3)                 |
| Pneumonitis                      | 4 (1.9)                   | 0                      | 4 (3.6)        | 1 (0.9)                     | 8 (4.6)                  | 0                       |
| Pneumocystis jirovecii pneumonia | 2 (1.0)                   | 0                      | 4 (3.6)        | 1 (0.9)                     | 9 (5.2)                  | 0                       |
| Septic Shock                     | 5 (2.4)                   | 1 (0.5)                | 0              | 2 (1.9)                     | 5 (2.9)                  | 1 (1.2)                 |
| TransaminasesIncreased           | 8 (3.9)                   | 0                      | 3 (2.7)        | 1 (0.9)                     | 2 (1.2)                  | 0                       |
| Rash                             | 6 (2.9)                   | 0                      | 1 (0.9)        | 0                           | 5 (2.9)                  | 1 (1.2)                 |
| RespiratoryTractInfection        | 3 (1.4)                   | 5 (2.4)                | 0              | 1 (0.9)                     | 2 (1.2)                  | 2 (2.3)                 |
| Autoimmune Haemolytic Anaemia    | 0                         | 5 (2.4)                | 0              | 0                           | 1 (0.6)                  | 0                       |
| Rash Maculo-Papular              | 1 (0.5)                   | 0                      | 1 (0.9)        | 0                           | 4 (2.3)                  | 0                       |

## 2.3.3.11.Discussiononclinicalsafety(Rapporteur)

Qualitativelytherearenonewadversereactionsidentified,butquantitativelythereisanon-trivial

AnySAEis thusincreasedfrom45to70%,grade≥3eventsfrom78to95%.AEsleadingto IDL/placebo discontinuation were reported in 33% vs. 15%.Data on dose reductions/discontinuations withrespecttoBRwill be askedfor.

Grade≥3infectiouseventswereincreasedfrom26to41%.Skin,diarrhoeaandhepaticeventswere alsorelevantlyincreased.TheeventsofpneumocystisorCMvinfectiousevents,however,werelowin bothtreatmentarms.Adherencetoprophylacticmeasuresshouldbediscussed.

To increase the understanding, AEs should be reported separately for BR+IDL and BR+Pl for the period

## 2.3.3.12.Conclusionsonclinicalsafety

IDL+BR cannotbe characterised asa well-tolerated CLLregimen,but theSPC is considered toprovide reasonable guidance.

## 2.3.3.13.CoRappSafetyDiscussion:

ThesafetyevaluationtoexpandtheCLLindicationforZydeligtoincludeitsuseincombinationwith bendamustine and rituximab(BR)is based on the results of the primary analysis of pivotal Study GSUS-312-0115 and supported by data from other IDL monotherapy or combination therapy studies (combination with rituximab or ofatumumab).Study GS-US-312-0115 was stopped early as recommendedby theDMCbasedonefficacyof theformalinterimanalysis(at75%of thePFSevents). Demographicsandbaselinecharacteristics instudyGS-US-312-0115representanelderlyfitCLL population. In comparison to the other combination therapy studies (GS-US-312-0116, and GS-US312-0119), study GS-US-312-0115 set out specific inclusion criteria for haematopoietic laboratory parameters (ANC ≥ 1.5 10 9/L, platelets ≥75 10 9/L and Hb ≥10 g/dl).

<div style=\"page-break-after: always\"></div>

InstudyGS-US-312-0115thetypeofAEsreported&gt;10%ofsubjectsareinlinewithwhatisexpected from the studied population (CLL), the use of IDL, bendamustine， and/or rituximab， e.g. gastrointestinal AEs,myelosuppression,infusionrelated and infectionrelated AEs.In theIDL+BR arm 23.7%of subjectsreported febrile neutropenia(compared to6.2%inBR alone),evenwhen adjusted forexposuredurationtheincidencerateforfebrileneutropeniawasincreasedcomparedtoBRalone (adjusted incidencerate0.20(IDL+BR)versus0.06). (71.o%).This is reflectedin highrates of dose interruption and frequentlygive rise to dose modifications(dose interruptions,dosereduction or dose discontinuation).Serious AEs were reported with &gt;5% of subjects were febrile neutropenia (IDL + BR 20.8%),pneumonia (IDL + BR 17.4%), pyrexia (IDL + BR 12.1%). deathduetoanAEwasreportedforIDL+R3.6%andIDL+O15%.DeathsduetoPDwerenot reported asAEsorSAEs.Adverseeventsleadingtodeathreportedfor&gt;1subjectweremainlyin the SOC infections and infestations, e.g. pneumonia (5 subjects, 2.4%), sepsis (3 subjects, 1.4%), and septic shock(2 subjects,1.0%). It is noticed that a significant proportion of patients in IDL + BR and BR arm have treatment-emergent toxicities occur with bendamustine treatment inCLL such as neutropenia，thrombocytopenia，and anaemia.For subjects with CLL in Studies GS-US-312-0115, GS-US-312-0116,and GS-US-312-0119, and 63.2%.Neutrophil count monitoring is recommended in the SmPC. In the event of severe neutropenia,treatment should be interrupted and may be restarted at a lower dose upon resolution. Noticeable,dose interruptiondue toneutropeniawas onlyreported in3.9%，whereas discontinuations ordosereductionswerereported&lt;2%ofthecases. Theidentifiedrisksforidelalisibtreatment，includingtransaminaseelevations，severediarrhoea/colitis, compared to BR alone.In study GS-US-312-0115,28 subjects(13.5%)in the IDL + BR group and 4 majorityof≥Grade3Diarrhoeaand/orColitiscouldberesolvedwithadosereductionordose interruption. 28.7%BR(study GS-US-312-0115）including 14 deathin IDL+BR and 10 death inBR due to in the IDL + BR group (no subject in placebo + BR) had PJP of any grade. One subject

<div style=\"page-break-after: always\"></div>

had PJP infection while receiving PJP prophylaxis(within 4 weeks of start prophylaxis). In study GS-US had CMV of any grade.

The number of subjects with dose discontinuations, dose reductions and interruptions due to AEs was high with IDL + BR treatment(respective 32.9%,16,4%,and 58,9%).The main AEs (≥5%)leading to dose modification were pneumonia, ALT increase, febrile neutropenia, and diarrhoea with IDL + BR treatment.Themediantimetoanddurationofthedoseinterruptionhasnotbeenprovided.Asubject couldhavehadmultipledosemodifications.Accordingto theprotocolreescalationofthedoseisnot needed，evenif thereisminimalornotoxicitywiththereduceddose(atthediscretionof the investigator).As such, dose re-escalation was only performed in 9 subjects(4.3%）withIDL +BR in influenced the percentageof expected doses takencomparedtothe actualdosagestaken，as this reflects the tolerability of the treatment.Moreover,it is notknown how manyAEs leading to dose modificationwhereduetobendamustinetoxicity.

Analysis of safety data by age group (&lt; 65, 65 to &lt; 75, and 75 to &lt; 85), revealed no clear differences for younger or older subjects in the duration of exposure to IDL+BR, as well as in the rates of AEs, in17ppatientswasnotperformed.

## 2.3.3.14.CoRappconclusiononclinicalsafety

In general, the safety findings of idelalisib combined with bendamustine rituximab are consistent with treatedCLLpatients.No newsafetyissueshavebeenraised.Themost frequentlyreportedAEs assessed by the investigator as related to study drug (IDL + BR) were neutropenia, diarrhoea, and alanineaminotransferaseincreased.

Thetolerabilityof IDL+BRgivesrisetodosereductionsor drugdiscontinuationdue toAEsandhigh disease duration) study population in Study GS-US-312-0115 than subjects in Studies GS-US-3120116 andGS-US-312-0119.Althoughahead-to-headcomparison with IDL + R has not been performed, it appears that the addition of bendamustine to IDL+R leads to increased toxicity.

## 2.3.4. PSUR cycle

The PSuR cycle remains unchanged.

## 2.3.5.DirectHealthcareProfessionalCommunication

Notwarranted

<div style=\"page-break-after: always\"></div>

## 2.3.6. Update of SmPC

RefertoappendedSmPC

## 2.3.7. Risk management plan

RMPversion2.2 is dated 23January2017.

## SummaryTableofSafetyConcerns

|                           | Transaminase elevation                                                                                         |
|---------------------------|----------------------------------------------------------------------------------------------------------------|
|                           | Severe dianhoea/colitis                                                                                        |
|                           | Pneumonitis                                                                                                    |
|                           | Neutropenia                                                                                                    |
|                           | Rash                                                                                                           |
|                           | Stevens-Johnson syndrome - Toxic epidermal necrolysis                                                          |
|                           | Senious infections including opportunistic infections such as PJP and CMV                                      |
|                           | Off-label use (first line CLL therapy in patients without 17p deletion/TP53 mutation, early lime INHL therapy) |
|                           | Reproductive toxicity including teratogenicity                                                                 |
|                           | Drug-drug interaction with CYP3A inducers                                                                      |
| Important Potential Risks | Drug-drug interaction with CYP3A substrates                                                                    |
| Important Potential Risks | Photosensitivity                                                                                               |
| Important Potential Risks | Skin cancer                                                                                                    |
|                           | Development of drug resistance                                                                                 |
|                           | Carcinogenicity                                                                                                |
|                           | Long-term safety                                                                                               |
|                           | Safety in patients with severe hepatic impairment                                                              |
|                           | Safety in patients with severe renal impaiment                                                                 |
| Missing Information       | Safety in patients with chronic active hepatitis                                                               |
| Missing Information       | Safety in patients with concomitant immunization                                                               |
| Missing Information       | Immunological effects and auto-immunity                                                                        |
| Missing Information       | Safety in children                                                                                             |
| Missing Information       | Safety ofbreastfeeding                                                                                         |
| Missing Information       | Drug-drug interaction with oral contraceptive                                                                  |

Comment:Forimportantidentifiedrisks;rashandSJSmaybereplaced with\"Severe toxicskin reactions,includingSJSand TEN\"andreplacetransaminaseelevationswith\"severetransaminase elevations\",similarly neutropeniawith\"severeneutropenia\".

PleaserefertoappendedSmPCandleaflet.

## 2.3.8. User consultation

has been submitted by the applicant and has been found acceptable by the Rapporteur and Corapporteur.

<div style=\"page-break-after: always\"></div>

JustificationsubmittedbytheMAH:

idelalisibwithbendamustineandrituximabanddoesnotsignificantlyimpactthereadabilityofthe package leaflet.In accordance with this assessment, readabilitytestinghasnot beenperformed on the packageleafletsubmitted inthisvariation.\"

## 2.3.9.QuickResponse(QR)code

N.a.

## 3.Benefit-RiskBalance

Proposedindication:Zydeligisindicatedincombinationwithbendamustineandrituximabforthe treatment of adult patientswith CLL whohavereceived at least oneprior therapy.

Patientswithdel17p/TP53positivediseasewereenrolled,butBRbackgroundisconsideredacceptable asthestudywasinitiatedin2012.

## Benefits

The aims of treatment of CLL includeimproved survival and a reduction in disease-related signs and symptomssuchascytopeniasandB-symptoms.ORRandPFSbenefitsare likelytoreflectatleast symptomaticbenefit.

## Beneficial effects

45% and as regards PFS the HR was 0.33 (p&lt;0.0001) with a median difference of about 10 months (21 vs. 11 months)at event rates of 40 and 70%.Improvements in cytopaenia were also demonstrated.

## Uncertaintyintheknowledgeaboutthebeneficialeffects

Due to the design, maintenance IDL vs. placebo (and the toxicity profile), benefit beyond PFS1 is analysis,however,wasonlyabout30%and thep-value borderline(0.036,HR 0.66).

In response to the LoI an updated analysis with cut-off 31 March 2017 was submitted. At event rates follow up (LTFU) declined participation or left TFU in the idelalisib arm vs. 24/116 (21%) in the control group.

PFS2datawere also submitted and theresults wereseeminglyfavourable,HR0.57.IntheIDL arm, however,the percentage of deaths was81%and in the control64%(q7).Furthermore in40%and 30% of patients are reported as next-line \"unknown\"(vs. next-line yes or no)

<div style=\"page-break-after: always\"></div>

## Risks

This is an add-on study to an acceptable background therapy in patients likely to tolerate BR. Thus the riskisconfinedtoadversereactions.

## Unfavourable effects

There is a clinically relevant increase in SAEs and grade ≥3 events, especially infectious events (please refer totablebelow)and the discontinuationrates due toAEs arehigh(IDL 33%,placebo15%).

## Uncertaintyintheknowledgeabouttheunfavourableeffects

Toimprovetheunderstandingthereisaneed toseparatethe\"induction\"phasefromthe \"maintenance\"phase.

## EffectsTable

|                                       |                            |                            | Uncertainties/ Strength of evidence                                         | References   |
|---------------------------------------|----------------------------|----------------------------|-----------------------------------------------------------------------------|--------------|
| Favourable Effects                    | Favourable Effects         | Favourable Effects         |                                                                             |              |
| OS(02May 2016)                        | IDL+BR (N=207)             | PI+BR (N=209)              |                                                                             | Study report |
| Number(%)ofSubjectswith Events        | 53(25.6)                   | 70(33.5)                   | Borderline statistically significant                                        | Study report |
| KMEstimateofOS（Months)a               | KMEstimateofOS（Months)a    | KMEstimateofOS（Months)a    |                                                                             | Study report |
| Q1(95%CI)                             | 23.5（16,NR)                | 15.7(13.2, 20.3)           | Uncertainty about missingness in follow-up                                  | Study report |
| Median (95% CI)                       | NR(NR, NR)                 | 40.6 (31.6, NR)            | after endofstudy                                                            | Study report |
| Adjusted HR(95%CI)b                   | 0.67 (0.47, 0.96)          | 0.67 (0.47, 0.96)          |                                                                             | Study report |
| P-value from Stratified Log- RankTest | 0.036                      | 0.036                      |                                                                             | Study report |
| OS（31March2017)                       | IDL+BR (N=207)             | PI+BR (N = 209)            | Note shift in HR and loss of \"significance\"                                 |              |
| Number(%)ofSubjectswith Events        | 75(36.2)                   | 86 (41.1)                  | Data unstable,i.e.still immature.                                           |              |
| KM Estimate of OS(Months)a            | KM Estimate of OS(Months)a | KM Estimate of OS(Months)a |                                                                             |              |
| Q1(95% CI)                            | 21.4(15.2; 27.5)           | 15.7(13.2, 20.3)           | In the idelalisibarm30/84 patients eligible for long term follow-up did not |              |
| Median(95%CI)                         | NR(40.1, NR)               | 43.1(38.4, NR)             | participate in LTFU                                                         |              |
| Adjusted HR(95% CI)b                  | 0.8 (0.59; 1.09)           | 0.8 (0.59; 1.09)           | In the control corresponding figureswere24/116                              |              |
| P-valuefromStratified Log-Rank Test   | 0.20                       | 0.20                       |                                                                             |              |
| PFS（070ctober2015)                    | IDL+BR (N=207)             | PI+BR (N=209)              |                                                                             |              |
| Number (%) of Subjects with Events    | 84(40.6)                   | 149 (71.3)                 | Convincing                                                                  |              |
| Disease Progression                   | 60 (29.0)                  | 130(62.2)                  |                                                                             |              |

<div style=\"page-break-after: always\"></div>

Death

KMEstimateof PFS（Months)a

Median (95% CI)

At24weeks

At48weeks

Adjusted HR (95% CI)b

P-valuec

ORR(070ctober2015)

Best Overall Response, n (%)a

Complete Response (CR)

Partial Response(PR)

Progressive Disease (PD)

ORR(CR+CRi+PR)

95%CI°

24(11.6)

20.8(16.6,

26.4)

88.5(83.0,

19(9.1)

11.1 (8.9,

11.1)

82.1 (76.0,

92.3)

86.7)

75.0(68.0,

50.5（43.2,

80.6)

57.5)

0.33(0.25,0.44)

6.540×10-16

IDL+BR

PI+ BR

(N=207)

(N=209)

3(1.4)

142(68.6)

1(0.5)

145(70.0)

63.3,76.2

## Unfavourable Effects(02 May2016)

## AdverseEvents≥Grade3

| Preferred Term                                                       | IDL+BR (N=207) n(%)   | PI+BR (N=209) n(%)   |
|----------------------------------------------------------------------|-----------------------|----------------------|
| Subjects with AE≥ Grade3                                             | 197(95.2)             | 163(78.0)            |
| Any SAE                                                              | 149(72.0)             | 94(45.0)             |
| AE IDL/placebo discontinuation                                       | 83(40.1)              | 31 (14.8)            |
| AE leading to death                                                  | 27(13.0)              | 19(9.1)              |
| Number of subjects(%o) with dose reductionsof IDL/placebo due to AE. | 35(16.9)              | 13(6.2)              |
| Pneumonia                                                            | 29 (14.0)             | 17(8.1)              |
| Febrile Neutropenia                                                  | 49(23.7)              | 13(6.2)              |
| Diarrhoea                                                            | 25(12.1)              | 4(1.9)               |
| Alanine Aminotransferase Increased                                   | 22(10.6)              | 1(0.5)               |
| Sepsis                                                               | 12 (5.8)              | 6(2.9)               |
| Colitis                                                              | 3(1.4)                | 0                    |

0

93(44.5)

19 (9.1)

94 (45.0)

38.1,52.0

## Uncertainties/ Strength of evidence

Convincing Note small proportion of CR

Clinicallyrelevant increase insevere ADRs.

High discontinuation rates

References

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                  |        |        | Uncertainties/ Strength of evidence   | References   |
|----------------------------------|--------|--------|---------------------------------------|--------------|
| Pneumonitis                      | 4(1.9) | 0      |                                       |              |
| Pneumocystis jirovecii pneumonia | 2(1.0) | 0      |                                       |              |
| Septic Shock                     | 5(2.4) | 1(0.5) |                                       |              |
| Rash                             | 6(2.9) | 0      |                                       |              |

## Benefit-RiskBalance

## C.I.6.ExtensionofindicationofZydeligincombinationwithBendamustineandrituximabin patients with relapsed CLL

Inordertooutbalancetheclinicallyrelevantincreasein≥Grade3infectiousevents,hepaticevents, colitisandskintoxicityasreflectedinthehighdiscontinuationrateintheIDLarmandapparent increase in deaths,reliable and stable Os data are needed fora properB/R assessment.Reliability, theshiftinOSHRfrom0.66to0.8.

As the meaning ofprogression on maintenance differsfromprogression onplacebo,favourable outcome databeyondPFS1 areneeded.SubmittedPFS2data are atthis stage non-interpretable(see above).Time tofirst and second next-line therapy mayprovide somereassurance as regardsbenefit beyond PFS1.

- Followingtheassessmentoftheextensionofindication,thebenefit/riskwas considered negative.
- In responseto the secondlistofoutstanding issues,the applicationfor the extension ofindicationforZydelig(idelalisib)incombinationwithbendamustineandrituximab forthetreatmentofadultpatientswithrelapsedchroniclymphocyticleukemia(CLL) hasbeenwithdrawnbytheMAH.

C.1.13.Submissionofinterimreportfromstudy101-08:aPhase2SingleArmStudyto InvestigatetheSafetyandClinicalActivityofidelalisibinCombinationwithRituximabinElderly tolerate chemotherapy(22%discontinued due to diarrhea/colitis).This,however,should be put in contextofdurableactivity,medianPFS&gt;2years.Infectiouseventsandcausalityarehard toassessin the absenceof acontrolgroup.Monotherapyisclearlyveryactive.

- ThissubmissionfulfilsPAMOo8adoptedduringtheinitialMAA.

SubmissionofthefinalreportfromstudyGS-Us-312-0123:aphase3randomizedstudy evaluatingidelalisibincombinationwithbendamustineandrituximab(IDL+BR)vs.Pl+BRinsubjects withpreviouslyuntreatedCLL.

2016,article20procedure).Duetoearlystudytermination,thepre-specifiedefficacyanalyseswere notconducted.

<div style=\"page-break-after: always\"></div>

Theidelalisibdevelopmentprogramexperiencetodatedoesnotsupportaby-line,overallincreased add-ontoxicity.Theunderlyingmechanismfor theincreasedearlyinfectiouseventsand associated fatalitiesseenintheidelalisibfront-lineCLLstudiesdoesnotappearattributabletoasingleidentified butismorelikelyduetoheightenedimmunomodulatoryeffectsexperiencedbysomepatientswitha treatment-naiveimmune system.

- Followingthewithdrawaloftheextensionofindication(C.I.6)andassessmentofthe submissionsunderC.I.13-theoverallB/RofZydeligremainspositive.

## 4. Recommendations

The following application has been withdrawn by the MAH in response to the second list of outstanding issues:

| Variation withdrawn   | Variation withdrawn                                                                                               | Type    | Annexes affected   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a-Change(s) to therapeutic indication(s)-Addition ofanewtherapeuticindicationormodificationofan approvedone | Type II | I and IIIB         |

C.1.6.Extension of Indication:Extension of the approved chronic lymphocytic leukemia(CLL)indication forZydelig toinclude itsuse incombinationwithbendamustine andrituximabbasedon theresults of controlledstudyevaluatingtheefficacyandsafetyofidelalisib(GS-1101)incombinationwith bendamustineandrituximabforpreviouslytreatedchroniclymphocyticleukemia\"asaconsequence,

Inaddition,theMarketing authorisationholder(MAH)tooktheopportunity toupdatethelistof local representativesinthePackageLeaflet.TheRMPversion2.2has alsobeensubmitted.Afterwithdrawal ofC.I.6,basedonthereviewof thesubmitteddata,theCHMPconsidersthefollowinggroupof variationsacceptableandthereforerecommendsthevariationstothetermsoftheMarketing Authorisation,concerning thefollowingchanges:

| Variationsaccepted   | Variationsaccepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.13               | C.I.13-Other variationsnot specifically covered elsewhereinthisAnnexwhichinvolvethesubmissionof studiestothecompetentauthority | Type II | None               |
| C.I.13               | C.I.13-Othervariationsnotspecificallycovered elsewhereinthisAnnexwhichinvolvethesubmissionof studiestothecompetentauthority    | Type II | None               |

C.I.13:Submission of the finalreport from study 101-08,a phase 2，single-arm study evaluated theevaluationof theuseofidelalisib inpatientswithCLL.Submissionof thisreportis alsomade in

<div style=\"page-break-after: always\"></div>

fulfilmentofPAMo08.

C.I.13: Submission of the final report from study GS-US-312-0123, a phase 3 randomized study evaluatedidelalisibincombinationwithbendamustineandrituximabinsubjectswithpreviously untreated CLL.Inclusion of this report is supportive of a complete safety evaluation concerning the useofthiscombinationinpatientswithCLL.

<div style=\"page-break-after: always\"></div>

## Annex 1: 1st Request for supplementary information

## Clinical pharmacology aspects Otherconcerns

- 1.A discussion onpotential DDI of Bendamustine withidelalisib and rituximab, supported by a presentation of the pharmacokinetics from the 2 different arms in study GS-US-312-0115 shouldbeprovidedbytheMAH.

## Clinicalefficacyaspects

## Otherconcerns

- 2.Due to the toxicity of IDL add-on to BR and the maintenance phase comparing IDL with placebo,asmatureaspossiblesurvivaldatawithinthisprocedureareconsideredessential fortheproperassessmentofbenefit-risk.Fullyacknowledgingthattheeventrateovertime is low,neverthelessplease submit a survivalupdate.
- 3.After end of study, survival data were collected every 6 months.Pleaseprovide details as relationtothedatacut-off.
4. Part of the pivotal study population previously received BR treatment (14.5% in the IDL + treatment may be repeated if the relapse or progression occurs at least 24-36 months after prior regimen,please discuss the activity of the studyregimens inthesepatients.This is of specialrelevanceincaseoftooearlyre-treatment(withine.g.24months).
5. Theapplicantisaskedtodiscusswhetherthiswasthecaseinpatientspreviouslytreated with BR.
6. Please provide data on time from PD to next-line therapy.
7. To further substantiate the efficacy of IDL+ BR, the applicant is asked to present PFS2 data, if available,or time to next subsequent and second subsequent therapy if not, as well as the typeofsubsequentotheranticancertherapies.
- 8.Please resubmit the forest plots including also medians (for the EPAR).
- 9.If data on MRD were collected,please report.
10. The proposed indication is for patients\"who have received at least one prior therapy\". However,most included patientsreceived 2or moreprior treatments,and the applicant is requested to present the proportion of patients that received only 1 prior therapy.
- 11.Insection 4.2of theSmPC it isrecommendedtoreduce thedose to100mg twicedaily after The median time to dose interruption,the number of dose interruptions per subject, and the

<div style=\"page-break-after: always\"></div>

- durationofthedoseinterruptionshouldbeprovided.Theapplicantshoulddiscusswhether thepresentedefficacyresults arestillrepresentativeforthe150mgtwicedailydosetaking intoaccount thepercentageofexpecteddoses tobetakenand thenumberofdays(or infusions)withtreatment.
- 12.The applicant is asked topresent and discussPFSKMcurves forpatientswith orwithout17p differences inPFS and OS results between the 17p deletion patient group and the 17p deletionand/orTp53mutationpatientgroup.
- 13.In 12.9% of placebo treated patients (vs. 0% in the IDL + BR treatment group) the reason for study discontinuation was study wide unblinding. It is not known why this occurred, and toelaborate.
14. Disposition of patients has been presented several times by the applicant, with slightly instudyGS-US-312-0115iscorrect.
- 15.The applicantstated that75%ofPFSeventshadoccurred atthe timeof theinterim analysis,whichexceedstheplannedfrequencyof66%.Basedonthenumberofevents presented inTable^PrimaryEndpoint:PFS byIRCAssessment,07October2015(ITT),the actual frequencyofPFSeventsseemed tobelower(56%).Theapplicantis asked toclarify.
- been observed for theIDL+BR treated patients.This would be similar to the 10 points increase observed with IDL + R alone. However,based on the median scores provided in Table 15(baseline 90,bestchangefrombaseline/highestvalue 90),animprovementof 0 asked to clarify.
- 17.Efficacyresultsin studyGS-US-312-0115havebeenpresented forpatients&lt;65 and≥65 75 (N = 60),and 75 to &lt; 85 (N = 16)years of age).Since the median age of the intended these3agegroupsaswell.
- Dec2012.However,results ofthe pre-specified sensitivity analyseswith thePPanalysisset submitthesedataanddiscusswhetherresultswerecomparabletotheITTanalysisset.
- 19.In the studyreport of the pivotal study,the applicant stated that a separate biomarker analysisplanwillbepreparedtodetailpharmacodynamicsandbiomarkeranalyses. Biomarkerresults,however,couldnotbefound inthedossierand the applicantisrequested tosubmitinformationregardingdisease-associatedbiomarkers，andtodiscusspotential PI3K mutation status.
20. PI3K mutations have been reported in a number of malignancies (Chaloub Ann Rev Pathol 2009).Please discuss if this is a concernin the treatmentwithIDL that would justify assessingPI3KstatusinpatientswithresistancetoIDL.

<div style=\"page-break-after: always\"></div>

- 21.Is thereadifferenceinbaseline characteristicsin theIDL+BR armbetweenpatientswith eventsofPFS≤6months,&gt;6 months and≤18months and&gt;18 months?Tocontextualise, similardatamaybereportedforthePl+BRarm.
- associated with the additionofIDL toBR,as these results could notbefound.

## Clinicalsafetyaspects

## Otherconcerns

- 23.Safetydata shouldbereportedseparatelyfor theinductionphase(IDL/placebo+BR)and the maintenance phase(IDL vs.placebo).This should include the reporting of ≥grade 3 events,dosereductions,interruptions and discontinuationfor alldrugsseparatelyand if combined (IDL, placebo, bendamustine and rituximab).
- 25.Adverse reactions led to the stopping of all first-line studies.Please compare adverse events of special interest per 2 months period IDL+BR vs.BR in studies 0015 and 0023.Please also discuss whether there is a\"true\"increase in add-on toxicity related to line of therapy and if soif thereareunderlyingmechanismsmakingthisplausible.
- 26.In the protocol of study GS-US-312-0115it was stated(in the section of dose modifications) combinationwithbendamustine orbendamustinerituximab.In thesafetysummaryandin theinterimCSRof studyGS-US-312-0115 nocasesof TLS have beenreported.The applicantisrequestedtoclarify.
- 27.It has not been reported whether cases of overdose in study GS-US-312-0115 have occurred.If so,narrativesshouldbeprovided.
- 28.Thelaboratory abnormalities observed in studyGS-US-312-0115 related to IDL + BR exposure should be further elucidated with respect to potassium, albumin and phosphate.
- 29.NeutrophilcountmonitoringisrecommendedintheSmPC.Intheeventofsevere neutropenia,treatment should be interrupted and maybe restarted at a lower dose upon resolution. Noticeable, dose interruption due to neutropenia was only reported in 3.9%, whereasdiscontinuationsor dosereductionswerereported&lt;2%of thecases.Assuch the applicantisrequestedtoreportwhatmeasureswheretakentoaddresstheseverecasesof spontaneously.
- 30.Data cut-off for the interim study report of study GS-US-312-0115 was 02 May 2016,as follow-up,is requested.
31. Is there a relationship between degree of neutropenia and onset of pneumonia, colitis and pyrexia?

<div style=\"page-break-after: always\"></div>

## RMP

## Other concerns

- 32.Pleaserevise the safety concerns:

Forimportantidentifiedrisks;rashandSJSmaybereplacedwith\"Severe toxicskinreactions, includingSJSandTEN\"andreplacetransaminaseelevationswith\"severetransaminase elevations\"，similarlyneutropeniawith\"severeneutropenia\".

## Assessment of the responses to the 1st Request for SupplementaryInformation

## Clinicalpharmacologyaspects

## Otherconcerns

## Question 1

presentation ofthe pharmacokineticsfrom the 2 different armsinstudy Gs-us-312-0115 shouldbeprovidedbytheMAH.

## SummaryofMAHanswer

TheStudyGS-US-312-0115Protocol(Amendment9)included thefollowingsecondary evaluationsofIDLplasmaconcentrationsovertime.Noanalysisofbendamustineorrituximabwas planned,asno drug-drug interactions(DDIs)were anticipated based oninvitrostudies.Bendamustine isprimarilymetabolizedbycytochromeP450(CYP)1A2viahydrolysisto2minormetaboliteswithlow activity.IDLdoesnotinhibitCYP1A2,thusisnotanticipated toaffectthemetabolismofbendamustine. Therefore, bendamustine plasma concentrations were not evaluated.Idelalisib is primarily metabolized by aldehyde oxidase(AO)and CYP3A4.Bendamustine is not a CYP3A4inhibitorand is not anticipated toaffectthemetabolismofIDLthroughthatpathway.However，thepossibleinteractionof bendamustinewithAOisunknown;therefore,thepotentialeffectofbendamustineonIDL hours postdose on Days 1, 29, 57, 85, 113, 141, and 169. Concentrations of IDL were determined usingavalidatedhighperformanceliquid-chromatography-tandemmassspectrometrybioanalytical andWeek24(Table1).Inaddition,troughconcentrationsofIDLwerecomparabletothoseobserved in other studies (eg, Studies 101-02, GS-US-312-0116, and GS-US-312-0119) and to population PK modelingestimatesfollowingmonotherapywith150mgIDLtwice daily.Theseresults areconsistent withthelackofeffectofBRcoadminisonIDLPK.Thusitisunlikelythatbendamustineinteractswith clearanceassmallmolecules,and isnotexpectedtointeractwithIDL,aswaspreviouslyestablished in clinical Study 101-07.

<div style=\"page-break-after: always\"></div>

Table 1 GS-US-312-0115:IdelalisibPlasma ConcentrationsFollowing150 mg IdelalisibTwiceDailyin CombinationwithBendamustineand RituximabinPreviously Treated Subjectswith ChronicLymphocytic Leukemia (PKAnalysisSet)

|                 | Sanpling Time        | Sanpling Time           | Sanpling Time        | Sanpling Time           | Sanpling Time        | Sanpling Time           |
|-----------------|----------------------|-------------------------|----------------------|-------------------------|----------------------|-------------------------|
|                 | Week4                | Week4                   | Week 12              | Week 12                 | Week 24              | Week 24                 |
| IDL (ng/mL)     | Predose              | 1.5 Hours Postdose      | Predose              | 1.5 Hours Postdose      | Predose              | 1.5 Hours Postdose      |
| N               | 153                  | 169                     | 140                  | 150                     | 105                  | 117                     |
| Median (Q1, Q3) | 363.0 (221.0, 633.0) | 2040.0 (1280.0, 2600.0) | 330.0 (187.5, 546.0) | 1995.0 (1450.0, 2610.0) | 317.0 (184.0, 578.0) | 2100.0 (1380.0, 2790.0) |

Source: GS-US-312-0115 Interim 1 CSR Table 10-1

## Rapporteur

TheMAHhasprovidedadiscussiononpotentialDDIofBendamustinewithidelalisibandrituximab.In short,Rituximabisaprotein,andthereforedoesnotusethesamemechanismsofclearanceassmall molecules,andisnotexpectedtointeractwithIDL.BendamustineismetabolizedbycytochromeP450 (CYP）1A2andIDLdoesnotinhibitCYP1A2,thusisnotanticipatedtoaffectthemetabolismof bendamustine.Idelalisib is primarily metabolized by aldehyde oxidase(AO)and CYP3A4. BendamustineisnotaCYP3A4inhibitorbutBendamustineseffectonaldehydeoxidaseisnotknown. Therefore,studyGS-US-312-0115secondaryobjectivewastocharacterizetheeffectofBRonIDL exposurethroughevaluations(presentedintable1above).Plasmaconcentrationswerecomparableat predoseand1.5hourspostdosebetweenWeek4andWeek24andtroughconcentrationsofIDLwere comparabletothoseobservedinotherstudies.

forrelevantDDIofBendamustinewithidelalisibandrituximab.

## Issue resolved

## 3.Clinicalefficacyaspects

## Other concerns

## Question 2

DuetothetoxicityofIDL add-ontoBR and themaintenancephasecomparingIDLwith placebo,asmatureaspossiblesurvivaldatawithinthisprocedureareconsideredessential fortheproperassessmentofbenefit-risk.Fullyacknowledging thattheeventrateover time is low,neverthelessplease submita survivalupdate.(Rapp +CoRapp)

## SummaryofMAHanswer

Overallsurvival(OS)datainthisreportwereestimatedfortheIntent-to-Treat(ITT)AnalysisSet basedonadatacutoffdateof31March2017(medianfollow-upof31months)andarepresentedin Table3.andFigure2.OSdatapresentedintheStudyGS-US-312-0115Interim1clinicalstudyreport (CSR)withadatacutoffdateof02May2016（medianfollow-upof21months)arealsopresentedin Table3.andFigure2forcomparison.TheITTAnalysisSetincludedallsubjectswhowererandomized inthestudywithtreatmentgroupdesignatedaccordingtoinitialrandomization.Datafromsurviving subjectswerecensored atthelasttimethatthesubjectwasknowntobealiveonstudyorin subjectsintheplaceboarmreceivednewtherapycomparedtotheIDLarm,whichalsocontributed to thedilutionofthecomparison.

Betweenthedatacutoff datefor theInterim1CSR(02May2016),andthedatacutoff dateforthis rituximab(IDL+BR)groupand16deathsintheplaceboplusbendamustine andrituximab

<div style=\"page-break-after: always\"></div>

(placebo + BR) group. By that date, 161 subjects had died: 75 subjects (36.2%) in the IDL + BR group and 86 subjects(41.1%)in the placebo +BR group.The adjusted hazard ratio(HR)(95%confidence interval[CI]) for OSwas 0.8(0.59,1.09).The median OS of the IDL+ BR group remained not reached,while themedianOSof theplacebo+BR group changed from 40.6 months to 43.1 months.

Table 2 GS-US-312-01l5:Overall Survival (ITTAnalysisSet)

|                                         | IDL+BR (N=207)    | PI+BR (N = 209)   |
|-----------------------------------------|-------------------|-------------------|
| 31 March 2017 Data Cutoff Date          |                   |                   |
| Number (%) of Subjects with Events      | 75 (36.2)         | 86 (41.1)         |
| Death                                   | 75 (36.2)         | 86 (41.1)         |
| Number (%) of Subjects Censored         | 132 (63.8)        | 123 (58.9)        |
| Discontinued Study                      | 90 (43.5)         | 116 (55.5)        |
| Ongoing in Study                        | 42 (20.3)         | 7 (3.3)           |
| KM Estimate of OS (Months)              |                   |                   |
| Q1 (95% CI)                             | 21.4 (15.2, 27.5) | 15.7 (13.2, 20.3) |
| Median (95% CI)                         | NR (40.1, NR)     | 43.1 (38.4, NR)   |
| Q3 (95% CI)                             | NR (NR, NR)       | NR (NR, NR)       |
| Adjusted HR (95% CI)b                   | 0.8 (0.59, 1.09)  | 0.8 (0.59, 1.09)  |
| P-value from Stratified Log-Rank Test   | 1.995 × 10-1      | 1.995 × 10-1      |
| P-value from Unstratified Log-Rank Test | 2.782 × 10-1      | 2.782 × 10-1      |
| 02 May 2016 Data CutoffDate             |                   |                   |
| Number (%) of Subjects with Events      | 53 (25.6)         | 70 (33.5)         |
| Death                                   | 53 (25.6)         | 70 (33.5)         |
| Number (%) of Subjects Censored         | 154 (74.4)        | 139 (66.5)        |
| Discontinued Study                      | 84 (40.6)         | 116 (55.5)        |
| Ongoing im Study                        | 70 (33.8)         | 23 (11.0)         |
| KM Estimate of OS (Months)              |                   |                   |
| Q1 (95% CI)                             | 23.5 (16, NR)     | 15.7 (13.2, 20.3) |
| Median (95% CI)                         | NR (NR, NR)       | 40.6 (31.6, NR)   |
| Q3 (95% CI)                             | NR (NR, NR)       | NR (40.6, NR)     |
| Adjusted HR (95% CI)*                   | 0.67 (0.47, 0.96) | 0.67 (0.47, 0.96) |
| P-value from Stratified Log-Rank Test   | 3.637 × 10-       | 3.637 × 10-       |
| P-value from Unstratified Log-RamkTest  | 5.874 × 10-       | 5.874 × 10-       |

CI = confidenceinterval; HR = hazard ratio; IDL + BR =idelalisib plus bendamustineand rituximab; KM = Kaplan-Meier; NR=notreached; OS = overallsurvival; Pl +BR=placebo phus bendamustine andrituximab;Q1 = first quartile, Q3 = third quartile

Hazard ratios and 95% Cls werecaleulated usingthe Cox proportional hazards model, adjustedfor randomization

OS (months)=(date of death -date ofrandomization+ 1)/30.4375.

stratification factors (1 7p deletion/TP53 mutation, IGHV mutation status, and disease status). Source:CHMP Table 2.1and GS-US-312-0115Interim 1 CSR Table9-5

<div style=\"page-break-after: always\"></div>

Figure 2 GS-US-312-0115:Kaplan-MeierPlotsofOverallSurvivalBasedonDatabase

## CutoffDate:31March2017(ITTAnalysisSet)

<!-- image -->

## Databasecutoffdate:02May2016(ITTAnalysisSet)

<!-- image -->

Piacebe R/B

209 (0) 204 (5) 198 (1) 182,(21)168 (30)-166 (34)139 (35);151 (43) 340 (50),123 (56)107 (9). 78 (64) 52 (66) 42.(6%).31.(68) 24.368) 17 (69)8 (69).3 (69)3 (69). .2)(69)0 (20) - .0 (70) . 0.(70)-.0(70)

<div style=\"page-break-after: always\"></div>

## Rapporteur (SE)

At event rates of 36 and 41% and a change in the OS HR from 0.67(95%CI 0.47;0.96)in the prior OS analyses to 0.8 (95% CI 0.59; 1.09) data appear unstable and are moving in a non-favorable direction.Thisconstitutesamajorconcernfromabenefit/riskperspective.

## Not resolved

## Co-Rapporteur(NL)

ItisagreedwiththeRapporteurthat theunfavourablechangeinpointestimatesof HRwiththe significant to a non-significant difference in OS between the treatment arms, the change in the KM curvesisconsideredsubtle,and seemsmostlyrelated to therightpartofthe curves,inwhichonlyfew patientswereatriskforanOsevent.

Toinvestigate theimpactfurther,it is suggested thatthe discussionshould atleast include the extendsfrom16-31 months in the 02MAY2016 analysis to16-36monthsinthe31MAR2017 analysis, but after that survival curves are similar between 37-43 month.In that period,however, only 10-15% of patients are at risk,sono conclusions aboutsimilarity(loss ofefficacy of IDL+BR)inthatperiod can 0.67 to 0.8 could be caused by this 37-43 months period.2)As noted in the response to RSI#14, Gileadstopped thestudyearlyduetoefficacyandtreatmentassignmentswereunblindedstudy-wide arm crossed overto the experimental arm and if so,discussitsimpact.3)The impact of informative censoringonOsisrequested tobeinvestigatedbyadditional analyses,notonlythepossible informative censoring within 26 (IDL+BR) vs 19 (placebo + BR) patients that did not enter the long beexpected as theestimated studycompletiondatawasDec2017,andpresentthe dataassoon as possible.

Theby theRapporteurraised uncertaintyduetoinformativecensoring(notenteringLTFUorlostfrom substantialwith36vs21%ofthediscontinuedpatientsintheexperimentaland thecontrol arm (30/84IDL+BRand25/116placebo+BR),itrepresents\"only\"12%and11%,respectivelyfromthe totalstudypopulation(25/207and22/209).

updatedOsdatainamajorobjection,andwepropose thatthediscussionshould include atleastthe4 topicshighlighted above.

## Issuenotresolved

## Question3

Afterendofstudy,survival datawerecollectedevery6months.Pleaseprovidedetailsasregards cut-off.

## Summary ofresponse

<div style=\"page-break-after: always\"></div>

## Overall Survival and Long-Term Follow-Up Status Based on Data Through 02 May 2016 (ITT Analysis Set)

|                                         | IDL + BR (N = 207)   | PI + BR (N = 209)   |
|-----------------------------------------|----------------------|---------------------|
| Number(%)ofSubjectswithEvents           | 53 (25.6)            | 70 (33.5)           |
| Death during LTFU                       | 20 (9.7)             | 38 (18.2)           |
| Death on Study                          | 33 (15.9)            | 32 (15.3)           |
| Number(%)ofSubjectsCensored             | 154 (74.4)           | 139 (66.5)          |
| Ongoing in Study                        | 70 (33.8)            | 23 (11.0)           |
| Discontinued Study                      | 84 (40.6)            | 116 (55.5)          |
| Discontinued Study, No LTFU             | 26 (12.6)            | 19 (9.1)            |
| Discontinued Study, Entered LTFU        | 58 (28.0)            | 97 (46.4)           |
| Ongoing in LTFU                         | 54 (26.1)            | 91 (43.5)           |
| Discontinued during LTFU                | 4 (1.9)              | 6 (2.9)             |
| KM Estimate of OS (Months)a             |                      |                     |
| Q1 (95% CI)                             | 23.5 (16.0, NR)      | 15.7(13.2, 20.3)    |
| Median (95% CI)                         | NR (NR, NR)          | 40.6 (31.6, NR)     |
| Q3 (95% CI)                             | NR (NR, NR)          | NR (40.6, NR)       |
| Adjusted HR (95% CI)b                   | 0.67 (0.47, 0.96)    | 0.67 (0.47, 0.96)   |
| P-valuefromStratified Log-RankTest      | 3.637 × 10-2         | 3.637 × 10-2        |
| P-value from Unstratified Log-Rank Test | 5.874 × 10-2         | 5.874 × 10-2        |

LTFU = long-term follow-up

## Reasons for Study Discontinuation, SubjectsWho Did Not Enter Long-Term Follow-Up (ITT Analysis Set)

| Subject Disposition                 | IDL + BR (N = 26) (%)u   | PI + BR (N = 19) (%)u   | Total (N = 45) (%) u   |
|-------------------------------------|--------------------------|-------------------------|------------------------|
| ReasonforStudyDiscontinuation       |                          |                         |                        |
| Adverse Event                       | 5 (19.2)                 | 3 (15.8)                | 8 (17.8)               |
| Physician Decision                  | 0                        | 4 (21.1)                | 4 (8.9)                |
| Withdrawalby Subject                | 10 (38.4)                | 7 (36.8)                | 17 (37.8)              |
| Progressive Disease                 | 6 (23.1)                 | 5 (26.3)                | 11 (24.4)              |
| Noncompliance with Study Drug       | 2 (7.7)                  | 0                       | 2 (4.4)                |
| Other                               | 1 (3.8)                  | 0                       | 1 (2.2)                |
| OtherAnticancer/ExperimentalTherapy | 1 (3.8)                  | 0                       | 1 (2.2)                |
| Lost to Follow-Up                   | 1 (3.8)                  | 0                       | 1 (2.2)                |

## Rapporteur

<div style=\"page-break-after: always\"></div>

In the idelalisib arm,26 patients who discontinued the study did not participate in long termfollow up (LTU)andanadditional4individualsleftLTUmeaningthataltogether30/84or36%ofpatients eligibleforLTUarenot availableforOSfollow-up.

Corresponding figures for the control arm were 19 + 5, i.e. 24/116, 21%.

missingness is an issue.Data notably refer to the May2016 cut-off.

Missingnessisby defaultnot arandomphenomenon and mayberelated toprognosis.

## Not resolved

## Question 4

8.1%intheplaceboarm).Accordingtocurrenttreatmentguidelines,firstlinetreatmentmaybe repeated if the relapse orprogression occurs at least 24-36 months afterchemo-immunotherapy and if provided.Ifbendamustinewaspartofthelastpriorregimen,pleasediscusstheactivityofthestudy 24 months).

## Summaryofresponse

WhenStudyGS-US-312-0115wasinitiated,thetreatmentguidelinesfromSeptember2011werenot as specific as the currentguidelinesquoted in thequestion.In theStudyGS-US-312-0115Interim1 CSR,37subjects(17.9%)in theIDL+BRgroupreportedbendamustine aspartof themostcommon

Bendamustine was reported to be the last regimen prior to study entry for 25 subjects (12.1%) in the

## Comparison ofConfirmedBoRforSubjectsWithout17pDeletionwhoReceived Analysis Set)

| Subject         |                    | StudyGS-US-312-0115   | StudyGS-US-312-0115   | StudyGS-US-312-0115   | StudyGS-US-312-0115   |
|-----------------|--------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Treatment Group | Number of Subjects | PR                    | SD                    | PD                    | NE                    |
| IDL + BR        | 20                 | 15 (75.0%)            | 4 (20.0%)             | 0                     | 1 (5.0%)              |
| Placebo + BR    | 11                 | 4 (36.4%)             | 5 (45.5%)             | 2 (18.1%)             | 0                     |

chemoimmunotherapywhenthe17pdeletionwasexcluded.Nosubjectswithouta17pdeletionhad to treatmentwithIDL+BR,but the sample size was too small to draw anymeaningful conclusions.

## Rapporteur:

was notfavouredby the use of BR in thelastpriorregimen.It is alsoacknowledged thattreatment guidelineshavechanged since the studywas initiated,i.e.are stricter inrelation tore-treatment.

## Resolved.

<div style=\"page-break-after: always\"></div>

## Question5 Theapplicantisaskedtodiscusswhetherthiswasthecaseinpatientspreviouslytreated with BR.(CoRapp)

## SummaryofMAHanswer

Dataforthesubsetofsubjectsreferredtointhisquestion,thosewhohadBRaspartofanyprior the IDL + BR group, and Table 10 for the placebo + BR group. There were 24 subjects (11.6%) in the IDL + BR group and 13 subjects (6.2%)in the placebo + BR group with no 17p deletion who had received BR as part of any regimen prior to entry into Study GS-US-312-0115 (Table 11). Thus, the IDL+BRgrouphadmoresubjectswhohad alreadyfailed torespond toBR than theplacebo+BR group. Nineteen subjects (79.2%)had a BOR of PR to treatment with IDL + BR, compared with only +    sa   +    d o a  () ss

<div style=\"page-break-after: always\"></div>

<!-- image -->

Table 9. GS-US-312-0115:SubsetofSubjects Without17pDeletion TreatedwithBendamustine+Rituximab as Part ofAnyRegimen Prior to Study Entry andTreatedwith IDL+BRon Study(ITTAnalysis Set)

|         |         |              |                                | PDDate          | Study GS-US-312-0115   | Study GS-US-312-0115   | Study GS-US-312-0115   |
|---------|---------|--------------|--------------------------------|-----------------|------------------------|------------------------|------------------------|
| Subject | Regimen | Regimen Type | Regimen Start/ EndDate         | (Prior Regimen) | PFS (Months)           | OS (Months)            | Confirmed BOR          |
|         | 1       | BR           | 15 Feb 2010/22Jume 2010        | March 2012      | 25.0 (Censor)          | 25.0 (Censor)          | PR                     |
|         | 2       | BR           | 18 April 2011/07 Sept 2011     | 27 May 2013     | 13.8 (Event)           | 16.0 (Event)           | PR                     |
|         | 2       | BR           | 09 Jam 2012 /16 July 2012      | 30 April 2013   | 6.0 (Event)            | 24.4 (Event)           | SD                     |
|         | 3       | BR           | 18 July 2011/ 13 Oct 2011      | 11 April 2013   | 28.5 (Censor)          | 29.0 (Censor)          | PR                     |
|         | 2       | BR           | 01 Jam 2011 / 01 July 2011     | 28 June 2013    | 25.1 (Censor)          | 25.8 (Censor)          | PR                     |
|         | 2       | BR           | 25 Feb 2010 / 04 August 2010   | 30 Nov 2012     | 11.3 (Event)           | 18.4 (Censor)          | PR                     |
|         | 3       | BR           | 16 October 2011 /13 March 2012 | Oct2012         | 5.5 (Censor)           | 18.1 (Censor)          | PR                     |
|         | 5       | BR           | 12 Oct 2009/09 Sept 2010       | 28 Jan 2013     | 8.8 (Event)            | 13.1 (Event)           | PR                     |
|         | 2       | BR           | 01 Jan 2005 / 01 Jan 2005      | 2006            | 30.3 (Event)           | 30.3 (Censor)          | PR                     |
|         | 3       | BR           | 01 Jan 2012 /21 June 2012      | 25 Nov 2013     | 19.5 (Event)           | 20.8 (Censor)          | PR                     |
|         | 6       | BR           | 01 August2011/01 August 2011   | August 2011     | 5.7 (Censor)           | 6.4 (Censor)           | SD                     |
|         | 4       | BR           | 12.March 2012/07August 2012    | 29 August 2013  | 19.2 (Censor)          | 19.4 (Censor)          | PR                     |
|         | 3       | BR           | 07 Dec 2011 / 20 March 2012    | Oct2012         | 19.7 (Censor)          | 19.7 (Censor)          | PR                     |
|         | 2       | BR           | 01 June 2011 /22 Dec 2011      | 31 Dec 2012     | 25.3 (Censor)          | 25.3 (Censor)          | PR                     |
|         | 5       | BR           | 07 Jume 2012/13 Sept 2012      | May 2014        | 13.8 (Censor)          | 13.8 (Censor)          | PR                     |
|         | 1       | BR           | 01 Jan 2011 /01 Jan 2011       | 10 Aprl 2013    | 21.8 (Event)           | 27.3 (Censor)          | PR                     |
|         | 3       | BR           | 08 Mar 2013 / 05 August 2013   | May 2014        | 4.2 (Event)            | 10.2 (Cemsor)          | SD                     |
|         | 2       | BR           | 02 August 2011 /29 Feb 2012    | 28 Nov 2013     | 0.0 (Censor)           | 9.4 (Event)            | NE                     |
|         | 3       | BR           | 25 Feb 2010/17 May 2010        | 2013            | 17.4 (Censor)          | 18.5 (Censor)          | PR                     |
|         | 3       | BR           | 25 Aprl 2011 / 26 Sept 2011    | 11 June 2013    | 13.9 (Censor)          | 19.9 (Censor)          | PR                     |
|         | 2       | BR           | 18 June 2012 /08 Nov 2012      | 03 Feb 2014     | 13.8 (Cemsor)          | 13.9 (Censor)          | PR                     |
|         | 5       | BR           | 01 Jam 2013 / 25 April 2013    | 24 Feb 2014     | 4.6 (Censor)           | 10.6 (Censor)          | SD                     |
|         | 5       | BR           | 18 July 2013 / 19 July 2013    |                 | 16.5 (Censor)          | 17.2 (Censor)          | PR                     |
|         | 5       | BR           | 19 Dec 2012 / 25 April 2013    | 25 Oct 2013     | 13.6 (Event)           | 16.6 (Censor)          | PR                     |

Source: CHMP Listing4.2

Table 10. GS-US-312-0115:Subset of SubjectsWithout17pDeletionTreatedwithBendamustine +Rituximab as Partof Any Regimen Prior to Study Entry and TreatedwithPlacebo+BR OnStudy (ITT Analysis Set)

|         |                |              |                             |                         | Study GS-US-312-0115   | Study GS-US-312-0115   | Study GS-US-312-0115   |
|---------|----------------|--------------|-----------------------------|-------------------------|------------------------|------------------------|------------------------|
| Subject | Regimen Number | Regimen Type | Regimen Start/ End Date     | PD Date (Prior Regimen) | PFS (Months)           | OS (Months)            | Confirmed BOR          |
|         | 4              | BR           | 20 Sept 2011 / 11 Nov 2011  | 18 Feb 2014             | 8.3 (Event)            | 18.2 (Censor)          | PR                     |
|         | 2              | BR           | 19 June 2012 / 06 Nov 2012  | 14 Feb 2014             | 11.6 (Event)           | 14.3 (Censor)          | SD                     |
|         | 3              | BR           | 03 April 2010/30 Sept 2010  | 27 Oct 2011             | 11.2 (Event)           | 14.8 (Censor)          | PR                     |
|         | 4              | BR           | 26 May 2010 / 17 Sept 2010  | 01 Nov 2012             | 14.3 (Event)           | 32.3 (Censor)          | PR                     |
|         | 3              | BR           | 10 July 2009 / 15 Dec 2009  | August 2012             | 2.9 (Censor)           | 25.2 (Censor)          | SD                     |
|         | 4              | BR           | 21 May 2012/ 08 Oct 2012    | 22 July 2013            | 2.7 (Event)            | 3.6 (Event)            | PD                     |
|         | 4              | BR           | 18 Feb 2011 / 19 July 2011  | 10 April 2012           | 8.5 (Censor)           | 13.9 (Censor)          | SD                     |
|         | 2              | BR           | 01 Jan 2011 / 01 Jan 2011   | Feb 2012                | 3.0 (Censor)           | 12.6 (Event)           | SD                     |
|         | 4              | BR           | 01 Dec 2011 / 20 April 2012 | 19 Feb 2013             | 6.2 (Event)            | 7.1 (Event)            | PR                     |
|         | 2              | BR           | 01Jan 2011/01Jumne 2011     | Oct 2012                | 14.9 (Event)           | 17.2 (Event)           | PR                     |
|         | 4              | BR           | 18 Sept 2013 / 28 Nov 2013  | 16 April 2014           | 8.5 (Event)            | 16.8 (Censor)          | SD                     |
|         | 5              | BR           | 02 Jume 2010/28 July 2010   | 29 March 2011           | 5.7 (Event)            | 5.7 (Event)            | SD                     |
|         | 5              | BR           | 17 Jan 2012 / 29 May 2012   |                         | 16.6 (Censor)          | 16.6 (Censor)          | PR                     |

Source: CHMP Listing4.2

<div style=\"page-break-after: always\"></div>

Table 1l. GS-US-312-01l5:Comparisonof ConfirmedBORforSubjectsWithout17pDeletionTreatedwith Bendamusine +RituximabasPart ofAnyRegimen PriortoStudyEntry (ITT AnalysisSet)

|                         |                    | Study GS-US-312-0115   | Study GS-US-312-0115   | Study GS-US-312-0115   | Study GS-US-312-0115   |
|-------------------------|--------------------|------------------------|------------------------|------------------------|------------------------|
| Subjeet Treatment Group | Number of Subjects | PR                     | SD                     | PD                     | NE                     |
| IDL +BR                 | Z                  | 19 (79.2%)             | 4 (16.7%)              | 0                      | 1 (4.1%)               |
| Placebo +BR             | 13                 | 6 (46.2%)              | 6 (46.2%)              | (%)1                   | 0                      |

Source: CHMPListing4.2

## Co-Rapporteur

Thisquestion5shouldbeseeninconjunctionwithOC4.Only2patientsmetthecriteriaof relapseor progression occurring 24 to 36 months after initial chemoimmunotherapy when the 17p deletion was excluded.Nopatientswithouta17pdeletionhad diseaseprogression&lt;24months afterinitial chemoimmunotherapy. However, as stated before, it is acknowledged that treatment guidelines have changed since the studywasinitiated,i.e.arestricterinrelation tore-treatment.Moreover,itis reassuring thatinthepatientsthatpreviouslyreceivedBRtreatment,19patients(79.2%)hadaBOR ofPR to treatmentwithIDL+BR,compared with only6patients(46.2%）achieving BORofPR in the placebo + BR group, even though the IDL + BR group had more subjects that did not previously respondtoBR alone.

Issue resolved.

## Question 6.

PleaseprovidedataontimefromPDtonext-linetherapy.

## Summaryofresponse

Seventysubjects in theIDL+BRgroupand 146subjects intheplacebo+BRgrouphad Independent Review Committee (IRC)-confirmed PD. Twenty-nine (41.4%) of the subjects in the IDL + BR group IDL+BR group showswidely scattered distribution(Figure 2).The median(Q1,Q3)time fromPD to next-line therapy was 81(36, 218) days for subjects in the IDL + BR group and 109 (45, 204) days for subjects in the placebo + BR group.

## SummaryofTime(Days)fromProgressiveDiseasetoNext-LineTherapy(ITTAnalysisSet)

|                                          | IDL + BR (N = 207)   | Placebo + BR (N =209)   |
|------------------------------------------|----------------------|-------------------------|
| Subjects with PD, n (%)                  | 70 (33.8)            | 146 (69.9)              |
| Treated with Next-line Therapy, n (%)a   |                      |                         |
| Yes                                      | 29 (41.4)            | 89 (61.0)               |
| No                                       | 13 (18.6)            | 13 (8.9)                |
| Unknown                                  | 28 (40.0)            | 44 (30.1)               |
| Time (Days) from PD to Next-line Therapy |                      |                         |
| N                                        | 28                   | 89                      |
| Mean (StD)                               | 147.2 (144.14)       | 141.4 (119.04)          |

<div style=\"page-break-after: always\"></div>

| Median          | 80.5    | 109.0   |
|-----------------|---------|---------|
| Q1,Q3           | 36,218  | 45,204  |
| Minimum,Maximum | 11, 443 | 1, 557  |

StD=standarddeviation

- aPercentagewasbasedonthenumberofsubjectswithPD

## Rapporteur

Immature data in combinationwith missingness make further analyses meaningless.

## Willnotbefurtherpursued.

## Question7

if available, or time to next subsequent and second subsequent therapy if not, as well as the typeofsubsequentotheranticancertherapies.as-well asthe-type ofsubsequent-other anticancer therapies. (CoRapp)

## SummaryofMAHanswer

Progression-freesurvivalonsecond-line therapy(PFS2)isdefined asthetimefromrandomizationto the date of disease progression on next-line treatment or deathfrom any cause.Because the date of of the second next-line therapy is used as a proxy. Table 4 summarizes PFS2 based on data through 02May2016andtheKMplotispresented inFigure3.

Fifty-eight subjects (28.0%)in the IDL + BR group and 90 subjects (43.1%)in the placebo + BR group reported a PFS2 event. The median (95% CI) time to PFS2 was not reached (33.7 months, NR) for subjects in the IDL + BR group and was 26.6 (22.8, 38.5) months for subjects in the placebo + BR group.The unadjusted HR(95%CI)was 0.57(0.41,0.79) and the p-value based on an unstratified log-rank test was 6.648 × 10-4.

<div style=\"page-break-after: always\"></div>

Table 4 GS-US-312-0115: Progression-Free Survival on Second-Line Therapy(ITT Analysis Set)

|                                    | IDL + BR (N =207)   | PI+ BR (N = 209)   |
|------------------------------------|---------------------|--------------------|
| Number(%)ofSubjectswithEvents      | 58 (28.0)           | 90 (43.1)          |
| PD                                 | 11 (19.0)           | 32 (35.6)          |
| Death                              | 47 (81.0)           | 58 (64.4)          |
| Number (%) of Subjects Censored    | 149 (72.0)          | 119 (56.9)         |
| KM Estimate of PFS2 (Months)a      |                     |                    |
| Q1 (95% CI)                        | 18.4 (15.2, 28.9)   | 14.1 (11.8, 16.9)  |
| Median (95% CI)                    | NR (33.7, NR)       | 26.6 (22.8, 38.5)  |
| Q3 (95%CI)                         | NR (NR, NR)         | 38.5 (38.5, 40.6)  |
| Unadjusted HR (95% CI)b            | 0.57 (0.41, 0.79)   | 0.57 (0.41, 0.79)  |
| P-value Unstratified Log-Rank Test | 6.648 × 10-4        | 6.648 × 10-4       |

PFS2= progression-free survival on second-line therapy

- b HRs and 95% CIs were calculated using the Cox proportional hazards model without any adjustments.

a PFS2 (months) = (start date of second subsequent post anti-cancer therapy, date of death]- date of randomization + 1)/ 30.4375.

Source:CHMPTableZ

Figure 3 GS-US-312-0115: Kaplan-Meier Curve of Progression-Free Survival on SecondLineTherapy(ITTAnalysisSet)

<!-- image -->

47 (80)

PFS2=progression-freesurvivalonsecond-linetherapy

Source:CHMPFigureZ

12(88)

<div style=\"page-break-after: always\"></div>

## Co-Rapporteur

Additional reassurance regarding the overall benefit of IDL+BR could be obtained from the KM curve of PFS on second line therapy time to subsequent anti-cancer treatment analysis, showing a favourable HRof0.57forIDL+BR treatmentvsBR alone.However,reliabilityof thedata is questioned due to the highproportionofmissing dataasalsodiscussed inresponsetoefficacyRSI#3.PFs2dataasreported appear non-reliable due to the very high event rates in terms of deaths (81% vs. 64%). Furthermore next-line therapy is reported as unknown in 30 to 40% of patients (vs. yes or no).

Issuepartlyresolved,remainingquestions:Timetofirstandsecondnext-linetherapyshouldbe reported based on the most recent study update. In the time to next-line analyses, deaths and informativecensoringshouldbeperformed,asreasonsforcensoringarenotprovided(72%inthe IDL=BR arm versus 56.9%in the placebo+ BR arm).Furthermore,the type of subsequent therapies is notprovidedandshouldbepresented(bothinoneoc).

## 8.Please resubmit the forest plots including also medians(for the EPAR).

## Applicant'sResponse

Therequested forestplotforprogression-free survival(PFS)based on a data cutoff date of 07October2015ispresentedinFigure4.TheforestplotforOSbasedonadatacutoffdateof 02May2016ispresentedinFigure4.

October2015(ITTAnalysisSet)

<!-- image -->

Source:Data on file

Figure 4. Forest Plot of Hazard Ratios for Overall Survival by Subgroup, Data Cutoff of 02May2016(ITTAnalysisSet)

0

0.5

1.5

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:Dataonfile

## Rapporteur:

Requesteddatahavebeensubmitted,butpreferablythelatestsurvivalcut-offshouldhavebeen submitted

Not resolved

## 9.If data on MRDwere collected,pleasereport.

Applicant'sResponse

Data on minimalresidual disease(MRD)were not collected in this study.

## Rapporteur:

TherearenoMRDdata.

Resolved

## Question10

The proposed indication is for patients\"whohave received at leastone prior therapy\". However, most included patients received 2 or more prior treatments, and the applicant is requested to present the proportion of patients that received only1 prior therapy.(CoRapp)

## SummaryofMAHanswer

Overall,121 subjects(29.1%)received only 1priortherapyregimen:59subjects(28.5%)in the IDL + BR group, and 62 subjects (29.7%) in the placebo + BR group. The number of prior regimens is presented in Table 5.

<div style=\"page-break-after: always\"></div>

Table 5

## GS-US-312-0115:Number of Prior Regimens(ITT AnalysisSet)

|                           | IDL + BR (N =207)   | PI + BR (N =209)   | Total (N = 416)   |
|---------------------------|---------------------|--------------------|-------------------|
| NumberofPriorRegimens(n%) |                     |                    |                   |
| 1                         | 59 (28.5)           | 62 (29.7)          | 121 (29.1)        |
| 2                         | 53 (25.6)           | 57 (27.3)          | 110 (26.4)        |
| 3                         | 42 (20.3)           | 37 (17.7)          | 79 (19.0)         |
| ≥4                        | 53 (25.6)           | 53 (25.4)          | 106 (25.5)        |

Source:CHMPTable10

## Rapporteur

## Resolved

## Question11

Insection4.2oftheSmPCitisrecommendedtoreducethedoseto1o0mgtwicedailyafter a dose interruption.The applicant is asked to explain why a large percentage of patients thatinterruptedstudytreatmentwasrechallengedatadoselevelof150mgBID,andto discussthefrequencyoffurtherdosemodifications andtreatmentdiscontinuationsafter rechallenge.Themedian time to dose interruption,the number of dose interruptions per subject,and the durationof the doseinterruptionshouldbeprovided.Theapplicantshould discusswhetherthepresentedefficacyresultsarestillrepresentativeforthe150mgtwice daily dose taking into account the percentage of expected doses to be taken and the number of days(orinfusions)with treatment.(CoRapp)

## SummaryofMAHanswer

Themanagementofdoseinterruptionsandrechallengesevolvedasexperiencewithidelalisibincreased duringclinical trials.Ingeneral,after asubjectexperienced anadverseevent(AE)suspected tobe related toIDL(basedoninvestigator assessment),study drug could bewithheld.Thereafter, dependingontheAE andseveritygrade,studydrugcouldbereinstituted ateitherthesamedoselevel dailydose)attheinvestigator'sdiscretion,usingtheprotocolguidelines.Forexample,ifa subject experienced Grade3 or 4fatigue,IDL was interrupted and resumed atthe same level,whereas, if Grade3increased alanineaminotransferase(ALT)/aspartateaminotransferase(AST)wasobserved, IDLwaswithhelduntil abnormalitieswere≤Grade1.Thereafter,if thesubjecthadincreasedbilirubin &lt;Grade3,IDLwasresumedatthesamelevelwhereasifbilirubinwas≥Grade3,IDLwasresumedat alowerlevel.A summaryofdosemodifications ispresented inTable 15.

Among subjects in theIDL + BR group,119 subjects(57.5%)had anIDL dose modification.Most of these subjects(101 subjects, 84.9%)had dose modifications due to AEs.The most frequently reported neutropenia.

<div style=\"page-break-after: always\"></div>

Mostof these subjects(46subjects,83.5%)had dose modificationsdue toAEs.Themostfrequently neutropenia,granulocytopenia,anddiarrhea.

dose interruption.Thisincluded subjects with dose interruptions unrelated toAEs.Two subjects(1.5%) haddosereductionswithoutinterruption(the dosefor1subjectwaslaterre-escalated).Eighty-seven subjects(73.1%）with dose interruptionswere rechallenged at 150 mg twice daily and 30subjects (25.2%)wererechallengedatalowerdose.IfthesubjecttoleratedthelowerdoseofIDLfor particularly if further evaluationrevealed that the AE leading tointerruptionwasnotstudy-drug (36.7%) met this criterion and were re-escalated to IDL 150 mg twice daily.

Most of the 117 subjects with dose interruptions in the IDL + BR group had either 1 interruption interruptionwas 2.1 months.Themedian duration of IDL interruptions(all interruptionperiods combined)was 1.1 monthscompared with the median durationof exposure toIDL of 18.2 months. Given the relatively short median duration of dose interruptions and the large proportion of subjects twice daily,the efficacyresults arerepresentative ofthe 150-mg twice daily dose.

<div style=\"page-break-after: always\"></div>

## GS-US-312-01l5:SummaryofDoseModificationofIdelalisib/Placebo

Table 15 (Safety Analysis Set)

|                                                    | IDL+BR (N=207)   | PI+BR (N = 209)   |
|----------------------------------------------------|------------------|-------------------|
| Subjects with Dose Modifications, n (%)            | 119 (57.5)       | 55 (26.3)         |
| Modification due to AE                             | 101 (48.8)       | 46 (22.0)         |
| Modification due to Other                          | 1 (0.5)          | 2 (1.0)           |
| Modification due to AE and Other                   | 17 (8.2)         | 7 (3.3)           |
| Subjects with Dose Reductions without Interruption | 2 (1.0)          | 1 (0.5)           |
| Subjects with Dose Re-escalations                  | 1 (0.5)          | 0                 |
| Subjects with Dose Interuptions                    | 117 (56.5)       | 54 (25.8)         |
| Mean (StD)                                         | 1.8 (1.08)       | 1.4 (0.81)        |
| Median                                             | 2.0              | 1.0               |
| Q1, Q3                                             | 1.0, 2.0         | 1.0, 1.0          |
| Min, Max                                           | 1.0, 7.0         | 1.0, 4.0          |
| Number of Dose Interruptions, n (%)                |                  |                   |
|                                                    | 90 (43.5)        | 155 (74.2)        |
| 1                                                  | 58 (28.0)        | 41 (19.6)         |
| 2                                                  | 36 (17.4)        | 6 (2.9)           |
| ≥3                                                 | 23 (11.1)        | 7 (3.3)           |
| Time to First Dose Interruption (months)           |                  |                   |
| Mean (StD)                                         | 4.2 (5.45)       | 4.2 (3.63)        |
| Median                                             | 2.1              | 2.8               |
| Q1, Q3                                             | 1.1, 4.3         | 1.0, 6.0          |
| Min, Max                                           | 0.1, 28.3        | 0.0, 13.1         |
| Duration of Dose Interruptions (months)            |                  |                   |
| N                                                  | 117              | 54                |
| Mean (StD)                                         | 1.5 (1.62)       | 0.9 (1.12)        |
| Median                                             | 1.1              | 0.5               |
| Q1, Q3                                             | 0.5, 1.7         | 0.3, 1.0          |
| Min, Max                                           | 0.1, 12.4        | 0.1, 5.7          |
| Subjects with Dose Rechallenged                    | 117 (54.5)       | 54 (25.8)         |
| Subjects Rechallenged at 150 mg                    | 87 (42.0)        | 40 (19.1)         |
| Subjects Rechallenged at 100 mg                    | 30 (14.5)        | 14 (6.7)          |
| Subjects With Dose Re-escalation                   | 11 (5.3)         | (6D)              |

<div style=\"page-break-after: always\"></div>

|                                               | IDL+BR (N=207)   | PI+BR (N =209)   |
|-----------------------------------------------|------------------|------------------|
| Duration of Exposure to IDL/Placebo (months)d |                  |                  |
| N                                             | 207              | 208              |
| Mean (StD)                                    | 16.1 (10.25)     | 11.4 (6.49)      |
| Median                                        | 18.2             | 11.1             |
| Q1,Q3                                         | 5.8, 24.0        | 5.8, 16.6        |
| Min, Max                                      | 0, 43.4          | 0.5, 28.5        |

AE = adverse event

- b Duration of doseinternuption included all interuptions, not just the first interruption.
- Ineludes subjects with at least 1 do se interruption
- First gechallenged dose afterthe first interuption was considered forthis analysis.
- d Duration of exposure(months) = (min [last IDL/Pldosing date as captured on study drug completion electronic case report form (eCRF) page, data cutoff date] -firstIDL/Pl dosing date + 1)/ 30.4375.

Source: CHMP Table 11 and GS-US-312-0115 Interim 1 CSR Section 15.1 Tables 5.12.1 and 5.12.2

## Co-Rapporteur

withidelalisibincreasedduringclinical trials.

Eighty-sevenpatients(73.1%)withdoseinterruptionswererechallenged at150mg twicedaily.Ofthe werere-escalated toIDL150mgtwicedaily.ThemediandurationofIDLinterruptions(allinterruption periods combined) was 1.1 months compared with the median duration of exposure to IDL of 150mgtwicedaily,itisagreedwiththeapplicantthatefficacyresultswererepresentativeofthe 150-mg twice daily dose.

## Issue resolved.

## Question12

TheapplicantisaskedtopresentanddiscussPFSKMcurvesforpatientswithorwithout 17pdeletionand/orTP53mutation.Theapplicantisfurthermoreaskedtodiscussthe observeddifferencesinPFSandOSresultsbetweenthe17pdeletionpatientgroupandthe 17p deletion and/or TP53mutationpatientgroup.

## SummaryofMAHanswer

Progression-freesurvival,asassessedbytheIRCbasedontheITTAnalysisSetaresummarizedin Table 6 by 17p deletion and/or TP53 mutation status (either vs neither); the KM plots are presented in Figure 5.

<div style=\"page-break-after: always\"></div>

Table 6 GS-US-312-0115:Progression-FreeSurvivalbyIRCAssessment,Subjectswith s Mutation(Neither)(ITTAnalysisSet)

|                                    | Subjectswith17pDeletion and/or TP53 Mutation (Either)   | Subjectswith17pDeletion and/or TP53 Mutation (Either)   | Subjectswithout 17p Deletion or TP53 Mutation(Neither)   | Subjectswithout 17p Deletion or TP53 Mutation(Neither)   |
|------------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                    | IDL + BR (N = 69)                                       | PI + BR (N = 68)                                        | IDL + BR (N = 138)                                       | PI + BR (N = 141)                                        |
| Number(%)of Subjects with Events   | 41 (59.4)                                               | 51 (75.0)                                               | 43 (31.2)                                                | 98 (69.5)                                                |
| PD                                 | 30 (43.5)                                               | 42 (61.8)                                               | 30 (21.7)                                                | 88 (62.4)                                                |
| Death                              | 11 (15.9)                                               | 9 (13.2)                                                | 13 (9.4)                                                 | 10 (7.1)                                                 |
| Number (%)of Subjects Censored     | 28 (40.6)                                               | 17 (25.0)                                               | 95 (68.8)                                                | 43 (30.5)                                                |
| Ongoing                            | 16 (23.2)                                               | 3 (4.4)                                                 | 66 (47.8)                                                | 28 (19.9)                                                |
| Discontinued Study                 | 11 (15.9)                                               | 13 (19.1)                                               | 28 (20.3)                                                | 14 (9.9)                                                 |
| ReceivedAnotherAntitumor Treatment | 1 (1.4)                                                 | 1 (1.5)                                                 | 1 (0.7)                                                  | 1 (0.7)                                                  |
| KM EstimateofPFS(Months)a          | KM EstimateofPFS(Months)a                               | KM EstimateofPFS(Months)a                               | KM EstimateofPFS(Months)a                                | KM EstimateofPFS(Months)a                                |
| Q1 (95% CI)                        | 6.3 (4.9, 8.5)                                          | 3.4 (2.8, 5.6)                                          | 14.8 (11.4, 19.5)                                        | 8.1 (6.2, 8.8)                                           |
| Median (95% CI)                    | 11.3 (8.8, 16.6)                                        | 8.3 (5.9, 8.5)                                          | 24.6 (19.5, 30.3)                                        | 11.2 (11.1, 13.6)                                        |
| Q3 (95% CI)                        | 26.4 (16.6, NR)                                         | 11.1 (8.5, 17.8)                                        | 30.3 (27.9, 30.3)                                        | 19.1 (14.3, 20.5)                                        |
| KMEstimateofPFSRate (95% CI)       |                                                         |                                                         |                                                          |                                                          |
| At 24 weeks                        | 78.3 (66.1, 86.6)                                       | 67.8 (54.6, 77.9)                                       | 93.7 (87.8, 96.8)                                        | 88.4 (81.8, 92.8)                                        |
| At 48weeks                         | 56.9 (43.7,68.1)                                        | 27.5 (16.3, 40.0)                                       | 84.3 (76.5, 89.7)                                        | 60.1 (51.2, 67.9)                                        |
| Unadjusted HR (95% CI)b            | 0.47 (0.31, 0.72)                                       | 0.47 (0.31, 0.72)                                       | 0.27 (0.18, 0.39)                                        | 0.27 (0.18, 0.39)                                        |

a PFS (months) =(minimum [date of PD, date of death] - date of randomization + 1) / 30.4375.

b HR and 95% CIs were calculated using the Cox proportional hazards model without any adjustment.

Source: GS-US-312-0115 Interim 1 CSR Section 15.1 Tables 2.1.1.1 and 2.1.1.2

Figure 5 Kaplan-Meier Plots of Progression-Free Survival by IRC Assessment, Subjects with17pDeletionand/orTP53Mutation(Either)vsSubjectswithout17pDeletionorTP53 Mutation(Neither)(ITT Analysis Set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Subjectswith17pDeletionand/orTP53Mutation(Either) Source: GS-US-312-0115 Interim 1 CSR Section 15.1Figure 1.1.1

<!-- image -->

Subjectswithout17pDeletionorTP53Mutation(Neither) Source: GS-US-312-0115 Interim 1 CSR Section 15.1 Figure 1.1.2

Progression-freesurvival,asassessedbytheIRCbasedontheITTAnalysisSet，forsubjectswith 17pdeletiononlyandforsubjectswith17pdeletionand/orTP53mutationissummarizedinTable7 and theKMplots arepresentedinFigure6.

Amongsubjectswith17pdeletiononly,PFSfollowingtreatmentwithIDL+BRwassuperiortotreatment withplacebo+BR,with anunadjusted HR(95%CI)of 0.62(0.37，1.04).Among subjectswith 17pdeletionand/orTP53mutation,PFSfollowing treatmentwithIDL+BRwassuperiortotreatmentwith

<div style=\"page-break-after: always\"></div>

Among subjects treated with IDL + BR, the KM estimate of median PFS(95% CI)was 11.0 (7.9,13.3) months for subjects with 17p deletion only,and 11.3 (8.8,16.6) months for subjects with 17p deletion and/orTP53mutation(Table7).TheKMestimatefor medianPFSwassimilarforsubjectswith

Table 7 GS-US-312-0115:Progression-FreeSurvivalbyIRCAssessment(Subjects with17pDeletionOnlyvsSubjectswith17pDeletionand/orTP53Mutation)(ITTAnalysis Set)

|                                    | Subjectswith 17pDeletion Only   | Subjectswith 17pDeletion Only   | Subjectswith 17pDeletion and/orTP53Mutation   | Subjectswith 17pDeletion and/orTP53Mutation   |
|------------------------------------|---------------------------------|---------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                    | IDL + BR (N =38)                | PI+ BR (N = 40)                 | IDL + BR (N = 69)                             | PI+BR (N = 68)                                |
| Number (%)of Subjects with Events  | 28 (73.7)                       | 32 (80.0)                       | 41 (59.4)                                     | 51 (75.0)                                     |
| PD                                 | 20 (52.6)                       | 25 (62.5)                       | 30 (43.5)                                     | 42 (61.8)                                     |
| Death                              | 8 (21.1)                        | 7 (17.5)                        | 11 (15.9)                                     | 9 (13.2)                                      |
| Number (%) of Subjects Censored    | 10 (26.3)                       | 8 (20.0)                        | 28 (40.6)                                     | 17 (25.0)                                     |
| Ongoing                            | 7 (18.4)                        | 2 (5.0)                         | 16 (23.2)                                     | 3 (4.4)                                       |
| Discontinued Study                 | 3 (7.9)                         | 5 (12.5)                        | 11 (15.9)                                     | 13 (19.1)                                     |
| ReceivedAnotherAntitumor Treatment | 0                               | 1 (2.5)                         | 1 (1.4)                                       | 1 (1.5)                                       |
| KM Estimate of PFS (Months)a       | KM Estimate of PFS (Months)a    | KM Estimate of PFS (Months)a    | KM Estimate of PFS (Months)a                  | KM Estimate of PFS (Months)a                  |
| Q1 (95% CI)                        | 5.1 (2.0, 8.3)                  | 2.9 (1.5, 5.2)                  | 6.3 (4.9, 8.5)                                | 3.4 (2.8, 5.6)                                |
| Median (95% CI)                    | 11.0 (7.9, 13.3)                | 5.9 (3.4, 8.4)                  | 11.3 (8.8, 16.6)                              | 8.3 (5.9, 8.5)                                |
| Q3 (95%CI)                         | 16.6 (11.1, 26.4)               | 13.7 (8.3, 18.5)                | 26.4 (16.6, NR)                               | 11.1 (8.5, 17.8)                              |
| KMEstimateofPFSRate(95%CI)         | KMEstimateofPFSRate(95%CI)      | KMEstimateofPFSRate(95%CI)      | KMEstimateofPFSRate(95%CI)                    | KMEstimateofPFSRate(95%CI)                    |
| At 24weeks                         | 73.2 (55.9, 84.6)               | 57.9 (40.7,71.7)                | 78.3 (66.1, 86.6)                             | 67.8 (54.6, 77.9)                             |
| At 48 weeks                        | 48.7 (31.9, 63.5)               | 30.4 (16.1, 46.1)               | 56.9 (43.7, 68.1)                             | 27.5 (16.3, 40.0)                             |
| Unadjusted HR (95% CI)b            | 0.62 (0.37, 1.04)               | 0.62 (0.37, 1.04)               | 0.47 (0.31, 0.72)                             | 0.47 (0.31, 0.72)                             |

a PFS (months) = (minimum [date of PD, date of death] - date of randomization + 1) / 30.4375.

b HR and 95%CIs were calculated using the Cox proportional hazards model without any adjustment.

Source: GS-US-312-0115 Interim 1 CSR Section 15.1 Tables 2.1.1.1, 2.1.1.2, and 2.1.1.5

<div style=\"page-break-after: always\"></div>

Figure 6.Kaplan-Meier Plots of Progression-Free Survival by IRC Assessment, (ITT Analysis Set)

<!-- image -->

Placebo + R/B

Subjectswith17pDeletionOnly

Source:GS-US-312-0115Interim1CSRSection 15Figure 1.1.5

<div style=\"page-break-after: always\"></div>

<!-- image -->

Subjectswith17pDeletionand/orTP53Mutation(Either)

Source: GS-US-312-0115 Interim 1 CSR Section 15.1 Figure 1.1.1

<div style=\"page-break-after: always\"></div>

Overall survival,based ontheITTAnalysisSet,forsubjectswith17p deletiononly andforsubjects with17pdeletionand/orTP53mutationissummarized inTable8and theKMplotsarepresented in Figure 7.

Among subjects with 17p deletion only, OS following treatment with IDL + BR was superior to OS following treatment with placebo + BR,with an unadjusted HR (95% CI) of 0.79 (0.42,1.48).Among subjects with 17p deletion and/orTP53 mutation,OS following treatment with IDL+ BRwas superior to OS for subjects treated with placebo + BR,with an unadjusted HR(95% CI)of 0.70 (0.43,1.15).

For subjects treated with IDL + BR, the KM estimate of median OS (95% CI) was 23.5 (12.2, not reached[NR])months for subjectswith17p deletion only and wasNR(18.4 months,NR)for subjects

Table 8 GS-US-312-0115: Overall Survival by IRC Assessment, Subjects with 17p DeletionOnlyvsSubjectswith17pDeletionand/orTP53Mutation(ITTAnalysisSet)

|                                    | Subjectswith17pDeletion Only   | Subjectswith17pDeletion Only   | Subjectswith 17pDeletion and/orTP53Mutation   | Subjectswith 17pDeletion and/orTP53Mutation   |
|------------------------------------|--------------------------------|--------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                    | IDL + BR (N =38)               | PI+BR (N =40)                  | IDL + BR (N = 69)                             | PI+ BR (N = 68)                               |
| Number (%) of Subjects with Events | 18 (47.4)                      | 22 (55.0)                      | 29 (42.0)                                     | 34 (50.0)                                     |
| Death                              | 18 (47.4)                      | 22 (55.0)                      | 29 (42.0)                                     | 34 (50.0)                                     |
| Number(%)of Subjects Censored      | 20 (52.6)                      | 18 (45.0)                      | 40 (58.0)                                     | 34 (50.0)                                     |
| DiscontinuedStudy                  | 16 (42.1)                      | 16 (40.0)                      | 28 (40.6)                                     | 31 (45.6)                                     |
| Ongoing                            | 4 (10.5)                       | 2 (5.0)                        | 12 (17.4)                                     | 3 (4.4)                                       |
| KM Estimate of OS(Months)a         |                                |                                |                                               |                                               |
| Q1 (95% CI)                        | 9.9 (2.8, 16.1)                | 7.5 (5.4, 13.2)                | 12.2 (6.3, 16.9)                              | 7.9 (5.7, 12.6)                               |
| Median (95% CI)                    | 23.5 (12.2, NR)                | 18.6 (12.1, 31.6)              | NR (18.4, NR)                                 | 18.6 (13, NR)                                 |
| Q3 (95% CI)                        | NR (NR, NR)                    | 31.6 (NR, NR)                  | NR (NR, NR)                                   | 31.6 (31.6, NR)                               |
| Unadjusted HR (95% CI)b            | 0.79 (0.42, 1.48)              | 0.79 (0.42, 1.48)              | 0.7 (0.43, 1.15)                              | 0.7 (0.43, 1.15)                              |

a OS(months）=(date of death-date ofrandomization+ 1)/30.4375.

b HRand95%CIwerecalculatedusing theCoxproportionalhazardsmodelwithoutany adjustments.

Source: GS-US-312-0115 Interim 1 CSR Section 15.1 Tables 7.1.1, Z.1.2, and Z.1.5

<div style=\"page-break-after: always\"></div>

Figure 7 Kaplan-Meier Plots of Overall Survival by IRC Assessment, Subjectswith 17p

<!-- image -->

Subjectswith17pDeletionOnly

Source:GS-US-312-0115Interim1CSRSection15Figure1.4.5

<!-- image -->

Subjectswith17pDeletionand/orTP53Mutation(Either)

Source:GS-US-312-0115Interim1CSRSection15.1Figure1.4.1

<div style=\"page-break-after: always\"></div>

## Co-Rapporteur

The primary endpoint PFS showed a treatment benefit for IDL + BR in patients with only 17p deletion s

OS following treatment withIDL+ BR was superior in both 17p deletion only(HR 0.79)and 17p deletion and/or TP53 mutation (HR 0.70) groups. However, the KM estimate for OS was longer for subjectswith17pdeletionand/orTP53mutation(23.5months)comparedwithsubjectswith s infavour of theBR arm.It ishowever acknowledged that thestudywas underpowered to show statistically significant differences inOSsubgroup analysis.

Issueresolved,butconcernsregardingOsdataarefurther discussed inOc 2.

## Question 13

In 12.9% of placebo treated patients (vs. 0% in the IDL + BR treatment group) the reason forstudydiscontinuationwasstudywideunblinding.Itisnotknownwhythisoccurred,and whether the blinding was sufficiently preserved throughout the study. The applicant is askedtoelaborate.

## Summaryofresponse

Based onresultsfrom theprespecified interim analysis,theIndependentDataMonitoring Committee (IDMC)recommendedstopping thestudyforefficacy.Uponreviewof thedata andfollowingdiscussion unblindedstudy-wideon16November2015.Atthattime,subjectsrandomized totreatmentwith placeboappropriatelydiscontinuedreceivingplaceboandcontinuedwithstudyproceduresper protocol.

<div style=\"page-break-after: always\"></div>

## Subject Disposition before unblinding data cut-off 07 October 2015(ITTAnalysisSet)

| Subject Disposition      | IDL + BR (N =207) (%) u   | PI+ BR (N =209) (%) u   | Total (N = 416) (%) u   |
|--------------------------|---------------------------|-------------------------|-------------------------|
| Randomized               | 207 (100)                 | 209 (100)               | 416 (100)               |
| Treated                  | 207 (100)                 | 209 (100)               | 416 (100)               |
| Treatment Ongoing        | 90 (43.5)                 | 45 (21.5)               | 135 (32.5)              |
| MetPrimaryStudy Endpoint | 34 (16.4)                 | 100 (47.8)              | 134 (32.2)              |
| PD                       | 32 (15.5)                 | 99 (47.4)               | 131 (31.5)              |
| Death                    | 2 (1.0)                   | 1 (0.5)                 | 3 (0.7)                 |
| Discontinued Treatmentb  | 83 (40.1)                 | 64 (30.6)               | 147 (35.3)              |
| AE                       | 56 (27.1)                 | 28 (13.4)               | 84 (20.2)               |
| Physician Decision       | 7 (3.4)                   | 24 (11.5)               | 31 (7.5)                |
| Withdrawal by Subject    | 12 (5.8)                  | 8 (3.8)                 | 20 (4.8)                |
| Other                    | 8 (3.9)                   | 4 (1.9                  |                         |

## Subject Disposition after unblinding data cut-off 02 May 2016 (ITT Analysis Set)

|                                        | IDL + BR (N = 207)   | PI+BR (N = 209)   | Total (N = 416)   |
|----------------------------------------|----------------------|-------------------|-------------------|
| Subject Disposition                    | (%)u                 | (%) u             | (%) u             |
| Randomized                             | 207 (100)            | 209 (100)         | 416 (100)         |
| Randomized but Not Treated With IDL/PI | 0                    | 1 (0.5)           | 1 (0.2)           |
| Treated with Any Druga                 | 207 (100)            | 209 (100)         | 416 (100)         |
| Treatment Ongoingb                     | 65 (31.4)            | 1 (0.5)           | 66 (15.9)         |
| Met Primary Study Endpointc            | 42 (20.3)            | 115 (55.0)        | 157 (37.7)        |
| PD                                     | 40 (19.3)            | 114 (54.5)        | 154 (37.0)        |
| Death                                  | 2 (1.0)              | 1 (0.5)           | 3 (0.7)           |
| DiscontinuedTreatmentc                 | 100 (48.3)           | 92 (44.0)         | 192 (46.2)        |
| AE                                     | 64 (30.9)            | 29 (13.9)         | 93 (22.4)         |
| Physician Decision                     | 9 (4.3)              | 24 (11.5)         | 33 (7.9)          |
| Study-Wide Unblinding                  | 0                    | 27 (12.9)         | 27 (6.5)          |
| WithdrawalbySubject                    | 16 (7.7)             | 8 (3.8)           | 24 (5.8)          |
| Other                                  | 11 (4.9)             | 4 (1.9)           | 9 (2.2)           |

a \"Any drug\" refers to any protocol-specified drug, ie, bendamustine, IDL, placebo, or rituximab.

C Reasonfor discontinuationwas determined by theinvestigator.

b For1subjectintheplacebo+BRgroup(Subject D,treatmentwaslisted as ongoing due to a data entry error; no subject in the placebo + BR group was continuing treatment at the data cutoff date of 02 May 2016.

## Rapportuer:

<div style=\"page-break-after: always\"></div>

TheMAHhasclarified.NotethatAEled tostudydrugdiscontinuationin31%ofpatientsinthe

The cross-over possibility was removed from the protocol in March 2016 (study wide unblinding November 2015) due to safety concerns (article 20).It is unclear how many patients crossed over after progression and after unblinding.

## Resolved

## Question 14

differentfrequencies.The applicantisasked toclarifywhichdataregarding thepatientflow in study GS-US-312-0115is correct.(CoRapp)

## SummaryofMAHanswer

BasedupontherecommendationoftheIDMCandfollowingreviewofthedataanddiscussionwith regulatoryagencies,Gileadstopped thestudyearlydue toefficacy.Treatmentassignmentswere unblinded study-wideon16November2015.Atthat time,subjectsrandomized totreatmentwith

Theprimaryanalysisofdataused adatacutoffdateof 07October2015,justpriortounblindingon 16 November 2015.Thepresentationsreferred toin thisresponse were correct,and differed slightly based onthe datacut-off dateusedfor the output.TheStudyGS-US-312-0115Interim1CSRcontains a discussion of the disposition of subjects using theprimary analysis data cutoff of 07 October 2015, andpresentstabular datafrom thedata cutoff datefor theInterim1CSR(after unblinding)of 02 May 2016.

withrespecttostudytreatment(IDLorplacebo)atthetimeoftheCSRdatacutoffdate (02 May 2016). Subject disposition data presented in the Study GS-US-312-0115 Interim 1 CSR Section 15.1, Table 5.1 summarized data with respect to continuation on study, whether or not subjectswerestillreceivingtreatment.

## Co-Rapporteur

## Issue resolved.

## Question 15

analysis,whichexceedstheplannedfrequencyof66%o.Basedonthenumberofevents clarify. (CoRapp)

## SummaryofMAHanswer

In theInterim1 CSR,thefollowing statementwasbased on thetotalnumberof plannedPFSevents at thefinalPFS analysis,ie,66%of260the total number ofplannedPFSevents.Based onresultsfrom

<div style=\"page-break-after: always\"></div>

thisprespecified interimanalysis(datacutoff date of15June2015),bywhichtime23moreevents hadactuallyoccurred,or75%ofPFSeventshadoccurred),theIDMCrecommendedstoppingthe study for efficacy.\"

The discussed frequency for PFS events of56%,Study GS-US-312-0115Interim 1 CSR,Section15.1, Table 2.1.1, is based on a data cutoff date of 07 October 2015, and represents the reported numbersbased on the total number of subjects in the ITTAnalysis Set(N= 416).

## Co-Rapporteur

Thedifferencesinplanned and actualfrequencyofPFSeventshavebeenclarified.

Issue resolved.

## Question16

The applicantstated that anincrease of10pointsinKarnofskyPerfomanceStatus(KPS)has beenobservedfor theIDL+BR treatedpatients.Thiswouldbe similartothe 10points increase observed withIDL+R alone.However,basedon the medianscoresprovided in asked to clarify.(CoRapp)

## SummaryofMAHanswer

placebo+BRgroup shifted tohigherKPSvalues.This shiftwashighestbetweenscoresof 90and100, + subjectsintheplacebo+BRgroup.

To determine \"Change from Baseline,\"the best change from baseline score was first derived for each subject,and then themedianof those changeswas calculated.This is differentfromdirectly comparing the 2 medians at baseline and at best postbaseline,which sometimes does not reflect the postbaseline of 90,90,and 100,also with median=90 points;however, the median change from baseline would be 10 points.

Table 9 GS-US-312-0115:Baseline andHighestPostbaselineKarnofskyPerformance Status Values

|           | IDL + BR (N =207)   | IDL + BR (N =207)         | Placebo + BR (N =209)   | Placebo + BR (N =209)      |
|-----------|---------------------|---------------------------|-------------------------|----------------------------|
| KPS Score | Baseline            | HighestPostbaseline Value | Baseline                | Highest Postbaseline Value |
| 50        | 0                   | 0                         | 1 (0.5)                 | 1 (0.5)                    |
| 60        | 5 (2.4)             | 3 (1.4)                   | 6 (2.9)                 | 1 (0.5)                    |
| 70        | 22 (10.6)           | 4 (1.9)                   | 18 (8.6)                | 7 (3.3)                    |

<div style=\"page-break-after: always\"></div>

|   80 | 61 (29.5)   | 26 (12.6)   | 58 (27.8)   | 31 (14.8)   |
|------|-------------|-------------|-------------|-------------|
|   90 | 81 (39.1)   | 75 (36.2)   | 79 (37.8)   | 87 (41.6)   |
|  100 | 38 (18.4)   | 95 (45.9)   | 47 (22.5)   | 79 (37.8)   |

KPS=KarnofskyPerformanceStatus

Source:CHMPTable16

## Co-Rapporteur

Theapplicantclarifiedthatthe10pointimprovementinKPSvalueswasbasedonthebestchange frombaselinescore.Thiswasfirstdeterminedforeachpatient,andthenthemedianofthosechanges postbaseline,whichsometimes doesnotreflectthe true change.

## Issue resolved.

## Question17

EfficacyresultsinstudyGS-US-312-0115havebeenpresentedforpatients&lt;65and≥65 years of age, safety results have been presented for 3 age groups: (&lt; 65 (N = 131), 65 to &lt; 75 (N =60),and 75to&lt;85(N =16)years ofage).Since the median age of the intended targetpopulationisrelativelyhigh,the applicantis asked topresentefficacyresultsfor these3agegroupsaswell.

## SummaryofMAHanswer

Therequested additionalposthoc analysesofefficacyresultsforsubjects&lt;65,65to&lt;75,and caution.

## Progression-FreeSurvival

Progression-free-survival by age subgroup (&lt; 65, 65 to &lt; 75, and ≥ 75 years of age), as assessed by theIRCbasedontheITTAnalysisSet,is summarized inTable10.PFSfollowingtreatmentwith unadjusted HRs (95% CIs) of 0.34 (0.24,0.49) for subjects &lt; 65years of age,0.41(0.25,0.69)for 9   &gt;

(71.8%) in the placebo + BR group had a PFS event. The KM estimate of median PFS (95% CI) was in the placebo + BR group.

Among subjects 65 to&lt; 75yearsof age,22 subjects(36.7%)in theIDL +BR group and 56subjects ( was 24.6 (11.9, 30.3) months for subjects in the IDL + BR group and 11.0 (8.4,14.1) months for subjectsintheplacebo+BRgroup.

in the placebo + BR group reported a PFS event. The KM estimate of median PFS (95% CI) was not reached (15.2 months, NR) for subjects in the IDL + BR group and was 11.1 (5.6, 13.7) months for subjects in the placebo + BR group.

<div style=\"page-break-after: always\"></div>

Table 10 GS-US-312-0115:Progression-FreeSurvival byAge Group(&lt;65,65 to&lt;75, and≥75YearsofAge)byIRCAssessment(ITTAnalysisSet)

|                                     | <65YearsofAge                    | <65YearsofAge                    | 65 to<75Years of Age             | 65 to<75Years of Age             | ≥75Years ofAge                   | ≥75Years ofAge                   |
|-------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                     | IDL + BR (N = 131 ）              | PI+ BR (N = 110 ）                | IDL + BR (N =60)                 | PI + BR (6L = N)                 | IDL + BR (N = 16)                | PI + BR (N =20)                  |
| Number (%) of Subjects with Events  | 57 (43.5)                        | 79 (71.8)                        | 22 (36.7)                        | 56 (70.9)                        | 5 (31.3)                         | 14 (70.0)                        |
| PD                                  | 42 (32.1)                        | 73 (66.4)                        | 15 (25.0)                        | 48 (60.8)                        | 3 (18.8)                         | 9 (45.0)                         |
| Death                               | 15 (11.5)                        | 6 (5.5)                          | 7 (11.7)                         | 8 (10.1)                         | 2 (12.5)                         | 5 (25.0)                         |
| Number(%)ofSubjects Censored        | 74 (56.5)                        | 31 (28.2)                        | 38 (63.3)                        | 23 (29.1)                        | 11 (68.8)                        | 6 (30.0)                         |
| Ongoing                             | 51 (38.9)                        | 16 (14.5)                        | 24 (40.0)                        | 13 (16.5)                        | 7 (43.8)                         | 2 (10.0)                         |
| Discontinued Study                  | 22 (16.8)                        | 14 (12.7)                        | 13 (21.7)                        | 9 (11.4)                         | 4 (25.0)                         | 4 (20.0)                         |
| ReceivedAnother Antitumor Treatment | 1 (0.8)                          | 1 (0.9)                          | 1 (1.7)                          | 1 (1.3)                          | 0                                | 0                                |
| KMEstimateofPFS(Months)a            | KMEstimateofPFS(Months)a         | KMEstimateofPFS(Months)a         | KMEstimateofPFS(Months)a         | KMEstimateofPFS(Months)a         | KMEstimateofPFS(Months)a         | KMEstimateofPFS(Months)a         |
| Q1 (95% CI)                         | 11.1 (8.3, 13.8)                 | 6.9 (5.4, 8.3)                   | 9.2 (4.9, 13.3)                  | 8.0 (5.4, 8.3)                   | 15.2 (0.8, NR)                   | 5.6 (1.5,10.8)                   |
| Median (95% CI)                     | 19.5 (16.1, 25.8)                | 11.1 (8.8, 11.3)                 | 24.6 (11.9, 30.3)                | 11.0 (8.4, 14.1)                 | NR (15.2, NR)                    | 11.1 (5.6, 13.7)                 |
| Q3 (95% CI)                         | 27.9 (25.8, NR)                  | 15.2 (11.6, 19.3)                | 30.3 (24.6, 30.3)                | 17.8 (14.3, 22.2)                | NR (16.5, NR)                    | 13.7 (11.1, NR)                  |
| KM Estimate of PFS Rate (95% CI)    | KM Estimate of PFS Rate (95% CI) | KM Estimate of PFS Rate (95% CI) | KM Estimate of PFS Rate (95% CI) | KM Estimate of PFS Rate (95% CI) | KM Estimate of PFS Rate (95% CI) | KM Estimate of PFS Rate (95% CI) |
| At 24weeks                          | 90.1 (83.3, 94.3)                | 80.9 (72, 87.2)                  | 87.2 (74.9, 93.7)                | 84.5 (74.3, 90.9)                | 80.4 (50.6, 93.2)                | 78.8 (52.8, 91.5)                |
| At48weeks                           | 76.1 (67.3, 82.9)                | 51.6 (41.2, 61)                  | 70.6 (55.9, 81.2)                | 49.4 (37.4, 60.3)                | 80.4 (50.6, 93.2)                | 50.0 (25.7, 70.3)                |
| Unadjusted HR (95% CI)b             | 0.34 (0.24, 0.49)                | 0.34 (0.24, 0.49)                | 0.41 (0.25, 0.69)                | 0.41 (0.25, 0.69)                | 0.26 (0.09, 0.75)                | 0.26 (0.09, 0.75)                |

a PFS(months）=(minimum(date ofPD,date ofdeath)-date of randomization+1)/30.4375.

b Hazard ratio and 95% CIs were calculated using the Cox proportional hazards model without any adjustments.

Source:CHMPTables17.1.1and17.1.2,andGS-US-312-0115Interim1CSRSection15.1Table 2.1.1.11

## OverallResponseRate

A summary of overall response rate (ORR) by age subgroup is presented in Table 11. ORR for subjects treatedwithIDL+BRwassuperiorto thatforsubjects treatedwithplacebo+BRineach age subgroup.

Among subjects &lt; 65 years of age, the ORR (95% CI) (classified as complete response (CR), complete response with incompletemarrowrecovery(CRi),orPRwithminimal durationof 12weeks）fortheITT Analysis Set was 73.3%(64.8%,80.6%)for the IDL + BR group and 41.8%(32.5%,51.6%)for the placebo + BR group. The odds ratio (95% CI) for ORR was 3.82 (2.22, 6.56), which favored IDL + BR over placebo + BR.

<div style=\"page-break-after: always\"></div>

Among subjects65 to&lt;75yearsof age,the ORR(95%CI)was63.3%(49.9%,75.4%)for the IDL + BR group and 50.6% (39.1%, 62.1%) for the placebo + BR group. The odds ratio (95% CI) for ORR was 1.68(0.85,3.34),which favored IDL + BR over placebo + BR.

Among subjects ≥ 75years of age,the ORR(95%CI)was 68.8%(41.3%,89.0%)for the IDL + BR ( )  9   +   (6) 3.3 (0.83,13.18),which favored IDL + BR over placebo + BR.

Table 11 GS-US-312-0115:Overall ResponseRateby Age Group(&lt; 65,65 to&lt; 75,and ≥75YearsofAge)byIRCAssessment(ITTAnalysisSet)

|                          | <65YearsofAge            | <65YearsofAge            | 65to<75Yearsof Age       | 65to<75Yearsof Age       | ≥75YearsofAge            | ≥75YearsofAge            |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                          | IDL + BR = N) i31)       | PI+ BR = N) 110)         | IDL + BR (N =60)         | PI+BR (N= (64            | IDL + BR (N = 16)        | PI+ BR = N) 20)          |
| BestOverallResponse,n(%) | BestOverallResponse,n(%) | BestOverallResponse,n(%) | BestOverallResponse,n(%) | BestOverallResponse,n(%) | BestOverallResponse,n(%) | BestOverallResponse,n(%) |
| CR                       | 2 (1.5)                  | 0                        | 1 (1.7)                  | 0                        | 0                        | 0                        |
| CRi                      | 0                        | 1 (0.9)                  | 0                        | 0                        | 0                        | 0                        |
| PR                       | 94 (71.8)                | 45 (40.9)                | 37 (61.7)                | 40 (50.6)                | 11 (68.8)                | 8 (40.0)                 |
| SD                       | 27 (20.6)                | 48 (43.6)                | 16 (26.7)                | 28 (35.4)                | 4 (25.0)                 | 9 (45.0)                 |
| PD                       | 0                        | 12 (10.9)                | 1 (1.7)                  | 5 (6.3)                  | 0                        | 2 (10.0)                 |
| NE                       | 8 (6.1)                  | 4 (3.6)                  | 5 (8.3)                  | 6 (7.6)                  | 1 (6.3)                  | 1 (5.0)                  |
| ORRa n (%)               | 96 (73.3)                | 46 (41.8)                | 38 (63.3)                | 40 (50.6)                | 11 (68.8)                | 8 (40.0)                 |
| 95% CIb                  | 64.8, 80.6               | 32.5, 51.6               | 49.9, 75.4               | 39.1, 62.1               | 41.3, 89.0               | 19.1, 63.9               |
| OddsRatioforORRc         | 3.82                     | 3.82                     | 1.68                     | 1.68                     | 3.30                     | 3.30                     |
| 95% CI                   | 2.22,6.56                | 2.22,6.56                | 0.85, 3.34               | 0.85, 3.34               | 0.83, 13.18              | 0.83, 13.18              |

CR = complete response; CRi = complete response with incomplete marrow recovery; ORR = overall responserate

b 95%CIforORRwasbasedontheexactmethod.

a ORR was the percentage of subjects that had best overall response of CR, CRi, or PR.

C Odds ratio and 95% CI were calculated without any adjustment.

SubjectswithCR,CRi,orPRwhomaintained theresponsefor atleast12weekswere definedtohave confirmed response; otherwise, response status was categorized as SD.

2.2.1.11

## LymphNodeResponse Rate

A summary of the lymph node response (LNR) rate by age subgroup is presented in Table 12.

Among subjects &lt; 65 years of age, the LNR rate (95% CI) was 96.7% (91.8%, 99.1%) for the IDL + BR group and 56.2% (46.2%, 65.9%) for the placebo + BR group. The odds ratio (95% CI) for the LNR rate was 23.00(7.90,66.95),which favored IDL + BR over placebo + BR.

Among subjects 65 to &lt; 75 years of age, the LNR rate (95% CI) was 98.2% (90.3%,100%) for the ( %)  s   + 0   (%8) %69    + the LNR rate was 23.29 (3.03, 179.19), which favored IDL + BR over placebo + BR.

Among subjects ≥ 75 years of age, the LNR rate (95% CI) was 93.3% (68.1%, 99.8%) for the IDL + BR group and 52.6% (28.9%, 75.6%) for the placebo + BR group. The odds ratio (95% CI) for theLNR rate was 12.60(1.37,115.97),which favored IDL+ BR over placebo+BR.

<div style=\"page-break-after: always\"></div>

Table 12 GS-US-312-0115: Lymph Node Response Rate by Age Group (&lt; 65, 65 to &lt; 75, and≥75YearsofAge)byIRCAssessment(ITTAnalysisSet)

|                       | <65YearsofAge      | <65YearsofAge    | 65to<75Yearsof Age   | 65to<75Yearsof Age   | ≥ 75 Years of Age   | ≥ 75 Years of Age   |
|-----------------------|--------------------|------------------|----------------------|----------------------|---------------------|---------------------|
|                       | IDL + BR (N = 131) | PI+ BR (N = 110) | IDL + BR (N =60)     | PI+BR (6L = N)       | IDL + BR (N = 16)   | PI+BR (N =20)       |
| LNR Ratea n/N (%)     | 118/122 (96.7)     | 59/105 (56.2)    | 54/55 (98.2)         | 51/73 (69.9)         | 14/15 (93.3)        | 10/19 (52.6)        |
| 95% CIb               | 91.8, 99.1         | 46.2, 65.9       | 90.3,100             | 58.0, 80.1           | 68.1, 99.8          | 28.9, 75.6          |
| Odds Ratioc           | 23.00              | 23.00            | 23.29                | 23.29                | 12.60               | 12.60               |
| 95% CI for Odds Ratio | 7.90, 66.95        | 7.90, 66.95      | 3.03, 179.19         | 3.03, 179.19         | 1.37, 115.97        | 1.37, 115.97        |

LNR = lymph node response; SPD = sum of the products of greatest perpendicular diameters

- b 95%CIfor response rate was based on the exact method.
- a LNRratewas defined as thepercentageofsubjectswhoachieved a≥5o%decreasefrombaseline intheSPDofindexlymphnodes.
- C

TheanalysisonlyincludessubjectsintheITTAnalysisSetwhohadbothbaselineand atleast 1 evaluablepost-baselineSPD.

Source:CHMP Tables 17.3.1 and 17.3.2, and GS-US-312-0115Interim 1 CSR Section 15.1 Table 2.4.1.11

## OverallSurvival

A summaryof Osbyage subgroupispresented inTable 13.

Among subjects&lt; 65years of age,54 subjects died on study:24subjects(18.3%)in the IDL + BR group and 30 subjects (27.3%) in the placebo + BR group. The unadjusted HR (95% CI) for OS was

IDL + BR group and 25 subjects (31.6%) in the placebo + BR group. The unadjusted HR (95% CI) for

Among subjects ≥ 75 years of age, 13 subjects died on study:3 subjects (18.8%)in the IDL + BR group and 10 subjects (50.0%) in the placebo + BR group. The unadjusted HR (95% CI) for OS was 0.30(0.08,1.09)whichfavoredIDL+BRoverplacebo+BR.

Table 13 GS-US-312-0115:OverallSurvivalbyAgeGroup(&lt;65,65to&lt;75,and≥75 YearsofAge)(ITTAnalysisSet)

|                                           | <65YearsofAge     | <65YearsofAge   | 65to<75Yearsof Age   | 65to<75Yearsof Age   | ≥ 75 Years of Age   | ≥ 75 Years of Age   |
|-------------------------------------------|-------------------|-----------------|----------------------|----------------------|---------------------|---------------------|
|                                           | IDL + BR (N =131) | PI+BR (N =110)  | IDL + BR (N =60)     | PI+BR (6L = N)       | IDL+BR (N =16)      | PI+ BR (N =20)      |
| Number (%) of SubjectswithEvents (Deaths) | 24 (18.3)         | 30 (27.3)       | 19 (31.7)            | 25 (31.6)            | 3 (18.8)            | 10 (50.0)           |
| Number (%) of Subjects Censored           | 107 (81.7)        | 80 (72.7)       | 41 (68.3)            | 54 (68.4)            | 13 (81.3)           | 10 (50.0)           |
| Discontinued Study                        | 45 (34.4)         | 55 (50.0)       | 23 (38.3)            | 45 (57.0)            | 9 (56.3)            | 9 (45.0)            |
| Ongoing                                   | 62 (47.3)         | 25 (22.7)       | 18 (30.0)            | 9 (11.4)             | 4 (25.0)            | 1 (5.0)             |

KM Estimate of OS (Months)a

<div style=\"page-break-after: always\"></div>

|                         | <65YearsofAge      | <65YearsofAge     | 65to<75Yearsof Age   | 65to<75Yearsof Age   | ≥ 75 Years of Age   | ≥ 75 Years of Age   |
|-------------------------|--------------------|-------------------|----------------------|----------------------|---------------------|---------------------|
|                         | IDL + BR (N = 131) | PI + BR (N = 110) | IDL + BR (N =60)     | PI + BR (N = 79)     | IDL + BR (N = 16)   | PI + BR (N =20)     |
| Q1 (95% CI)             | NR (16.0, NR)      | 15.0 (12.1, 20.3) | 16.7 (8.7, 27.5)     | 17.2 (8.7, 40.6)     | NR (0.8, NR)        | 12.7 (1.5, 20.8)    |
| Median (95% CI)         | NR (NR, NR)        | 31.6 (20.3, NR)   | NR (26.8, NR)        | 40.6 (NR, NR)        | NR (NR, NR)         | 26.6 (11.8, NR)     |
| Q3 (95%CI)              | NR (NR, NR)        | NR (31.6, NR)     | NR (NR, NR)          | 40.6 (NR, NR)        | NR (NR, NR)         | NR (26.6, NR)       |
| Unadjusted HR (95% CI)b | 0.59 (0.34, 1.01)  | 0.59 (0.34, 1.01) | 1.03 (0.57,1.89)     | 1.03 (0.57,1.89)     | 0.30 (0.08, 1.09)   | 0.30 (0.08, 1.09)   |

a OS (months) = (date of death - date of randomization + 1) / 30.4375

Source:CHMPTables 17.4.1 and 17.4.2, and GS-US-312-0115Interim 1 CSR Section 15.1 Table 2.5.1.11

b HRand95%CIwerecalculatedusing theCoxproportionalhazardsmodelwithoutany adjustments.

## Duration of Response

Asummaryofdurationofresponse(DoR)ispresented inTable14.

Among subjects&lt; 65years of age,the KM estimate of median DOR(95%CI)was 22.8 (14.9,24.8) months for subjects in the IDL + BR group and 8.7(8.3, 15.7) months for subjects in the placebo + BR group.

Amongsubjects65to&lt;75yearsofage,theKMestimateofmedianDOR(95%CI)was 27.2 (16.6, 27.2) months for subjects in the IDL + BR group and 11.7 (10.8, 18.5) months for subjectsintheplacebo+BRgroup.

Among subjects ≥ 75 years of age, the KM estimate of median DOR (95% CI) was not reached (13.4 months, NR) for subjects in the IDL + BR group and 8.6 (5.2,NR)months for subjects in the placebo + BR group.

Table 14 GS-US-312-0115:DurationofResponse by Age Group(&lt; 65,65to&lt; 75,and ≥75YearsofAge)byIRCAssessment(ITTAnalysisSet)

|                                          | <65YearsofAge     | <65YearsofAge   | 65to<75Yearsof Age   | 65to<75Yearsof Age   | ≥ 75 Years of Age   | ≥ 75 Years of Age   |
|------------------------------------------|-------------------|-----------------|----------------------|----------------------|---------------------|---------------------|
|                                          | IDL + BR (N =131) | PI+ BR (N =110) | IDL + BR (N= ：60)    | PI + BR (N = 79)     | IDL + BR (N = 16)   | PI+ BR (N =20)      |
| Number (%)of Subjects with CR, CRi,or PR | 96 (73.3)         | 46 (41.8)       | 38 (63.3)            | 40 (50.6)            | 11 (68.8)           | 8 (40.0)            |
| Number(%)of Subjects with Events         | 35 (36.5)         | 28 (60.9)       | 10 (26.3)            | 24 (60.0)            | 1 (9.1)             | 6 (75.0)            |
| PD                                       | 29 (30.2)         | 28 (60.9)       | 8 (21.1)             | 24 (60.0)            | 1 (9.1)             | 5 (62.5)            |
| Death                                    | 6 (6.3)           | 0               | 2 (5.3)              | 0                    | 0                   | 1 (12.5)            |
| Number (%) of Subjects Censored          | 61 (63.5)         | 18 (39.1)       | 28 (73.7)            | 16 (40.0)            | 10 (90.9)           | 2 (25.0)            |
| Ongoing                                  | 51 (53.1)         | 14 (30.4)       | 24 (63.2)            | 12 (30.0)            | 7 (63.6)            | 2 (25.0)            |
| Discontinued Study                       | 10 (10.4)         | 3 (6.5)         | 3 (7.9)              | 4 (10.0)             | 3 (27.3)            | 0                   |
| ReceivedAnother Antitumor Treatment      | 0                 | 1 (2.2)         | 1 (2.6)              | 0                    | 0                   | 0                   |

<div style=\"page-break-after: always\"></div>

|                             | <65YearsofAge               | <65YearsofAge               | 65to<75Yearsof Age          | 65to<75Yearsof Age          | ≥75YearsofAge               | ≥75YearsofAge               |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                             | IDL + BR (N = 131)          | PI + BR (N = 110)           | IDL + BR (N =60)            | PI+BR (6L = N)              | IDL + BR (N = 16)           | PI+BR (N =20)               |
| KM Estimate of DOR(Months)a | KM Estimate of DOR(Months)a | KM Estimate of DOR(Months)a | KM Estimate of DOR(Months)a | KM Estimate of DOR(Months)a | KM Estimate of DOR(Months)a | KM Estimate of DOR(Months)a |
| Q1 (95% CI)                 | 11.0 (9.0, 13.8)            | 5.8 (5.6, 8.3)              | 16.6 (7.4, 27.2)            | 8.3 (5.6, 11.3)             | NR (13.4, NR)               | 8.1 (5.2, 8.6)              |
| Median (95% CI)             | 22.8 (14.9, 24.8)           | 8.7 (8.3, 15.7)             | 27.2 (16.6, 27.2)           | 11.7 (10.8, 18.5)           | NR (13.4, NR)               | 8.6 (5.2, NR)               |
| Q3 (95% CI)                 | 24.8 (22.8, NR)             | 16.6 (13.6, NR)             | 27.2 (21.6, 27.2)           | 19.1 (16.2, 20.9)           | NR (13.4, NR)               | NR (8.2, NR)                |

DOR=duration ofresponse

- DOR(months）=(minimum[date ofPD,date of death]-date of first documented CR,CRi,or PR + 1)/ 30.4375.

Analysis onlyincluded subjectswho achieved CR,CRi,orPR.

SubjectswithCR,CRi,orPRwhomaintained theresponseforatleast12weeksweredefined tohave confirmed response; otherwise,response status was categorized as SD.

Source:CHMP Tables 17.5.1 and 17.5.2, and GS-US-312-0115 Interim 1 CSR Section 15.1 Table 2.6.1.11

## Co-Rapporteur

Efficacy results have been provided for the three age groups (&lt; 65 (N = 131 in the IDL + BR arm), 65 to&lt; 75(N=60),and 75to&lt; 85(N=16)years of age.Benefit has been observed withIDL+ BR over BR alone in all three age groups for the primary endpoint PFS, and secondary endpoints ORR, but theHRsuggest thatpatientsin the agegroup65to&lt;75havenoOSbenefitfrom the addition of IDLtoBRtreatment(HR 1.03).Itishowever acknowledgedthatthestudywasunderpoweredtoshow statisticallysignificantdifferencesinOSsubgroupanalysis.

Issueresolved,butconcernsregardingosdataarefurtherdiscussedinoc 2.

## Question18

Dec2012. However, results of the pre-specified sensitivity analyseswith the PP analysis set for the primary and secondary endpoints were not presented, and the applicant is asked to submitthesedataanddiscusswhetherresultswerecomparabletotheITTanalysisset. (CoRapp)

## SummaryofMAHanswer PrimaryEndpoint:Progression-FreeSurvival

Progression-free survival results were comparable between theITT and Per Protocol(PP)AnalysisSets.In bothanalysissets,IDL+BRwassuperiortoplacebo+BR.IntheITTAnalysisSet,theadjustedHR thePPAnalysis Set, the adjusted HR(95%CI)was 0.34(0.26,0.45)with a 2-sided p-value&lt;0.0001 based ona stratified log-ranktest(Table 15).

<div style=\"page-break-after: always\"></div>

Among subjects in the ITTAnalysisSet,84subjects(40.6%)in the IDL +BR group and 149 subjects (71.3%)in the placebo + BR group reported PFS events.The median (95% CI) PFS was in the placebo+ BR group.

Among subjects in the PP Analysis Set, a total of 84 subjects (41.6%) in the IDL + BR group and 143 subjects (71.1%) in the placebo + BR group reported a PFS event. The KM estimate of median PFS (95% CI) was 19.5 (16.5, 25.8) months for subjects in the IDL + BR group and 11.1 (8.8, 11.1) months for subjects in the placebo + BR group.

Table 15 GS-US-312-0115:Progression-FreeSurvivalbyIRCAssessment(ITTandPP AnalysisSets)

|                                   | ITT AnalysisSet   | ITT AnalysisSet   | PP Analysis Set   | PP Analysis Set   |
|-----------------------------------|-------------------|-------------------|-------------------|-------------------|
|                                   | IDL + BR (N =207) | PI+ BR (N =209)   | IDL + BR (N =202) | PI+ BR (N =201)   |
| Number(%)of Subjects withEvents   | 84 (40.6)         | 149 (71.3)        | 84 (41.6)         | 143 (71.1)        |
| PD                                | 60 (29.0)         | 130 (62.2)        | 60 (29.7)         | 125 (62.2)        |
| Death                             | 24 (11.6)         | 19 (9.1)          | 24 (11.9)         | 18 (9.0)          |
| Number (%) of Subjects Censored   | 123 (59.4)        | 60 (28.7)         | 118 (58.4)        | 58 (28.9)         |
| Ongoing                           | 82 (39.6)         | 31 (14.8)         | 81 (40.1)         | 31 (15.4)         |
| DiscontinuedStudy                 | 39 (18.8)         | 27 (12.9)         | 35 (17.3)         | 25 (12.4)         |
| ReceivedAnotherAntitumorTreatment | 2 (1.0)           | 2 (1.0)           | 2 (1.0)           | 2 (1.0)           |
| KM Estimate of PFS (Months)a      |                   |                   |                   |                   |
| Q1 (95% CI)                       | 11 (8.3, 13.6)    | 6.9 (5.6, 8.1)    | 11 (8.3, 13.3)    | 6.9 (5.6, 8.1)    |
| Median (95% CI)                   | 20.8 (16.6, 26.4) | 11.1 (8.9, 11.1)  | 19.5 (16.5, 25.8) | 11.1 (8.8, 11.1)  |
| Q3 (95% CI)                       | 30.3 (26.4, NR)   | 16.1 (14.0, 19.3) | 30.3 (26.4, NR)   | 16.6 (14.0, 19.3) |
| KM Estimate of PFS Rate (95% CI)  |                   |                   |                   |                   |
| At24 weeks                        | 88.5 (83.0, 92.3) | 82.1 (76.0, 86.7) | 88.3 (82.7, 92.1) | 82.5 (76.3, 87.1) |
| At 48weeks                        | 75.0 (68.0, 80.6) | 50.5 (43.2, 57.5) | 74.5 (67.5, 80.3) | 50.4 (42.8, 57.4) |
| Adjusted HR (95% CI)b             | 0.33 (0.25, 0.44) | 0.33 (0.25, 0.44) | 0.34 (0.26, 0.45) | 0.34 (0.26, 0.45) |
| P-valuec                          | 6.540 x 10-16     | 6.540 x 10-16     | 5.917 ×10-15      | 5.917 ×10-15      |

The PP Analysis Set included all subjects in the ITT Analysis Set who met the PP criteria defined in the Statistical Analysis Plan (SAP), with treatment group designated according to the actual treatment received.

- a PFS(months）=(minimum[date of PD,date of death]-date of randomization + 1)/ 30.4375.
- b HR and95%CIswerecalculated using theCoxproportionalhazardsmodel,adjustedfor randomization stratification factors in electronic data capture (EDC) (17p deletion/TP53 mutation, IGHVmutationstatus,anddiseasestatus).

Source: GS-US-312-0115 Interim 1 CSR Section 15.1 Tables 2.1.1 and 2.1.2

P-valuewasfromthestratifiedlog-ranktest,adjustedforrandomizationstratificationfactors.

## SecondaryEndpoint:OverallSurvival

<div style=\"page-break-after: always\"></div>

Per the study protocol Section 9.3.1.2, the PP Analysis Set was used in sensitivity analyses of the following primary and secondary efficacy endpoints:PFS,ORR,LNR rate,and CRrate.Therefore,no

## SecondaryEndpoint:OverallResponseRate

Overallresponserateresultswere comparablebetween the analysissets.The oddsratioforORRfavored IDL+BR over placebo + BRforthe ITT and PPAnalysis Sets (p-value&lt; 0.ooo1 for both analysis sets) (Table 16).

The ORR (95% CI) (classified as CR, CRi, or PR with minimal duration of 12 weeks) for the ITT Analysis Set was 70.0% (63.3%,76.2%) for the IDL + BR group and 45.0% (38.1%, 52.0%) for the placebo + BR group.The odds ratio(95% CI)for the ORR was 3.09(2.02,4.72),which favored IDL + BR compared with placebo + BR (p-value &lt; 0.0001).

The ORR (95% CI) for the PP Analysis Set was 70.3% (63.5%, 76.5%) for the IDL + BR group and 45.8%(38.7%, 52.9%)for the placebo + BR group.The odds ratio (95% CI) for the ORR was

<div style=\"page-break-after: always\"></div>

Table 16 GS-US-312-0115:Overall Response Rate by IRC Assessment(ITT and PP Analysis Sets)

|                               | ITT Analysis Set          | ITT Analysis Set          | PP Analysis Set   | PP Analysis Set   |
|-------------------------------|---------------------------|---------------------------|-------------------|-------------------|
|                               | IDL + BR (N =207)         | PI + BR (N =209)          | IDL + BR (N =202) | PI+ BR (N =201)   |
| Best OverallResponse,n(%)     | Best OverallResponse,n(%) | Best OverallResponse,n(%) |                   |                   |
| CR                            | 3 (1.4)                   | 0                         | 3 (1.5)           | 0                 |
| CRi                           | 0                         | 1 (0.5)                   | 0                 | 1 (0.5)           |
| PR                            | 142 (68.6)                | 93 (44.5)                 | 139 (68.8)        | 91 (45.3)         |
| SD                            | 47 (22.7)                 | 85 (40.7)                 | 45 (22.3)         | 82 (40.8)         |
| PD                            | 1 (0.5)                   | 19 (9.1)                  | 1 (0.5)           | 18 (9.0)          |
| NE                            | 14 (6.8)                  | 11 (5.3)                  | 14 (6.9)          | 9 (4.5)           |
| ORR (n%)a                     | 145 (70.0)                | 94 (45.0)                 | 142 (70.3)        | 92 (45.8)         |
| 95% CIb                       | 63.3, 76.2                | 38.1, 52.0                | 63.5, 76.5        | 38.7,52.9         |
| OddsRatioforOverall Responsec | 3.09                      | 3.09                      | 3.05              | 3.05              |
| 95% CI for Odds Ratio         | 2.02,4.72                 | 2.02,4.72                 | 1.98, 4.70        | 1.98, 4.70        |
| P-value                       | 1.054 × 10-7              | 1.054 × 10-7              | 2.323 × 10-7      | 2.323 × 10-7      |

PP=PerProtocolAnalysisSet

ThePPAnalysisSetincludedallsubjectsintheITTAnalysisSetwhometthePPcriteriadefined inthe SAP, with treatment group designated according to the actual treatment received.

- a ORR was the percentage of subjects who had best overall response of CR, CRi, or PR.

Subjects with CR,CRi,or PRwho maintained the response for at least 12weeks were defined to have confirmed response. Otherwise,response status was categorized as SD.

- b 95%CIforORRwasbasedontheexactmethod.
- C Odds ratio,95%CI,and p-value were calculated from theCochran-Mantel-Haenszel(CMH)ChisquareteststratifiedbystratificationfactorsinEDC(17pdeletion/TP53mutation,IGHVmutation status,and diseasestatus).

Source:GS-US-312-0115Interim1CSRSection15.1Tables2.2.1and2.2.2

## Secondary Endpoint:Lymph Node Response Rate

Lymph node response rate results were comparable between the analysis sets.The odds ratio for LNR rate favored IDL +BR over placebo+BRfor theITT and PPAnalysisSets(p-value&lt;0.ooo1 forbothanalysis sets) (Table 17).

The LNR rate (95% CI) for the ITT Analysis Set was 96.9% (93.3%, 98.8%) for the IDL + BR group and 60.9%(53.7%,67.8%) for the placebo + BR group.The stratified odds ratio (95%CI)for the LNR rate was 28.72 (10.48,78.72),favoring IDL + BR over placebo + BR (p-value &lt; 0.0001).

The LNR rate (95% CI) for the PP Analysis Set was 96.8% (93.1%, 98.8%) for the IDL + BR group and 61.8% (54.5%, 68.7%) for the placebo + BR group. The stratified odds ratio (95% CI) for the LNR rate was 26.62 (9.74,72.72),favoring IDL + BR over placebo + BR (p-value &lt; 0.0001).

## Table 17 GS-US-312-0115:Lymph Node Response Rate by IRC Assessment (ITT and PP Analysis Sets)

<div style=\"page-break-after: always\"></div>

|                      | ITT Analysis Set   | ITT Analysis Set   | PPAnalysis Set    | PPAnalysis Set   |
|----------------------|--------------------|--------------------|-------------------|------------------|
|                      | IDL + BR (N =207)  | PI+BR (N =209)     | IDL + BR (N =202) | PI+ BR (N =201)  |
| LNR Ratea, n/N (%)   | 186/192 (96.9)     | 120/197 (60.9)     | 181/187 (96.8)    | 118/191 (61.8)   |
| 95% CI for LNR Rateb | 93.3,98.8          | 53.7, 67.8         | 93.1, 98.8        | 54.5, 68.7       |
| Odds Ratioc          | 28.72              | 28.72              | 26.62             | 26.62            |
| 95%CIfor Odds Ratio  | 10.48, 78.72       | 10.48, 78.72       | 9.74, 72.72       | 9.74, 72.72      |
| P-value              | 1.681 x 10-19      | 1.681 x 10-19      | 1.548 x 10-18     | 1.548 x 10-18    |

Analysisonlyincluded subjectsinthe ITTAnalysisSet or PPAnalysisSetwhohadbothbaseline and at least1evaluablepostbaselineSPD.

- a LNRratewasdefinedasthepercentageofsubjectswhoachieveda≥5o%decreasefrombaseline in the SPD of index lymph nodes. (Denominator is the number of subjects with baseline and at least 1 postbaseline measurement.)
- C Odds ratio, 95% CI, and p-value was calculated from the CMH Chi-square test stratified by stratification factors in EDC(17p deletion/TP53 mutation, IGHV mutation status, and disease status).
- b 95%CI for response rate was based on the exact method.

Source:GS-US-312-0115 Interim 1 CSR Section 15.1 Tables 2.4.1 and 2.4.2

## Secondary Endpoint: Complete Response Rate

Complete response rate results were comparable between the analysis sets (Table 18). Of the 3 documented CRs on study, all were observed in the IDL + BR group (rate of 1.4% for the ITTAnalysisSet and 1.5%for thePPAnalysisSet).

Table 18 GS-US-312-0115: Complete Response Rate by IRC Assessment (ITT and PP Analysis Sets)

|                        | ITT Analysis Set   | ITT Analysis Set   | PP Analysis Set   | PP Analysis Set   |
|------------------------|--------------------|--------------------|-------------------|-------------------|
|                        | IDL + BR (N = 207) | PI+BR (N =209)     | IDL + BR (N =202) | PI+ BR (N =201)   |
| CompleteResponse,n (%) | 3 (1.4)            | 0                  | 3 (1.5)           | 0                 |
| 95% CIa                | 0.3, 4.2           | 0,1.7              | 0.3, 4.3          | 0,1.8             |
| P-valueb               | 1.223 ×10-1        | 1.223 ×10-1        | 2.481 × 10-1      | 2.481 × 10-1      |

- a 95%CI forresponse rate wasbased on the exactmethod.
- b P-valuefromFisher'sexacttest.

Source:GS-US-312-0115Interim1CSRSection15.1Tables2.3.1and2.3.4

<div style=\"page-break-after: always\"></div>

## Co-Rapporteur

noderesponserate,CRratewereallinfavourofIDL+BRandsupportedtheprimaryanalysisinthe ITT population.

NoPP analysisfor Os has beenperformed,as this was notpre-specified in the studyprotocol,which is accepted.

## Issue resolved.

## Question 19

analysisplanwill beprepared todetail pharmacodynamics andbiomarker analyses. Biomarkerresultscouldhowevernotbefoundinthedossier and theapplicantisrequested tosubmitinformationregardingdisease-associatedbiomarkers,andtodiscusspotential mechanismsofresistancetoIDL,basedonpublishedandin-housedata,eg,inrelationto PI3Kmutationstatus.(CoRapp)

## SummaryofMAHanswer

While IDL therapy in CLL is efficacious, progressive disease after response occurs and has been observedinasubsetofsubjectsonIDLtreatmentindicatingthatescapemechanismscandevelop; not been characterized.In order to explore progressive disease-associated biomarkers, whole-exome sequencing(WES)on matched samples(peripheral blood mononuclear cells) at baseline and time of CLL progressionwas conducted insubjects enrolled in thefollowingPhase3 clinical trials:

To date,13 high quality subject samples fromStudies GS-US-312-0116,GS-US-312-0117 and GS-US-312-0119meetingtheestablishedsamplecriteriahavebeenevaluatedtounderstand

Thisanalysisshowedthattherearenocodingmutationswithinthissubjectsetwhichwouldreveala \"gatewaymutation\")orconsistentmutationsinanyotherpathwayreflectiveofacommonescape existed,therewouldonlybe a≤5%chanceof notobserving thisineven1of the13testedsample set.

To date,wehaveusedwhole exomesequencing(WES)toevaluatea total of 33CLLsubjectsamples: were analyzed for thepresence of any mutations inPI3Ko,including theIDL bindingregion,and no mutationsinPI3k8wereidentified(95%exactconfidenceintervalfor theprevalenceofsuchmutation is:0-11%).The currentsample size of 33 is sufficiently large to allow a highchance(&gt;80% currentsamplesetofsubjectswithprogressivediseaseonIDL.Wethusconcludethatagateway mechanismwithIDL.

<div style=\"page-break-after: always\"></div>

Giventheseresults,profilingadditionalsamplesfromStudyGS-US-312-0115ishighlyunlikelytoadd toourcurrentknowledgeofIDL-mediatedmechanismsofresistance.

## Co-Rapporteur

tobealikely\"resistancecandidate\"

## Issue resolved.

## Question 20.

PI3Kmutationshavebeenreported in a number ofmalignancies(ChaloubAnnRevPathol 2009).Please discussif this is aconcern inthe treatmentwithIDL thatwould justify assessingPI3Kstatusinpatientswithresistance toIDL.

## Response

StudyPC-312-2018was conducted to evaluate mechanisms of resistance as apostauthorization clinical trials(Study GS-US-312-0116,Study GS-US-312-0117,and Study GS-US-312-0119)who progressed while onIDL treatment were evaluated.

Whole exome sequencing was used to evaluate a total of 33 CLL subject samples.The samples were analyzed for the presence of any mutations of PI3Ko,including the IDL-bindingregion,and no mutations were identified(95%exact CI for the prevalence of such mutation:0 to 11%).The sample sizeof 33subjectswassufficientlylargetoallowahighchance(&gt;80%probability)ofobserving at least 1 subject with an IDL-mediated mutation in the PI3Ko binding pocket, even if this resistance set ofsubjectswithprogressive disease onIDL.A gatewaymutation(a commonmechanism of

Nomechanisticexplanationsfor thedevelopmentofresistance to treatmentwithIDLhavebeen identified from clinical studies.Furtherinvestigation of this topic in current B-cell malignancy studies is not planned.

## Rapporteur

Atthisstage,thisis accepted.

## Resolved

## Question 21.

Is there a difference inbaseline characteristics in theIDL+BR armbetweenpatientswith eventsofPFS≤6months,&gt;6monthsand≤18months,and&gt;18months?To contextualise, similar data may be reported for the Pl + BR arm.

## Summaryofresponse

DemographicsandbaselinediseasecharacteristicsweresimilarbetweensubjectsintheIDL+BR group at each time-to-PFS-event category (≤ 6 months,&gt; 6 months, ≤ 18 months,and &gt; 18 months).

<div style=\"page-break-after: always\"></div>

Theexception was theKPS.In theIDL+BRgroup,subjects withbetterKPS(≥ 80%)were more likely tohaveevents-to-PFSthatoccurredlater(at&gt;18months).

|                | Events of PFS≤6Months   | Events of PFS≤6Months   | Events of PFS≤6Months   | Events of PFS>6Months   | Events of PFS>6Months   | Events of PFS>6Months   | Events of PFS≤18Months   | Events of PFS≤18Months   | Events of PFS≤18Months   | Events ofPFS>18Months   | Events ofPFS>18Months   | Events ofPFS>18Months   |
|----------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------------------|-------------------------|
| Characteristic | IDL+BR (N=25)           | PI+BR (N=46)            | Total (N=71)            | IDL+BR (N=59)           | PI+BR (N=103)           | Total (N=162)           | IDL+BR (N=73)            | PI+BR (N=138)            | Total (N=211)            | IDL+BR (N=11)           | (N=11)                  | Total (N=22)            |
| KPS,n (%)      |                         |                         |                         |                         |                         |                         |                          |                          |                          |                         |                         |                         |
| 40             | 0                       | 0                       | 0                       | 0                       | 0                       | 0                       | 0                        | 0                        | 0                        | 0                       | 0                       | 0                       |
| 50             | 0                       | 1 (2.2)                 | 1 (1.4)                 | 0                       | 0                       | 0                       | 0                        | 1 (0.7)                  | 1 (0.5)                  | 0                       | 0                       | 0                       |
| 60             | 0                       | 2 (4.3)                 | 2 (2.8)                 | 2(3.4)                  | 2 (1.9)                 | 4 (2.5)                 | 2(2.7)                   | 4 (2.9)                  | 6 (2.8)                  |                         | 0                       | 0                       |
| 70             | 7(28.0)                 | 9 (19.6)                | 16 (22.5)               | 7(11.9)                 | 2 (1.9)                 | 9 (5.6)                 | 14(19.2)                 | 11 (8.0)                 | 25 (11.8)                | 0                       | 0                       | 0                       |
| 80             | 8(32.0)                 | 12 (26.1)               | 20 (28.2)               | 16(27.1)                | 35 (34.0)               | 51 (31.5)               | 18(24.7)                 | 46 (33.3)                | 64 (30.3)                | 6(54.5)                 | 1 (9.1)                 | 7 (31.8)                |
| 90             | 10(40.0)                | 14 (30.4)               | 24 (33.8)               | 20(33.9)                | 39 (37.9)               | 59 (36.4)               | 28(38.4)                 | 49 (35.5)                | 77 (36.5)                | 2(18.2)                 | 4 (36.4)                | 6 (27.3)                |
| 100            | 0                       | 8 (17.4)                | 8 (11.3)                | 14(23.7)                | 25 (24.3)               | 39 (24.1)               | 11(15.1)                 | 27 (19.6)                | 38 (18.0)                | 3(27.3)                 | 6 (54.5)                | 9 (40.9)                |

BMI = body massindex;

b. BMI(kg/m²) = weight/height2

- a. Age (years)=(date ofrandomization-date ofbiuth+1)365.25

Noconsistentdifferencesindiseasehistorywereobservedbetweentime-to-PFSeventscategories.

SubjectsintheIDL+BRgroupwithashortertimesincecompletionofthelastpriorregimenhad earlierPFSevents.Therewerenootherconsistentdifferencesbetweentime-to-PFSeventcategories accordingtoprior therapy.

|                                                                 | Events ofPFS≤6months   | Events ofPFS≤6months   | Events ofPFS≤6months   | Events ofPFS>6months   | Events ofPFS>6months   | Events ofPFS>6months   | EventsofPFS≤18months   | EventsofPFS≤18months                | EventsofPFS≤18months   | EventsofPFs>18months   | EventsofPFs>18months   | EventsofPFs>18months   |
|-----------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|-------------------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                                 | IDL+BR (N=25)          | Pl+BR (N=46)           | Total (N=71)           | IDL+BR (N=59)          | Pl+BR (N=103)          | Total (N=162)          | IDL+BR (N=73)          | PI+BR (N=138)                       | Total (N=211)          | IDL+BR (N-11)          | PI+BR (N=11)           | Total (N=22)           |
| CompletionofLastPrior Median Time Since Regimen, Months(Q1, Q3) | 11.4 (3.4,19.0)        | 13.3 (7.5, 22.0)       | 12.6 (4.8, 21.3)       | 17.8 (5.1,26.0)        | 14.7 (7.0, 27.4)       | 15.0 (5.6, 27.3)       | 14.0 (4.6,22.3)        | 13.4 (6.4,26.6)(5.4,24.9)(4.4,30.4) | 13.5                   | 179                    | 25.5 (13.9,33.7)       | 25.1 (10.8, 30.4)      |

Subjectswitheithera17pdeletionand/orTp53mutationtreatedwithIDL+BRweremorelikelyto experienceearlyeventsofPFS，14subjects(56%)experiencedeventsofPFS≤6months,while 2subjects(18.2%)experiencedeventsofPFS&gt;18months.

<div style=\"page-break-after: always\"></div>

## Raporteur:

TherathercomprehensivedatasetpresentedbytheMAH(notshown),providelittleevidenceofvalue fortheproperclinicaluseofidelalisib.

## Resolved

## Question23（22accordingtoapplicant)

Theapplicantisaskedtopresentresultsoftheobjectivehealthresourceutilization associated with the addition of IDL to BR, as these results could not be found. (CoRapp)

## SummaryofMAHanswer

Healthresource utilization wasnotdirectly measured.However,theEuroQol 5 Dimension(EQ-5D)was converted intoa singleutilityindexbyapplying theUnitedStates(US)preference-weightedindex.This analysiswasperformedforatertiarypharmacoeconomicsendpointassessingchangeinhealthstatus, s assessedusingtheEQ-5Dutilitymeasure.

Heathstatus informationwasobtained withtheEQ-5D,whichis a self-administered,generic,indirect utilitymeasure{TheEuroQolGroup1990}.TheEQ-5Dconsistsofavisualanaloguescaleonwhich subjects areasked toratetheircurrentoverallhealthstatusand5single-itemdimensionswhichask subjectstorate theirhealth interms of mobility,self-care,usualactivities,pain/discomfort,and thatcanbeincorporatedintoanalysesofcosteffectivenessorusedasaquantitativemeasureof 2010}.

and at 6-month intervals thereafter for the EQ-5D Questionnaire Utility Index is provided in Table 19.

groups. Compared to baseline, at Week 12 the mean overall utility decreased by 0.01 in the IDL + BR

<div style=\"page-break-after: always\"></div>

Table 19 GS-US-312-0115:SummaryofEQ-5DQuestionnaireUtilityIndex,Actual Valuesand ChangefromBaseline(ITTAnalysisSet)

|            | IDL + BR (N = 207)   | IDL + BR (N = 207)   | Placebo+BR (N =209)   | Placebo+BR (N =209)   |
|------------|----------------------|----------------------|-----------------------|-----------------------|
|            | Actual               | Changefrom Baseline  | Actual                | Changefrom Baseline   |
| Baseline   |                      |                      |                       |                       |
| N          | 197                  | 二                    | 195                   | 二                     |
| Mean (StD) | 0.78 (0.217)         | 二                    | 0.78 (0.228)          | 二                     |
| Median     | 0.80                 | 二                    | 0.81                  | 二                     |
| Q1, Q3     | 0.73, 1.00           | 一                    | 0.73, 1.00            | 一                     |
| Week 4     |                      |                      |                       |                       |
| N          | 187                  | 182                  | 192                   | 181                   |
| Mean (StD) | 0.80 (0.219)         | 0.02 (0.213)         | 0.77 (0.233)          | -0.01 (0.198)         |
| Median     | 0.85                 | 0.00                 | 0.81                  | 0.00                  |
| Q1, Q3     | 0.69, 1.00           | -0.07, 0.12          | 0.69, 1.00            | -0.07, 0.00           |
| Week8      |                      |                      |                       |                       |
| N          | 176                  | 169                  | 188                   | 176                   |
| Mean (StD) | 0.79 (0.233)         | 0.00 (0.225)         | 0.79 (0.223)          | 0.01 (0.215)          |
| Median     | 0.81                 | 0.00                 | 0.81                  | 0.00                  |
| Q1,Q3      | 0.69, 1.00           | -0.11, 0.12          | 0.73, 1.00            | -0.05, 0.09           |
| Week 12    |                      |                      |                       |                       |
| N          | 173                  | 168                  | 187                   | 175                   |
| Mean (StD) | 0.77 (0.254)         | -0.01 (0.240)        | 0.76 (0.241)          | -0.02 (0.213)         |
| Median     | 0.81                 | 0.00                 | 0.81                  | 0.00                  |
| Q1, Q3     | 0.69, 1.00           | -0.11, 0.11          | 0.69, 1.00            | -0.12, 0.04           |
| Week24     |                      |                      |                       |                       |
| N          | 154                  | 149                  | 150                   | 141                   |
| Mean (StD) | 0.80 (0.245)         | 0.01 (0.211)         | 0.78 (0.216)          | -0.02 (0.227)         |
| Median     | 0.85                 | 0.00                 | 0.80                  | 0.00                  |
| Q1, Q3     | 0.71, 1.00           | -0.04, 0.12          | 0.69, 1.00            | -0.11, 0.05           |
| Week48     |                      |                      |                       |                       |
| N          | 128                  | 123                  | 104                   | 98                    |
| Mean (StD) | 0.83 (0.167)         | 0.03 (0.184)         | 0.80 (0.236)          | 0.02 (0.242)          |
| Median     | 0.85                 | 0.00                 | 0.85                  | 0.00                  |
| Q1, Q3     | 0.73, 1.00           | -0.07, 0.12          | 0.73, 1.00            | -0.07,0.12            |
| Week72     |                      |                      |                       |                       |
| N          | 77                   | 75                   | 50                    | 47                    |
| Mean (StD) | 0.81 (0.231)         | 0.02 (0.236)         | 0.76 (0.281)          | 0.01 (0.335)          |
| Median     | 0.85                 | 0.00                 | 0.80                  | 0.00                  |
| Q1, Q3     | 0.73, 1.00           | -0.10, 0.15          | 0.71, 1.00            | -0.10, 0.19           |

<div style=\"page-break-after: always\"></div>

|            | IDL + BR (N = 207)   | IDL + BR (N = 207)   | Placebo + BR (N =209)   | Placebo + BR (N =209)   |
|------------|----------------------|----------------------|-------------------------|-------------------------|
|            | Actual               | Change from Baseline | Actual                  | Change from Baseline    |
| Week96     |                      |                      |                         |                         |
| N          | 33                   | 33                   | 14                      | 13                      |
| Mean (StD) | 0.79 (0.270)         | -0.04 (0.216)        | 0.77 (0.306)            | -0.01 (0.219)           |
| Median     | 0.85                 | 0.00                 | 0.84                    | 0.00                    |
| Q1,Q3      | 0.73, 1.00           | -0.02,0.05           | 0.71, 1.00              | -0.12, 0.19             |
| Week120    |                      |                      |                         |                         |
| N          | 9                    | 9                    | 2                       | 2                       |
| Mean (StD) | 0.82 (0.154)         | 0.01 (0.187)         | 0.91 (0.132)            | 0.03 (0.038)            |
| Median     | 0.85                 | 0.00                 | 0.91                    | 0.03                    |
| Q1,Q3      | 0.69, 1.00           | -0.11, 0.16          | 0.81, 1.00              | 0.00, 0.05              |
| Week 144   |                      |                      |                         |                         |
| N          | 1                    | 1                    | 0                       | 0                       |
| Mean (StD) | 0.22                 | -0.63                | 一                       | 一                       |
| Median     | 0.22                 | -0.63                | 一                       |                         |
| Q1,Q3      | 0.22, 0.22           | -0.63,-0.63          | 一                       | 一                       |

Source:GS-US-312-0115InterimCSRSection15.1Table2.12.3.3

## Co-Rapporteur

Healthresourceutilizationwasnotdirectlymeasured,but theEQ-5Dwasconvertedintoa singleutility index,measuringthechangefrombaselineinoverallhealthandsingle-itemdimensionscores.No differencesinEQ-5DutilityindexresultswereobservedbetweentheIDL+BRand theplacebo+BR treatmentgroups.

## Issueresolved.

## 24.Pleaseprovidedetails asregards adherence toPJPand CMVprophylaxis.

## Applicant'sResponse

A summary of subjects who experienced PJp during the study by PJP prophylaxis status was provided in the Study GS-US-312-0115 Interim 1 CSR Section 15 Table 8.3.

However,please note that on 25 March2016,safety information and protocol guidelines fortoxicity managementwereupdatedforconsistencyacrossIDLstudies.Thesechangesincludedmandated prophylaxis for PJP and mandated CMV surveillance. Because the requirements for PJP prophylaxis and regardingadherencetoPJPprophylaxisandCMVsurveillancewerenotcollectedfortheentireduration of the study.

## Rapporteur

Interpretabledataarenotavailable.

<div style=\"page-break-after: always\"></div>

| Resolvedinthesensenotfurtherpursued.   |
|----------------------------------------|

## Question 25.

Adverse reactions led to the stopping of all first-line studies.Please compare adverse events ofspecialinterestper 2 monthsperiodIDL +BRvs.BR instudies 0015and 0023.Please also discuss whether there is a\"true\"increase in add-on toxicity related to line of therapy and ifso ifthere areunderlyingmechanismsmaking thisplausible.

## Summaryofresponse

and3intheIDL+ BRregimenof thefront-line study(GS-US-312-0123)compared with the same regimens in the relapsed study population(Study GS-US-312-0115), indicating poorer tolerability of IDL+ BR in thefront-line setting.Inboth studies,there were more infectiousSAEs overall in the IDL + BR regimen than in the placebo + BR regimen (40.1%vs 23.4% in the relapsed population and 30.8%vs 9.1% in the front-line population).However, the differencesbetween the regimensin the infectiousSAEsin thefront-line populationreceivingplacebo+BR(9.1%).

Similarly,duringthefirstmonthonstudythereweremoredeathsoverallintheIDL+BRregimen than in the placebo + BR regimen.In the relapsed CLL study, the slight imbalance over 1 month was reversedbetweenMonths1and3andattimepointsthereafter,whilethemoresignificantimbalance inearlydeathsinthefront-lineCLLsubjectsremained.Theabsenceofearlydeathsinthecomparator armofthefront-linestudyisnotable.Theearlydeathsinthefront-linestudywerealmostentirelydue toinfectiousAEs.

Adverseevents ofinterest(AEIs)forIDLinclude eventsobserved inpreviousstudieswithIDL aswell as disease-related events associated with CLL.AEIsforIDLincludebowelperforation of anygrade, CMVinfectionofanygrade,diarrhea/colitis≥Grade3，febrileneutropenia≥Grade3,infection ≥Grade3.NoeventsofPMLwerereported duringStudyGS-US-312-0115.

TheincidenceandprevalenceofAEIsforStudyGS-US-312-0115andStudyGS-US-312-0123are presented by12-weekinterval inTable 44.Twelve-week intervals,ratherthan2-monthintervals,are provided hereinto alignwithdataprovided intheCSRs.

relapsedpopulationsthroughWeek60,andthereafter appearshigherintherelapsedpopulation.The incidence and prevalence of ≥ Grade 3 infections appeared higher in thefront-line population for the first 12 weeks, and thereafter appeared higher in the relapsed population. The incidence and population.

add-ontoxicity.Theunderlyingmechanismfortheincreasedearlyinfectiouseventsandassociated fatalities seen in theidelalisibfront-line CLL studies does not appear attributable to a single identified but is more likely due to heightened immunomodulatory effects experienced bysome patientswith a treatment-naiveimmune system.

## Rapporteur

TheMAHsconclusions(yellowabove)aresupportiveonadescriptivelevel and areinlinewithPRAC conclusions.

## Resolved

<div style=\"page-break-after: always\"></div>

## Question 26.

In the protocol of study GS-Us-312-0115 it was stated (in the section of dose modifications) thattumourlysissyndrome(TLS)hadoccurredin5%ofsubjects treatedwithidelalisibin combinationwithbendamustineorbendamustinerituximab.In thesafetysummaryand in is requested to clarify.

## Applicant's Response

Study GS-US-312-0115 Protocol Amendment 9 included the following statement in the lysissyndromeisuncommonwitheitherIDL or rituximab.Tumorlysissyndromehasoccurredin~5% ofpatientswhenIDLhadbeencombinedwithbendamustineorbendamustine/rituximab.Investigators

In the integrated safety analysis of studies with IDL m2.7.4 (CLL sNDA ID+ BR Jan 2O17), tumorlysissyndromewasreportedforthefollowing:

- 11.1% of subjects treated with IDL+ B
- 3.4%ofsubjects treatedwithIDL+BR
- 2.1% of subjects treated withIDL+ R

## Rapporteur:

The approximations are accepted.

## Resolved

## Clinical Safety Aspects

## Question27

IthasnotbeenreportedwhethercasesofoverdoseinstudyGS-US-312-0115have occurred.Ifso,narrativesshouldbeprovided.

## Applicant'sResponse

Overall, 6 subjects had dosing errors of study drug: 4 subjects randomized to treatment with IDL + BR 1caseofunderdosing.Narrativesfor the6dosingerrorsareasfollows:

<div style=\"page-break-after: always\"></div>

- Subject (IDL + BR):Beginning 02 July 2014,the subject took 2 study drug tablets daily) for a 10-day period. No AE or SAE associated with this dosing error was reported.
- Subject (IDL+ BR):Beginning 07 October 2013,the subject took3 study drug tables twice daily(for 450 mgIDL twice daily)rather than1 tablet twice daily(for 150mg IDL twicedaily)fora9-dayperiod.NoAEorSAE associatedwiththisdosingerrorwasreported.Local laboratorysamplesdrawnfollowingthiseventwerewithinnormalparameters.
- Subject (IDL+BR):Overthe course of 82days,the subject took 4 more tablets thanprescribed:168tabletsrather than164tablets.NoAEorSAE associatedwiththisdosing errorwasreported.
- Subject (IDL+ BR):On10June 2014 the subject was assigned 3bottles of 100mg IDLtabletsrather than3bottlesof 150mgIDL tablets inerror.The subjecttookIDL 100mg twice dailyfrom10June2014through05August2014，atwhichtimetheerrorwasdiscoveredandthe subjectwasgiventhecorrecttabletstrengthfortheremainderofthestudy.NoAEorSAE associatedwiththisdosingerrorwasreported.
- Subject noted asmissing.The subjectmayhave taken1extra tableteachmorningfor8days.NoAE or SAE associated with this dosing error was reported.Local laboratory samples drawn following this eventwerewithinnormalparameters.
- Subject (Placebo+BR):From18September2013through16October2013,the subject took3placebotablestwicedaily(fora totalof 6tablets daily)ratherthan1placebo tablet twice daily(for a totalof 2tablets daily).The subjectreported Grade 3 neutropeniaassessed by investigator asrelated tobendamustine.

## Co-Rapporteur

ThemissinginformationhasbeenprovidedbytheMAHanddoesnotraiseanyconcernswithrespect tothenumberofcasesandthepotentialsafetyissueasfor5outof6casesthedosingerrorswerenot associatedwithAEorSAE.

## Issueresolved

Question 28 ThelaboratoryabnormalitiesobservedinstudyGS-US-312-0115relatedtoIDL+BR

## Applicant'sResponse

Furtherdiscussionofpotassium,albumin,andphosphatelaboratoryabnormalitiesisprovidedbelow.A summaryof theworstpostbaselinegradesoftheseabnormalitiesisprovidedinTable20,and a summaryofalltreatment-emergentserumchemistryabnormalitiesisprovidedintheStudy GS-US-312-0115Interim CSRSection 15.1Table8.3.2

Seven subjects(3.4%)in theIDL +BRgrouphadpostbaseline increases inpotassium(hyperkalemia) of any grade:no subject had a Grade 3 increase and 1 subject(0.5%)had a Grade 4 increase.Eight s potassiumof any grade: 7subjects(3.3%)had a Grade3 decrease and nosubject had a Grade 4 decrease.

<div style=\"page-break-after: always\"></div>

Forty-eight subjects (23.2%) in the IDL + BR group had postbaseline hypoalbuminemia of any grade: were Grade3orGrade 4.

Forty-seven subjects (22.7%) in the IDL + BR group had postbaseline decreased phosphate (hypophosphatemia)of any grade:26subjects(12.6%)had a Grade 3 decrease and no subject had a Grade 4 decrease. Thirty-four subjects (16.3%) in the placebo + BR group had postbaseline decreased phosphate of any grade: 14 subjects (6.7%) had a Grade 3 decrease and no subject had a Grade 4 decrease.

Table 20 GS-US-312-0115:Treatment-EmergentPotassium,Albumin,andPhosphate Laboratory Abnormalities,Worst Grade Post Baseline(SafetyAnalysisSet)

|                                   | IDL + BR (N = 207)   | PI+ BR (N = 209)   |
|-----------------------------------|----------------------|--------------------|
| WorstGradeAbnormalityPostBaseline | (%) u                | (%) u              |
| Potassium (Hyperkalemia)          |                      |                    |
| 1                                 | 3 (1.4%)             | 1 (0.5%)           |
| 2                                 | 3 (1.4%)             | 6 (2.9%)           |
| 3                                 | 0                    | 0                  |
| 4                                 | 1 (0.5%)             | 1 (0.5%)           |
| 3to 4                             | 1 (0.5%)             | 1 (0.5%)           |
| 1 to 4                            | 7 (3.4%)             | 8 (3.8%)           |
| Potassium (Hypokalemia)           |                      |                    |
| 1                                 | 42 (20.3%)           | 23 (11.0%)         |
| 2                                 | 0                    | 0                  |
| 3                                 | 11 (5.3%)            | 7 (3.3%)           |
| 4                                 | 2 (1.0%)             | 0                  |
| 3to 4                             | 13 (6.3%)            | 7 (3.3%)           |
| 1 to 4                            | 55 (26.6%)           | 30 (14.4%)         |
| Albumin (Hypoalbuminemia)         |                      |                    |
| 1                                 | 26 (12.6%)           | 9 (4.3%)           |
| 2                                 | 19 (9.2%)            | 21 (10.0%)         |
| 3                                 | 3 (1.4%)             | 0                  |
| 4                                 | 0                    | 0                  |
| 3 to4                             | 3 (1.4%)             | 0                  |
| 1 to 4                            | 48 (23.2%)           | 30 (14.4%)         |
| Phosphate (Hypophosphatemia)      |                      |                    |
| 1                                 | 0                    | 0                  |
| 2                                 | 21 (10.1%)           | 20 (9.6%)          |
| 3                                 | 26 (12.6%)           | 14 (6.7%)          |
| 4                                 | 0                    | 0                  |
| 3to 4                             | 26 (12.6%)           | 14 (6.7%)          |

<div style=\"page-break-after: always\"></div>

| WorstGradeAbnormalityPostBaseline   | IDL + BR (N = 207) n (%)   | PI + BR (N =209) (%)u   |
|-------------------------------------|----------------------------|-------------------------|
| 1 to 4                              | 47 (22.7%)                 | 34 (16.3%)              |

## Co-Rapporteur

It is noted that in the IDL+BR arm a higher proportion of patients have postbaseline hypokalemia, hypophosphatemia55%of thegr1-4eventsweregrade3or 4.TheMAHdoesnotprovide an explanationfortheelectrolytedisturbances.Moreinformationisneededtoassesswhether section4.8.oftheSmPC.

## Issue not resolved

## Question29

NeutrophilcountmonitoringisrecommendedintheSmPC.Intheeventofsevere resolution.Noticeable, dose interruption due to neutropenia was only reported in3.9%o, whereasdiscontinuationsordosereductionswerereported&lt;2%ofthecases.Assuchthe applicant isrequested toreportwhatmeasureswere takentoaddress theseverecases of neutropenia(e.g. concomitant medication) and to what extent these cases resolved spontaneously.

## Applicant'sResponse

until theneutropeniaisGrade3orless.Themeasurestakentoaddressseverecasesofneutropenia include use of growth factors as per established clinical guidelines (Study GS-US-312-0115

ProtocolAmendment9,Table5-6andSection5.6.6;{Rizz02008,Smith2006}.Granulocyte use should be considered if providing hematopoietic support might help to maintain study drug treatment

Grade 4 neutropenia that required IDL interruption occurred in 41 subjects(19.8%)in the IDL+ BR group and 19 subjects (9.1%) in the placebo + BR group.

IDL dose. Six of these 36 subjects with Grade 4 neutropenia also were not treated with concomitant growth factors.The disposition of these subjects follows:

- Subject
- Subject 2015
- Subject
- Subject 30 September 2014.

<div style=\"page-break-after: always\"></div>

- Subject Grade 4 neutropenia started on 14 April 2014 and resolved to ≤ Grade 3 by 28 April 2014
- Subject Grade4neutropeniastartedon06November2014andresolved to≤Grade 3 by 12 November 2014

Theother30subjectsreceivedgrowthfactors aspresented inTable46.In allbuttwocases,theGrade 4neutropeniaresolved.Inthose2cases,theneutropeniaeventswereongoingandthesubjects ultimatelywithdrewfromstudydrug.Subject wastreatedwith1courseoffilgrastimand 2 courses of pegfilgrastim, and subsequently the patient declined any additional treatment and study drugwasnotresumed.Subject wastreatedwith6coursesoffilgrastim，andwas withdrawn from the study by the physician, citing cytopenia and compliance issues (CHMP Listing 4.1).

Table 46 Study GS-US-312-01l5:SubjectswithGrade4NeutropeniawhoReceived GrowthFactors and hadNo Change in IDL Dose

|         | IDL Treatment   | IDL Treatment   | NumberofEpisodes of   |                    | GrowthFactor Courses   |
|---------|-----------------|-----------------|-----------------------|--------------------|------------------------|
| Subject | First Exposure  | Last Exposure   | Neutropenia           | Growth Factor Name | Received               |
|         | 12 May 2014     | 16 0ct 2014     | 4                     | filgrastim         | 5                      |
|         | 02 Jume 2014    | 16 Aug 2014     | 1                     | flgrastim          | 4                      |
|         | 09 June 2014    | 2 May 2016      | 1                     | filgrastim         | 3                      |
|         | 13 Aug 2013     | 02 May 2016     | 1                     | flgrastim          | 1                      |
|         | 07 Oct2013      | 15 Apr 2015     | 1                     | Regfilgrastim      | 1                      |
|         | 06 Aug 2013     | 28 Sept 2015    | 2                     | filgrastim         | 5                      |
|         | 30 Oct2013      | 14 Feb 14       | 1                     | filgrastim         |                        |
|         |                 |                 |                       | pegtilgrastim      | 2                      |
|         | 18 Nov 13       | 11 Feb 15       | 1                     | Regfilgrastim      |                        |
|         | 2 Jul 13        | 15 May 14       | 1                     | lenegrastim        | 7                      |
|         | 25-Jum-14       | 2-May-16        | 1                     | lenograstim        | 6                      |
|         | 20 Jam 14       | 13 Apr 15       | 1                     | filgrastim         | 2                      |
|         | 20 Aug 13       | 14 Apr 15       | 4                     | flgxastim          | 10                     |
|         | 29 May 14       | 1 0ct 14        | 1                     | flgrastim.         | 6                      |
|         | 01 Jul 14       | 02May 16        | 1                     | fgrastim           | 2                      |
|         |                 |                 |                       | flgrastim          | 2                      |
|         | 03 Jul 14       | 28 Nov 14       | 3                     | lenograsti         | 1                      |
|         |                 |                 |                       | pegfilgrastim.     | 2                      |
|         | 01 Apr 14       | 02 May 16       | 1                     | fugrastim          | 1                      |
|         | 02 June 14      | 02 May 16       | 1                     | flgrastin          | 2                      |
|         | 12 Aug 13       | 05 Jam 16       | 1                     | fulgxastim         | 5                      |

<div style=\"page-break-after: always\"></div>

|         | IDL Treatment       | IDL Treatment   | Numberof Episodes of   |                                     | Growth Factor Courses   |
|---------|---------------------|-----------------|------------------------|-------------------------------------|-------------------------|
| Subject | First Exposure      | Last Exposure   | Neutropenia            | GrowthFactor Name                   | Received                |
|         | 05 Mar 14           | 25 Apr 16       | 2                      | flgrastim.                          | 1 4                     |
|         | 29 Aug 13           | 26 Jan 15       | 3                      | lenograstim Regtilgxastin flgxastin | 5 1                     |
|         | 20 Feb 14           | 26 Sept 14      | 1                      | flgxastim.                          | 3                       |
|         | 24 Mar 14           | 02 May 16       | 2                      | flgxastin.                          | 11                      |
|         | 27 Mar 14           | 27 May 15       | 3                      | flgrastim.                          | 4                       |
|         | 19 Jun 14           | 05 Jan 16       | 1                      | pegfilgrastim                       | 5                       |
|         | 24 Apr 14           | 02 May 16       | 5                      | filgastiu                           | 13                      |
|         |                     | 02 May 16       | 3                      | filgrastim. Regtflgrastim           | 1 3                     |
|         | 08 Jul 14 22 Jul 14 | 02May 16        | 1 1                    | lenograstim. flgrastim.             | 1 6                     |
|         | 24 Jul 14           |                 |                        | flgxastin.                          | 2                       |
|         | 06 Aug 14           | 16 Nov 15       |                        |                                     |                         |
|         |                     | 10 Nov 15       | 1                      | flgxastim.                          | 10                      |

Source: StudyGS-US-312-0115,Section 16.2.7, Listing4.1, Listing 4.92,Listing6.11, CHMP Listing 30.3,Listing 30.18

A further 5 subjects in theIDL +BRtreatment grouphadIDL dose interruptions,reductions,or withdrawalduetoGrade4neutropenia.TwosubjectshadtheirIDLdosetransientlyinterrupteddueto neutropenia.Subject hadIDLinterruptedfrom02September2014to 17September2014duetoneutropenia,wasnottreatedwithanygrowthfactors,and ultimatelyhad theIDLdosereduced to100mgdueto anAEoftoxichepatitis.Thesubjectcontinued thestudy receiving 100 mg IDL (Study GS-US-312-0115 Interim 1 CSR,Listing 4.9.2). The second subject, hadadoseinterruptionduetoneutropeniafrom28January2014to04February2014, andnotreatmentwithgrowthfactors.Aftertheneutropeniaresolved,thedosewasincreasedto 150 mg IDL (Study GS-US-312-0115 Interim 1 CSR, Listing 4.9.2).

TwosubjectswithGrade 4neutropeniahad theirdosereducedto100mg.Onesubject, hadGrade4neutropeniathatstartedatrelativeDay601andendedonDay608,hadthedoseofIDL interruptedfor2days(25Sept2015to27Sept2015)afterwhichtheIDLdosewasincreasedto 150mgof IDL.TheIDLdosewassubsequentlyreduced to100mgon27April2016 due to neutropeniaandremainedreduced.Subject received11coursesoffilgrastim.Subject remainedatthe150mgIDLdoseuntil18January2016,whenthedoseofIDLwas of100mgIDLon27April2016.Asecondsubject, hadGrade4neutropeniathat startedatDay463andendedonDay499,withthedoseofIDLreducedto100mgon07August 2015,duetoGrade4neutropeniaandGrade2diarrhea.Subject received1courseof filgrastim(03August2015to05August2015)and thesubjectcontinuedonthereduceddoseof 100 mg IDL (Study GS-US-312-0115 Interim 1 CSR, Listing 1.9.4 and Listing 4.9.2).

Subject wasgiven1courseofpegfilgrastimand3coursesoffilgrastim(lastcoursewas completed06March2015),andhadIDLwithdrawnduetoneutropeniaon18February2015,and againfrom21February2015to06March2015duetoagranulocytosisduringhospitalization (Study GS-US-312-0115 Interim 1 CSR, Listing 1.9.4 and Listing 6.1.4). Subject discontinuedfrom thestudyonDay297(07May2015)duetoprogressivedisease.

## Co-Rapporteur

Morecasesofgrade4neutropeniaoccurredintheIDL+BRarmversustheplacebo+BRarm.The idelalisib,althoughsomecasesrecoveredspontaneously.Insomecasesasubsequentdosereduction wasrequiredbeforeresolutionoftheneutropenia.

## Issue resolved

<div style=\"page-break-after: always\"></div>

## Question30

Data cut-offfor theinterim study reportof study GS-US-312-0115was02May2016, as suchafullupdateofsafetyfromstudyGS-Us-312-0115,includingpatientsinlong-term follow-up, is requested.

Applicant'sResponse

Updated safety results based on a data cutoff date of 31 March 2017 are presented.

A summaryof themainresultsisdepicted here.For thefull updated safetytextpleaserefer to theRSI asprovided by theMAH.

## Extent of Exposure

Ofthe 416subjectsrandomized in the study,415receivedatleast1doseofstudydrug(IDL or placebo)andwereevaluableforstudydrugexposure.Themedian(Q1,Q3)durationofexposureto IDL in the IDL + BR group was 18.2 (5.8, 30.1) months (range: 0.0 to 54.4 months). The median (Q1,Q3)duration of exposure to placebo in the placebo + BR group was 11.1 (5.8,16.6)months (range:0.5 to 28.5months).

(97.1%)in theplacebo+BRgroup.Serious adverse events(SAEs)werereported for 149subjects (72.0%) in the IDL + BR group and 94 subjects (45.0%) in the placebo + BR group (Table 48). The subgroup analysesofAEsbygender,age(&lt;65yearsversus≥65years),andrace(whiteversus nonwhite)weregenerallyconsistentwiththeoverallanalysis.

Table 21 GS-US-312-0115:Study Drug(Idelalisib/Placebo)Exposure(SafetyAnalysis Set)

|                                               | IDL + BR (N =207)   | PI+ BR (N =209)   | Total (N =416)   |
|-----------------------------------------------|---------------------|-------------------|------------------|
| Duration of Exposure to IDL/Placebo (Months)a |                     |                   |                  |
| N                                             | 207                 | 208               | 415              |
| Mean (StD)                                    | 18.4 (13.08)        | 11.4 (6.47)       | 14.9 (10.88)     |
| Median                                        | 18.2                | 11.1              | 13.4             |
| Q1,Q3                                         | 5.8, 30.1           | 5.8, 16.6         | 5.8, 20.4        |
| Min, Max                                      | 0,54.4              | 0.5, 28.5         | 0,54.4           |
| Cumulative Exposure toIDL/Placebo,n (%)       |                     |                   |                  |
| ≥ 1 Day                                       | 207 (100)           | 208 (99.5)        | 415 (99.8)       |
| ≥2months                                      | 186 (89.9)          | 199 (95.2)        | 385 (92.5)       |
| ≥ 4 months                                    | 171 (82.6)          | 173 (82.8)        | 344 (82.7)       |
| ≥ 6months                                     | 154 (74.4)          | 154 (73.7)        | 308 (74.0)       |
| ≥ 12 months                                   | 127 (61.4)          | 90 (43.1)         | 217 (52.2)       |
| ≥ 18 months                                   | 104 (50.2)          | 34 (16.3)         | 138 (33.2)       |
| ≥ 24 months                                   | 74 (35.7)           | 8 (3.8)           | 82 (19.7)        |
| ≥30 months                                    | 52 (25.1)           | 0                 | 52 (12.5)        |
| ≥36 months                                    | 20 (9.7)            | 0                 | 20 (4.8)         |
| ≥42 months                                    | 9 (4.3)             | 0                 | 9 (2.2)          |
| ≥48 months                                    | 1 (0.5)             | 0                 | 1 (0.2)          |

<div style=\"page-break-after: always\"></div>

|       | IDL + BR (N =207)   | PI + BR (N =209)   | Total (N = 416)   |
|-------|---------------------|--------------------|-------------------|
| ≥ 75% | 204 (98.6)          | 204 (97.6)         | 408 (98.1)        |
| <75%  | 3 (1.4)             | 4 (1.9)            | 7 (1.7)           |

a completion CRF page, data cutoff date]-first IDL/Placebo dosing date + 1) / 30.4375.

b [total daily pills × dosing duration]), taking into account physician-prescribed reductions, escalations,and interruptions.

Source:CHMPTable 30.2.3

Table48 GS-US-312-0115:Overall Summary ofAdverseEvents (Safety Analysis Set)

|                                           | IDL+BR (N =207)   | PI+BR (N=209)   |
|-------------------------------------------|-------------------|-----------------|
| AdverseEvent Category                     | n (%)             | n (%)           |
| AnyAE                                     | 207 (100)         | 203 (97.1)      |
| AERelated to IDL orPlacebo                | 175 (84.5)        | 125 (59.8)      |
| AERelated toRituximab                     | 145 (70.0)        | 145 (69.4)      |
| AERelated toBendamustime                  | 168 (81.2)        | 173 (82.8)      |
| AnyAE≥ Grade3                             | 197 (95.2)        | 163 (78.0)      |
| AE≥Grade3 Related to IDL orPlacebo        | 145 (70.0)        | 68 (32.5)       |
| AE≥Grade3Related to Rituximab             | 105 (50.7)        | 83 (39.7)       |
| AE≥Grade3 Related to Bendamustine         | 148 (71.5)        | 120 (57.4)      |
| AnySAE                                    | 149 (72.0)        | 94 (45.0)       |
| SAERelated toIDLorPlacebo                 | 78 (37.7)         | 28 (13.4)       |
| SAERelated toRituximab                    | 48 (23.2)         | 28 (13.4)       |
| SAERelated toBendamustime                 | 71 (34.3)         | 40 (19.1)       |
| AELeadimg toIDL/PlaceboDoseReduction      | 35 (16.9)         | 13 (6.2)        |
| AELeadimg to IDL/PlaceboDose Interruption | 126 (60.9)        | 49 (23.4)       |
| AELeadimg toIDL/PlaceboDiscontinuation    | 83 (40.1)         | 31 (14.8)       |
| AELeadimg to Death                        | 27 (13.0)         | 19 (9.1)        |

SAE = serious adverseevent

Source: CHMPTable 30.3

Relationship to study drug was determined bytheinvestigator;AEs withmissingrelationships were consideredto berelated

## MostCommonAdverseEvents

Adverse events reported for  10% of subjects in either treatment group are summarized by SoC and PT by decreasing frequency in the IDL + BR group in Table 49.

The most commonly reported AEs (reported for ≥ 25% of subjects) by treatment group included the following:

<div style=\"page-break-after: always\"></div>

- IDL + BR: neutropenia (132 subjects, 63.8%), diarrhea (90 subjects, 43.5%), pyrexia (90 subjects, 43.5%), nausea (60 subjects, 29.0%), anemia (56 subjects, 27.1%), and cough (52 subjects, 25.1%)
- Placebo + BR: neutropenia (114 subjects, 54.5%), nausea (73 subjects, 34.9%), and pyrexia (63 subjects, 30.1%)

## Exposure-AdjustedIncidenceRatesofCommonAdverseEvents

Adverse events reported for ≥ 10% of subjects in either treatment group are summarized by PT and

Adverse events with the highest exposure-adjusted incidence rates(≥ 0.25 events/subject-year) by treatmentgroupincludedthefollowing:

- IDL + BR: neutropenia (0.99 events/subject-year), pyrexia (0.41 events/subject-year), diarrhea
- Placebo + BR: neutropenia (0.96 events/subject-year), nausea (0.50 events/subject-year), (0.29 events/subject-year),infusion-relatedreaction(0.29 events/subject-year),cough (0.25 events/subject-year).

Adverse events (any grade) with an exposure-adjusted incidence rate ≥ 0.10 events/subject-year more common in the IDL + BR group included the following: diarrhea, febrile neutropenia, and ALT increased.

## AdverseEventsofInterest

Tableshavebeenomittedforthissection-pleaserefertoResponsedocumentof theapplicant.

Adverse events of interestforIDL include bowel perforation of any grade,CMV infection of any grade, pneumonitis of any grade,PML of any grade,and rashper Gilead MST≥ Grade 3.

## BowelPerforation(AnyGrade)

Through the data cutoff date for this report(31 March 2017),1 subject (0.5%)in the IDL + BR group perforation (CHMP Table 30.27).

The exposure-adjusted incidence rate(95%CI)forbowel perforation of anygrade was 0.00 events/subject-year (0.00, 0.02) in the IDL + BR group and 0.00 events/subject-year (NEst, 0.02) in the placebo + BR group (Table 53).

Themedian(Q1,Q3)time toonsetof thefirsteventofbowelperforationintheIDL+BRgroupwas 28.3 (28.3, 28.3) weeks (n = 1), and the median (Q1, Q3) time to resolution was 0.1 (0.1, 0.1) weeks (CHMP Table 30.27.7).

Nosubjectineither treatmentgrouphadadosereductionordoseinterruptionduetobowel discontinued study drug due to bowel perforation (CHMP Tables 30.27.3, 30.27.4, and 30.27.5).

No deaths due to bowel perforation were reported in this study (CHMP Table 30.27).

<div style=\"page-break-after: always\"></div>

## CytomegalovirusInfection(AnyGrade)

()      +   ()  t in the placebo + BR group reported CMV of any grade (CHMP Table 3O.27).

(0.02, 0.07) in the IDL + BR group and 0.01 events/subject-year (0.00, 0.04) in the placebo + BR group (Table 55).

The median(Q1,Q3) time to onset of the first event of CMV in theIDL+ BR group was 18.3 (10.4,26.4)weeks (n = 14),and the median (Q1,Q3) time to resolution was 3.5 (2.4, 6.0) firstevent of CMV was7.4(5.9,44.0)weeks(n=3),and the median(Q1,Q3) time toresolution was 14.4 (2.3, 26.4) weeks (n = 2) (CHMP Table 30.27.7).

One subject(0.5%)in the IDL+ BR group and no subjects in theplacebo+BR had a dose reduction due to CMV. One subject (0.5%) in the IDL + BR group and 1 subject (0.5%) in the placebo + BR group had dose interruptions due to CMV. One subject (0.5%) in the IDL + BR group and 1 subject (0.5%) in the placebo + BR group discontinued study drug due to CMV (CHMP Tables 30.27.3, 30.27.4, and 30.27.5).

## Diarrhea/Colitis(≥Grade3)

TheanalysisfortheAEIofdiarrhea/colitisutilizedtheMedDRAPTs\"diarrhoea\"and\"colitis.\"Throughthe ) s     a

Theexposure-adjusted incidencerate(95%CI)for≥Grade3diarrhea/colitiswas 0.10 events/subject-year (0.07, 0.14) in the IDL + BR group and 0.02 events/subject-year (0.01,0.05)in the placebo+ BR group (Table 57).

Datacollectedthroughthedatacutoffdateforthisreportconfirmsthelateonsetofdiarrhea/colitis amongsubjectstreatedwithIDL.Themedian(Q1,Q3)time toonsetof thefirst≥Grade3eventof diarrhea/colitisintheIDL+BRgroupbasedonthedatacutoffdateforthisreportwas resultsreportedintheInterim1CSRwereidenticaltothoseobservedatthedatacutoffforthis report:themedian(Q1,Q3)time toonsetofthefirst≥Grade3eventof diarrhea/colitiswas 16.4 (10.4,29.6)weeks (n = 4),and the median (Q1, Q3) time to resolution of the highest grade diarrhea/colitis event (≥ Grade 3) was 0.9 (0.4, 1.8) weeks (n = 4) (CHMP Table 30.27.7 and Study GS-US-312-0115 Interim 1 CSR Section 11.2.4.2).

In the IDL + BR group, 4 subjects (1.9%) had a dose reduction due to ≥ Grade 3 diarrhea/colitis, subject had a dose reduction, 2 subjects (1.0%)had a dose interruption due to≥ Grade 3 diarrhea/colitis,and no subjects discontinued the study drug (placebo) due to ≥ Grade 3 diarrhea/colitis(CHMPTables 30.27.3,30.27.4, and30.27.5).

No deaths due to diarrhea/colitis were reported in this study (CHMP Table 30.27).

<div style=\"page-break-after: always\"></div>

## FebrileNeutropenia(≥Grade3)

Animbalanceintheincidenceof≥Grade3febrileneutropeniawasobservedinthisstudy:50subjects )   + o   () ss     +    () Table 30.27).

Throughthedatacutoff dateforthisreport(31March2017),theexposure-adjustedincidencerate )   +   ()  o

Themedian(Q1,Q3)time toonsetofthefirsteventof≥Grade3febrileneutropenia intheIDL+BR group was 10.0 (3.0,22.0) weeks (n =50),and the median(Q1,Q3) time to resolution was to onset of the first event of ≥ Grade 3 febrile neutropenia was 4.1 (2.1, 18.6) weeks (n = 13), and the median (Q1, Q3) time to resolution was 1.1 (0.9, 1.6) weeks (n = 12) (CHMP Table 30.27.7).

In the IDL + BR group, 2 subjects (1.0%) had a dose reduction, 15 subjects (7.2%) had a dose interruption,and5subjects(2.4%)discontinued the study drug(IDL)due to≥Grade3febrile dose interruption,and 2 subjects(1.0%)discontinued the study drug(placebo)due to≥ Grade 3 febrile neutropenia (CHMP Tables 30.27.3, 30.27.4, and 30.27.5).

No deaths among subjects in the IDL + BR group due to ≥ Grade 3 febrile neutropenia were reported neutropenia was reported (CHMP Table 30.2Z). A narrative for this subject was provided in the StudyGS-US-312-01115Interim1CSRSection15.2

## Infection (≥ Grade 3)

For theAEIof≥Grade3infection,the analysisutilized theMedDRASOC\"Infections andInfestations\" 2017), 112 subjects (54.1%) in the IDL + BR group and 60 subjects (28.7%) in the placebo + BR group reported ≥ Grade 3 infection (CHMP Table 30.27).

Theexposureadjustedincidencerate(95%CI)for≥Grade3infectionwas0.50events/subjectyear (0.41, 0.60) in the IDL + BR group and 0.32 events/subject year (0.24, 0.41) in the placebo + BR group (Table 62).

14.2 (5.3,29.0) weeks (n = 112), and the median (Q1, Q3) time to resolution was 1.3 (0.9, 2.6) the first event of ≥ Grade 3 infection was 13.1(4.1, 26.6) weeks (n = 60), and the median (Q1, Q3) time to resolution was 1.4 (1.0, 3.6) weeks (n = 50) (CHMP Table 30.27.7).

(18.4%)hadadoseinterruptiondueto≥Grade3infection,and20subjects(9.7%)discontinuedthe (CHMP Tables 30.27.3, 30.27.4, and 30.27.5).

theStudyGSUS3120115Interim1CSRSection15.2.

## PneumocystisjiroveciiPneumonia(AnyGrade)

For the AEI of PJP, the analysis utilized the MedDRA HLT\"Pneumocystis Infections.\"Through the data cutoff date for this report(31 March 2017),4 subjects (1.9%) in the IDL + BR group and no subjects in

<div style=\"page-break-after: always\"></div>

events of any grade were provided in the Study GS US 312 0115 Interim 1 CSR Section 15.2.

The exposure adjusted incidence rate (95% CI) for PJp of any grade was 0.01 events/subject year (0.00, a o        ( 64).

The median (Q1, Q3) time to onset of the first event of PJP of any grade in the IDL + BR group was 31.0 (21.6,48.7)weeks (n= 4),and the median(Q1,Q3)time toresolution was3.1(2.6,3.9)weeks (n = 4). No subjects in the placebo+BR group reported PJP of any grade(CHMP Table 30.27.7).

Nosubjectineither treatmentgrouphadadosereductionorstudydrugdiscontinuationduetoPJp.Two subjects(1.0%) in the IDL + BR and no subjects in the placebo + BR group had a dose interruption due to

## Pneumonitis(AnyGrade)

Through the data cutoff date for this report (31 March 2017), 8 subjects (3.9%) in the IDL + BR group 30.27).

The exposure adjusted incidence rate (95% CI) for pneumonitis of any grade was 0.02 events/subject +    (    o    +    () group (Table 66).

Themedian(Q1,Q3) time toonset of thefirstevent ofpneumonitis of anygrade inthe IDL+ BR group was 48.4 (23.1, 64.1) weeks (n = 8), and the median (Q1, Q3) time to resolution was 2.2 (1.1, weeks (n = 1) (CHMP Table 30.27.7).

reduction due to pneumonitis.One subject(0.5%)in the IDL + BR and 1 subject(0.5%)in the placebo + BR group had a dose interruption due to pneumonitis.Three subjects (1.4%)in the IDL + BR group and no subjects in the placebo + BR group discontinued the study drug due to pneumonitis (CHMP Tables 30.27.3, 30.27.4, and 30.27.5).

One subject(0.5%)in theIDL + BR group and no subjects in the placebo+ BR group died due to pneumonitis(CHMPTable30.27).A narrativeforthissubjectwasprovided intheStudyGSUS312 0115 Interim 1 CSR Section 15.2.

## ProgressiveMultifocal Leukoencephalopathy

No subject reported PML during this study.

## Rash per Gilead MST (≥ Grade 3)

Rash was defined per Gilead MST and included the following terms: dermatitis exfoliative, drug erythemanodosum,erythemamultiforme,neurodermatitis,prurigo,rash,rasherythematous，rash generalized, rash macular, rash maculopapular, rash morbiliform, rash papular, rash pruritic, rash pustular,rash vesicular,skin disorder,Stevens Johnson syndrome(SjS),and toxicskin eruption.

Throughthedatacutoffdateforthisreport(31March2017),14subjects(6.8%)intheIDL+BR e           t od   sn  e

<div style=\"page-break-after: always\"></div>

Theexposureadjustedincidencerate(95%CI)for≥Grade3rashperMSTwas0.04events/subject group (Table 68).

Themedian(Q1,Q3) time toonsetof thefirst≥Grade3eventofrashper MSTin theIDL+BRgroup was 8.5 (3.4, 11.6) weeks (n = 14), and the median (Q1,Q3) time to resolution was 8.0 (2.1, 10.1) weeks (n = 11). No ≥ Grade 3 rash per MST AEs were reported in the placebo + BR group (CHMP Table 30.27.7).

Two subjects (1.0%) in the IDL + BR group and no subjects in the placebo + BR group had a dose s (1.4%) in the IDL + BR group and no subjects in the placebo + BR group discontinued study drug due

Onesubject(0.5%)in theIDL+BRgroup andnosubjects intheplacebo+BRgroupdied due torash 0115Interim1CSRSection15.2.

Cases of SJS and toxic epidermal necrolysis (TEN) with fatal outcomes have been reported when IDL wasadministeredconcomitantlywithothermedicationsassociatedwiththesesyndromes.Inaddition to the event of Grade 5 SJS,one additional subject in the IDL +BR groupreported Grade 3 SJS(CHMP Table 30.7); concomitant medications included azithromycin followed by levofloxacin, acyclovir, furosemide, and omeprazole.No case of TEN was reported in this study.

<div style=\"page-break-after: always\"></div>

## SeriousAdverseEvents

summarizedinTable7o.

population. The most frequently reported SAEs included the following:

- pyrexia (25 subjects, 12.1%)
- Placebo + BR group: pneumonia (16 subjects, 7.7%), pyrexia (11 subjects, 5.3%), and febrile neutropenia(10subjects,4.8%)

(IDL/placebo) that occurred in ≥ 2% of subjects are summarized in Table 71.

The most frequently reported study drug-related SAEs included thefollowing:

- IDL + BR group: febrile neutropenia (21 subjects, 10.1%), pneumonia (12 subjects, 5.8%), and diarrhea(10subjects,4.8%)
- neutropenia (3subjects,1.4%)

Seriousadverseeventsassessedbytheinvestigatorasrelated torituximabwerereportedfor 48 subjects (23.2%) in the IDL + BR group and 28 subjects (13.4%) in the placebo + BR group (CHMP included the following:

- IDL + BR group: febrile neutropenia (11 subjects, 5.3%) and pneumonia (7 subjects, 3.4%)

Seriousadverseeventsassessedbytheinvestigatorasrelatedtobendamustinewerereportedfor a + od   (a) ss   e  + a   (t) san Table 30.26). The most frequently reported bendamustine-related SAEs (reported for ≥ 2% of subjects)included thefollowing:

<div style=\"page-break-after: always\"></div>

- pneumonia (5 subjects, 2.4%)

Table 70

| Preferred Term,n (%)              | IDL+BR (N = 207)   | Pl+BR (N = 209)   |
|-----------------------------------|--------------------|-------------------|
| Number ofSubjects(%) with any SAE | 149 (72.0)         | 94 (45.0)         |
| Febrile Neutropenia               | 44 (21.3)          | 10 (4.8)          |
| Pneumonia                         | 36 (17.4)          | 16 (7.7)          |
| Pyrexia                           | 25 (12.1)          | 11 (5.3)          |
| Sepsis                            | 11 (5.3)           | 4 (1.9)           |
| Dianhoea                          | 13 (6.3)           | 1 (0.5)           |
| Anaemia                           | 8 (3.9)            | 5 (2.4)           |
| Lower Respiratory Tract Infection | 7 (3.4)            | 5 (2.4)           |
| Neutropenia                       | 9 (4.3)            | 3 (1.4)           |
| Neutropenic Sepsis                | 3 (1.4)            | 6 (2.9)           |
| Respiratory Tract Infection       | 4 (1.9)            | 5 (2.4)           |
| Urinary Tract Infection           | 6 (2.9)            | 3 (1.4)           |
| Pulmonary Embolism                | 2 (1.0)            | 5 (2.4)           |
| Bronchitis                        | 1 (0.5)            | 5 (2.4)           |
| Colitis                           | 5 (2.4)            | 1 (0.5)           |
| Septic Shock                      | 5 (2.4)            | 1 (0.5)           |
| Squamous Cell Carcinoma           | 1 (0.5)            | 5 (2.4)           |

GS-US-312-0115:SeriousAdverse EventsReported for 2%of Subjects in Either Treatment Group (Safety Analysis Set)

AEs were classified according to MedDRA.Version 20.0.

Subjects who experienced multiple events within the samePT were counted once per PT.

PTs arepresented by descendingorder of total frequencies.

Source:CHMPTable30.23

Table 71 GS-US-312-0115:SeriousAdverseEventsReportedfor≥2%of SubjectsinEitherTreatmentGroupConsideredRelatedtoStudy Drug (Safety Analysis Set)

| Preferred Term,n (%)                          | IDL+BR (N =207)   | PI+BR (N = 209)   |
|-----------------------------------------------|-------------------|-------------------|
| Number ofSubjects(%) with SAEsRelatedtoIDL/P1 | 78 (37.7)         | 28 (13.4)         |
| Febrile Neutropenia                           | 21 (10.1)         | 3 (1.4)           |
| Pneumonia                                     | 12 (5.8)          | 4 (1.9)           |
| Diarhoea                                      | 10 (4.8)          | 1 (0.5)           |
| Colitis                                       | 5 (2.4)           | 1 (0.5)           |
| Pyrexia                                       | 4 (1.9)           | 5 (2.4)           |

AEs were classifiedaccording to MedDRA.Version 20.0.

Subjects who experienced multipleevents within the samePT werecounted once per PT.

Relationship to study drug was determimed byinvestigator;AEs withmissing relationships were considered to berelated.

Source:CHMPTable30.24

## Deaths

Through the data cutoff date for this report, 161 subject deaths were reported, 70 during the study Table 30.46). In the IDL + BR group, 75 subjects (36.2%) died: 38 subjects (18.4%) who died during the study and 37 subjects(17.9%)who died duringLTFU.In the placebo+BR group, 86 subjects (41.1%) died: 32 subjects (15.3%) who died during the study and 54 subjects (25.8%) who died during LTFU.

<div style=\"page-break-after: always\"></div>

- IDL + BR group: pneumonia (5 subjects, 2.4%), sepsis (3 subjects, 1.4%), and septic shock (2 subjects, 1.0%) (CHMP Table 30.21)
- Placebo + BR group: pneumonia (5 subjects, 2.4%), sepsis (2 subjects, 1.0%), and acute myocardial infarction (2 subjects, 1.0%) (CHMP Table 30.21)

## DiscontinuationsDueToAdverseEvents

## AEsLeading toDiscontinuationandInterruptionofStudyDrug(IDL/placebo)

A summaryofAEs thatled todiscontinuationofstudydrug(IDL/placebo)in≥2subjectsineither treatment group is summarized in Table 71. Overall, 83 subjects (40.1%) in the IDL + BR group and 31 subjects(14.8%) in the placebo+ BR group discontinued study drug due to an AE.Overall,126 + o (   +  s ≥ 5% of subjects in the IDL + BR group included the following:diarrhea (32 subjects,15.5%),ALT increased (19 subjects, 9.2%), febrile neutropenia (15 subjects, 7.2%), and pneumonia (12 subjects, Table 30.13).

had AEs leading to dose reduction of study drug (IDL/placebo). AEs leading to dose reduction for ≥ 2% of subjects in theIDL +BR group included the following:diarrhea(9 subjects,4.3%)and ALT increased (6 subjects, 2.9%). No AE led to dose reduction in the placebo + BR group for ≥ 2% of subjects (CHMP Table 30.12).

## AEsLeadingtoDiscontinuationandInterruptionofRituximab

Adverse events leading to rituximab discontinuation are summarized in CHMP Table 30.1Z, and AEs leading to interruption of rituximab dosing are summarized in CHMp Table 30.16.

## AEsLeadingtoDiscontinuationandInterruptionofBendamustine

leading to interruption of bendamustine dosing are summarized in CHMP Table 30.18.

<div style=\"page-break-after: always\"></div>

Table72 GS-US-312-0115:AdverseEventsLeading toStudyDrug Discontinuation for≥2 Subjects (Safety Analysis Set)

| Preferred Term,n (%)                                 | IDL + BR (N = 207)   | Pl+BR (N = 209)   |
|------------------------------------------------------|----------------------|-------------------|
| No.Subjects(%)withAEsLeading toIDL/P1Discontinuation | 83 (40.1)            | 31 (14.8)         |
| Pneumonia                                            | 11 (5.3)             | 4 (1.9)           |
| Diamhoea                                             | 13 (6.3)             | 0                 |
| FebrileNeutropenia                                   | 5 (2.4)              | 2(1.0)            |
| Pyrexia                                              | 4 (1.9)              | 2(1.0)            |
| Sepsis                                               | 3(1.4)               | 2 (1.0)           |
| Anaemia                                              | 3(1.4)               | 1 (0.5)           |
| Colitis                                              | 3 (1.4)              | 0                 |
| Hepatocellular Injury                                | 3 (1.4)              | 0                 |
| Neutropenia                                          | 3 (1.4)              | 0                 |
| Pneumonitis                                          | 3 (1.4)              | 0                 |
| Thrombocytopenia                                     | 3(1.4)               | 0                 |
| AbdominalPain                                        | 2 (1.0)              | 0                 |
| AcuteMyocardialInfarction                            | 0                    | 2 (1.0)           |
| Asthenia                                             | 0                    | 2(1.0)            |
| Autoimmumehaemolyticanaemia                          | 0                    | 2(1.0)            |
| Cough                                                | 2 (1.0)              | 0                 |
| Myelodysplastic syndrome                             | 2 (1.0)              | 0                 |
| Nausea                                               | 2(1.0)               | 0                 |
| Pancreatitis                                         | 2(1.0)               | 0                 |
| Pancytopenia                                         | 2 (1.0)              | 0                 |
| Vomiting                                             | 2 (1.0)              | 0                 |

AEs were classified according to MedDRA,Version 20.0

Source: CHMPTable 30.15

Subjects who experiencedmultiple events within the samePT were counted once per PT.

## ClinicalLaboratoryEvaluations

Notpresentedinthisreport，pleaserefertoResponsedocument

<div style=\"page-break-after: always\"></div>

## Co-Rapporteur

An update of approximately 11 months (previous data-cut: 2 May 2016, current DBL: 31 March 2017) wassubmitted.Thisdatashowed anincreasednumberof subjectswithanIDL+BRexposureof&gt;24 months from51 to 74 subjects(35.7%), while the exposure of the control arm was not increased.In general, the updated safety information is consistent with the known safety profile of idelalisib.

The increased exposure leads to more AEs leading to IDL dose interruption (122 previous DBL to 126 currentDLB)and IDL discontinuation(68previousDBL towards83current DBL).The AEleading toIDL

Among subjects in theIDL +BR group,126of 207 subjects(60.9%)had an AE that led toIDL dose s  od  ('n ) additional cases all had a dose interruption due to AE diarrhoea.

duringthepreviousround.

Inconclusion,it isnoticeable thatthe safetyupdatewith an additional11months ofexposure toIDL showsanhigher thanexpectedincreaseinnumberofsubjectswithadoseinterruptionofdose thetime todiscontinuation or dose interruption due to diarrhoea and the durationof theAE of diarrhoeashouldbereported.

## Issuenotresolved.

## Question 31

## pyrexia?

## Applicant'sResponse

Thegrade of neutropeniawithin7daysprior tothe onsetofpneumonia,diarrhea/colitis,orpyrexia is shown in Table 78. No apparent relationship between degree of neutropenia and onset of diarrhea/colitisorpyrexiawasobserved.

<div style=\"page-break-after: always\"></div>

Table78 GS-US-312-0115:RelationshipbetweenNeutropeniaSeverityGrade and OnsetfPneumonia,Diarrhea/Colitis,andPyrexia(Safety Analysis Set)

|                           | IDL+BR (N=207)   | Placebo+BR (N=209)   |
|---------------------------|------------------|----------------------|
| ANC Grade0, n(%)          |                  |                      |
| Any GradePneumonia        | 12/50 (24.0)     | 8/27 (29.6)          |
| Any GradeDiarrhea/Colitis | 24/86 (27.9)     | 13/49 (26.5)         |
| Any GradePyrexia          | 25/90 (27.8)     | 13/63 (20.6)         |
| ANC Grade 1, n(%)         |                  |                      |
| Any GradePneumonia        | 1/50 (2.0)       | 2/27 (7.4)           |
| Any GradeDiarrhea/Colitis | 6/86 (7.0)       | 5/49 (10.2)          |
| Any GradePyrexia          | 6/90 (6.7)       | 11/63 (17.5)         |
| ANC Grade2, n(%)          |                  |                      |
| Any GradePneumonia        | 1/50 (2.0)       | 3/27 (11.1)          |
| Any GradeDiarrheaColitis  | 6/86 (7.0)       | 4/49 (8.2)           |
| Any GradePyrexia          | 10/90 (11.1)     | 9/63 (14.3)          |
| ANC Grade 3, n(%)         |                  |                      |
| Any GradePneumonia        | 3/50 (6.0)       | 1/27 (3.7)           |
| Any GradeDiarrhea/Colitis | 4/86 (4.7)       | 2/49 (4.1)           |
| Any GradePyrexia          | 6/90 (6.7)       | 3/63 (4.8)           |
| ANC Grade4, n(%)          |                  |                      |
| Any Grade Pneumonia       | 6/50 (12.0)      | 1/27 (3.7)           |
| Any GradeDiarrheaColitis  | 3/86 (3.5)       | 2/49 (4.1)           |
| Any GradePyrexia          | 4/90 (4.4)       | 3/63 (4.8)           |

ANC=absoluteneutrophilcount

Denominatoris thenumberofsubjects with specificAEs.

Numeratoris the mumberof subjects withANC GradeX(X=0 to 4),within7days prior to AE onset

Source:CHMPTable31

## Co-Rapporteur Issue solved.

## 5.RMP

## 32.Pleaserevisethesafetyconcerns:

reactions, includingSJSandTEN\"andreplace transaminaseelevationswith\"severe transaminaseelevations\",similarlyneutropeniawith\"severeneutropenia\".

## MAH's Response

amendedto\"hepatotoxicityincludingtransaminaseelevationandhepatocellularinjury,\"and \"neutropenia\"was amended to\"severe neutropenia.\"Consistentwith the request of the

Pharmacovigilance Risk Assessment Committee(PRAC) during assessmentofPSUR/PBRER#5 (reportingperiod 23July2016to22January2017),theimportantidentified riskof\"transaminase elevation\"hasbeenamendedto\"hepatotoxicityincludingtransaminaseelevationandhepatocellular injury\".

## Rapporteur

Resolved

<div style=\"page-break-after: always\"></div>

## Annex 2: 2nd Request for Supplementary Information

## Clinicalefficacyaspects

## Major objection

A favourable effectonPFSisnot accepted as themainoutcomemeasureinsupportoftheproposed experimental arm.ThereforeafavourabletreatmenteffectbeyondPFS1isneeded.

In addition and ofmajorimportance,the toxicityofidelalisibadd-onmandatesreliable and stableOS dataforaproperbenefit/riskassessment.

no).

- Time to first and time to second next-line therapy should be reported based on the most recent studyupdate.Inthe time tonext-line analyses,deaths and missingness/lost tofollowup/unknownshouldbedetailed.

OS:Atevent rates of 36 and 41% and a change in the OS HR from 0.67(95%CI0.47;0.96) in the andaremovinginanon-favourabledirection.ThusOsdataarenotconsideredreasonablymatureand stable.

- LFTU data should be updated using the March 2017 (or later) cut-off.
- analyses,notonly thepossibleinformativecensoringwithin26(IDL+BR)vs19(placebo+BR) (placebo+BR)subjects,that discontinued during the long-termfollow-up(see alsoRSI#3). Preferably,thiswould includea\"worstcase\"scenarioinwhich theeventsexcluded due to informativecensoringareimputed as\"death\".

<div style=\"page-break-after: always\"></div>

## Efficacy

- 1.Tofurther clarify the shift inHR as observed for the OSanalysis(02MAY2016analysisversus 31MAR2017 analysis). The applicant is requested to investigate the following:
- a)Whether the shift in point estimates of the HR from 0.67 to 0.8could be caused by the 37-43 monthsperiodinwhichonly10-15%ofpatientsareatrisk.
- b) As noted in the response to RSI#14, Gilead stopped the study early due to efficacy and treatmentassignmentswereunblinded study-wideon16November2015.TheApplicantisasked to report whether patients in the placebo arm crossed over to the experimental arm and if so, to discuss itsimpact.
2. The applicant is asked topresent the type of subsequent therapies.In order toimprove censoring shouldbeperformed,asreasonsforcensoring arenotprovided(72%in theIDL=BR armversus56.9%in theplacebo+BR arm).
3. Please submit survival data (including medians) by predefined subgroups based on the latest survival cut-off.

## Safety

- 4.In light of the increased numbers of patients with hypokalemia, hypoalbuminemia, and hypophosphatemia in the IDL+BR arm, more information is needed to assess whether these specific electrolyte disturbances coincided, the time to event, time to resolution, and comedication required.Additionally,thelaboratory abnormalitiesneed tobepresented insection 4.8.of the SmPC.
5. Thesafetyupdateof studyGS-US-0312-0115withanadditional 11 monthsofexposuretoIDL shows ahigher thanexpectedincreaseinnumberofsubjectswithadoseinterruptionordose discontinuation due to diarrhoea.The applicant is requested to discuss.
- 6.Please report in tables and per induction phase and per maintenance phase, ADR as reported in table2ofsection4.8of theSPC,deaths,SAEandgrade≥3or moreAEs and discontinuationsdue to AEs.

## Assessment of the responses to the 2nd Request for SupplementaryInformation

Inresponseto the second listofoutstanding issues,the MAH decided to withdraw the application for theextensionofindicationforZydelig(idelalisib)incombinationwithbendamustineandrituximabfor thetreatmentofadultpatientswithrelapsed chroniclymphocyticleukemia(CLL).

progression-freesurvivalanddemonstratedaclinicallymeaningfulbenefitinoverallsurvival,longer

<div style=\"page-break-after: always\"></div>

## Annex 3: Product Information annotated with (Co)Rapporteur(s) comments

ThisAnnexcould alsobecirculated asaseparatedocument.